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Synthetic biology has become a promising field that aims at developing and using 
tools to work with recombinant DNA. In this field, cell-free protein expression 
systems have become a valuable asset to enable the in vitro transcription-
translation of recombinant proteins, as functional elements of synthetic biology. 
These systems are not dependent on a living organism and consequently offer full 
control of the reactions’ composition and environment, thus enabling protein 
expression in situations where in vivo systems would not perform efficiently. In this 
work, we aimed to explore their applications for in vitro display techniques, for 
protein and peptide evolution in drug discovery. Cell-free systems have the 
potential to allow for a higher number of library candidates to be selected and to 
enable the use of recombinant or unnatural candidates. These unnatural 
candidates are elements not used by organisms naturally, whether because they 
are toxic, they don’t have the metabolisms to process them or just because they are 
fully synthetic. The most researched targets for drugs are membrane proteins, but 
they are also some of the most challenging, as they require a proper lipid 
membrane to fold and settle correctly.  
The work presented in this thesis is focused on linking cell-free systems, in vitro 
display methods and membrane proteins, by characterising the effects of specific 
components on performance in a systematic step-by-step manner. The thesis first 





different types of cell-free systems, namely cell-extracts and purified components. 
A set of T7 promoter variants was constructed and tested in both systems, and the 
protein expression levels recorded and analysed. Both systems are driven by 
different expression dynamics for protein and mRNA. These expression dynamics 
represent the behaviour of certain parameters involved in synthesis, regulation, 
degradation, bottlenecks, etc … The limiting factors of both systems were identified 
for optimization of protein expression. Following conclusions from this analysis, 
purified components for protein translation were adopted and applied to both 
mRNA and cDNA display techniques. The results demonstrated the ability of the 
cell-free systems to provide a screening/selection method producing highly stable 
peptide conjugates and high sample purification. This proof of concept was tested 
and verified with the FLAG epitope, as a thoroughly characterised system. Several 
motifs with high affinity were obtained after 4 rounds of selection and further 
sequenced. Building further on these developments, cell-free systems were used to 
produce CX3CR1, a membrane protein from the G-protein-coupled receptors 
(GPCRs) family, within two types of synthetic lipid membranes, liposomes and 
nanodiscs. The thesis finishes by providing potential directions for the possible use 
of the cell-free expression systems, mRNA display and GPCR proteins for the 
creation of a peptide screening and selection method that could be used in the 
future for drug screening of membrane proteins.  
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This thesis explores the applications of cell-free protein expression systems in 
synthetic biology together with in vitro display methods and synthetic membranes 
for membrane protein production.  
 
As a quick summary of the thesis chapters:  
 
Chapter 1: Introduction.  This section is a literature review of the background 
information necessary to understand and follow this thesis.  
 
Chapter 2. Materials and Methodology. This chapter explains in detail the 
procedures and protocols carried out during the experimental part of this thesis. 
 
Chapter 3. Cell-free protein expression systems and promoter library 
mutants: uncovering their dynamics and tackling optimization processes. 
This topic covers research done on two different cell-free systems in order to 










Chapter 4. In vitro display techniques and cell-free systems: a refined and 
clean method for in vitro selection of drug targeted peptides. Explanation of 
a methodology that could be used for screening of peptide candidates for drug 
discovery using cell-free systems and mutant libraries. 
 
Chapter 5: Production of Lipid Vesicles and Nanodiscs Synthetic 
Membranes and G-protein-coupled receptors (GPCRs) using the PURE Cell-
free System. Expression of membrane proteins using cell-free system and two 
different types of synthetic membranes, liposomes and nanodiscs.  
 
Chapter 6: Conclusions and Future work. Conclusions of the thesis and 
explanation of posterior work that could be carried out to continue the research 
performed.  
 
Further explanation of the thesis aims and how all chapters come together will be 
done in section 1.6 Thesis Aims and Summary so as to provide reader first with a 
background knowledge of the research field of the thesis.   




Chapter 1. General Introduction 
 
1.1 Introduction Outline 
Major research and understanding of several topics were necessary prior in order 
to carry out the work in this thesis. The introduction of this thesis will focus on all 
the theoretical work and investigation performed before the experimental part. It 
has been divided into several sections for better explanation.  
The first section will focus on synthetic biology (Section 1.2); then, cell-free systems 
(Section 1.3); in vitro display techniques (Section 1.4); artificial lipid membranes 
and membrane proteins (Section 1.5); and to finalise, and outline of the thesis 
(Section 1.6). 
Section 1.2 will start with a summary of synthetic biology origins and their 
characteristics (Section 1.2.1). Then, it will go deeper into the major uses for 
synthetic biology, like protein engineering (Section 1.2.2), biosensors (Section 1.2.3), 
and artificial cells (Section 1.2.4). 
In Section 1.3, cell-free protein systems will be discussed. To start with, a quick 
explanation of their characteristics and origins (Section 1.3.1); then, it will continue 
to explore the two main types of cell-free systems (Section 1.3.2); and to finalise, a 
segment to explore their applications (Section 1.3.3). 
Section 1.4 will explain in detail different types of display methods. The first part 
(Section 1.4.1) will talk about display methods, their properties and uses in drug 




screening. Then several types will be explained: mRNA and cDNA display (Section 
1.4.2), ribosome display (Section 1.4.3), phage display (Section 1.4.4), cell display 
(Section 1.4.5) and liposome display (Section 1.4.6).  
In Section 1.5, artificial lipids membranes (Section 1.5.1) and GPCR membrane 
proteins will be the major focus (Section 1.5.2).  
To conclude, Section 1.6, will be an outline of the thesis.  
  




1.2 Synthetic Biology 
1.2.1 Origins and Characteristics 
In the last few years, there has been an increasing demand for research tools that 
offer a broad area to work with to solve very specific problems in short periods. In 
this context, synthetic biology has gained popularity for meeting those criteria, 
since it offers a great range of available options to work with recombinant DNA 1. 
Synthetic biology involves redesigning organisms for different goals. It focuses on 
the basics of genetic engineering to create new biological parts and/or systems, or 
redesign aspects already present in nature to give organisms new abilities. For 
example, it has been possible to engineer organisms that produce biofuels 2. As 
these features come very handy for multiple purposes, researchers and companies 
are harvesting this field to tackle many problems. Some areas where it is being used, 
for example,  are agriculture 3, food industry 4, and medicine5. Furthermore, thanks 
to the advancements in genetic engineering and the lower price for DNA synthesis 
and sequencing, this field is rapidly growing. Also, standardisation, regulation, and 
registration of biological parts and genes have been a great asset 6. This aspect 
allows anyone accesses to a collection of genetic parts that are the genetic building 
bricks (BioBricks) 7 (Figure 1.A) for the assembly of biological systems. The 
catalogue includes many different types of elements, such as backbones, promoters, 
terminators, reporters, and protein domains. Also, the Synthetic gene database 
(SGDB) gives access to artificially engineered genes 8. 




Within synthetic biology, there are two traditional ways of building new biological 
systems 9,10. The top-down approach has been the more common way to perform 
synthetic biology for years. This path seeks to insert new biological functions into 
unmodified organisms, using external elements (Figure 1.B). The newly added 
features range from inserting genes that proportionate new properties, to 
producing pathways that trigger a response from an external signal. Although it 
uses mechanisms similar to those in single gene manipulation, the overall process 
tends to be more complex. Integrating new functions into host cells without any 
side effects is challenging. Some of the mechanisms used to perform this are 
BioBricks 7, the Cas9-CRISPR system 11, or artificial DNA 12. An excellent example 
of this approach can be seen in yeast cells producing the precursor to antimalarial 
drug 13. This achievement alone serves a high purpose, as it brings the possibility 
for affordable mass production of the drug.  
  






Figure 1.A: Step by step on how to build a biological genetic circuit from BioBricks. (1) The 
first step is to select the appropriate BioBricks from the catalogue and make sure their restriction 
sites match; (2) then both samples are cut with the same restriction enzymes; (3) and to finish, both 
cut samples are ligated together to get the final genetic circuit.  
 
On the opposite side of this approach, is the bottom-up way. This method focuses 
on using individual parts ('non-living' components) to create full functional 
organisms or new biological systems, with specific desired properties 14 (Figure 1.B). 
The building blocks can be natural, modified, and/or synthetic in nature. One of 
the main ways this approach is used is to construct proto-cells or artificial cells 15 
(Section 1.2.4). These cells try to mimic the structure and functions of real cells by 
encapsulating certain components in a synthetic membrane. Emphasis is being put 




to achieve segregation within the cell, like organelles 16. Although it is a good way 
to avoid the complexity of full organisms, like ensuring cell survival, this is also 
more challenging than the top-down approach, as the most appealing general 
objective involves creating life from scratch. A way to ease the difficulties this 
approach brings is to use extracts from lysed cells since they already contain almost 
all the necessary components for protein production. These are called a cell-free 
system (Section 1.3). The bottom-up approach is quite challenging and still 
relatively new, so most of the advancements done are still basic and in the early 
stages, such as DNA replication in an enclosed space 17. Achievement of a fully 
synthetic cell includes the inclusion to sense and adapt to external and internal 
changes, and/or having the capability of full autonomous replication.  
 
 
Figure 1.B. Synthetic biology approaches: top-down and bottom-up. Both pathways show 
possible courses to reach a minimum system. The top-down approach can eliminate non-essential 
genes from already existing organisms and/or add additional elements. The bottom-down pathway 
uses simple non-living components together to make them function in sync.  
 




For both approaches, a clear challenge is knowing which minimal components are 
necessary for basic cell functions (cell division, energy regeneration, sensing and 
adapting, etc …). Making all these pathways work together in a non-natural in vitro 
environment can be challenging. As already mentioned, the majority of work that 
is being carried out uses the top-down approach in vivo. This brings some 
limitations, being the most problematic one, interferences between the host 
system and the introduced one. Other disadvantages include long production 
periods, weak environment monitoring, or laborious sample uptake. These 
constraints are to be expected when working with living organisms since noxious 
metabolites in the cell, unbalanced growth or low product yields are common 
factors.  
1.2.2 Synthetic Biology Applications: Protein Engineering  
Synthetic biology can build novel biomolecular elements, systems, and pathways, 
to modify organisms. De novo engineering of synthetic circuits is a promising way 
to tackle difficulties in industry and academic research  18. 
The more widespread application of synthetic biology is synthesis and production 
of products; both in vivo and in vitro. For in vivo production, the traditional 
approach involves the engineering of an organism by introducing foreign genes 
and posteriorly optimizing the production by directed evolution. For this case, the 
most used organisms are yeast (Saccharomyces being the dominant genus) and 
bacteria (mostly, Escherichia coli (E. coli)) are the preferred targets to work with 
for commercial production. Although the main industry objective is product 




production, this is not always the case, as sometimes plants can be engineered 
directly, for example to improve their nutritional value, add new components for 
a better diet 19; or just to withstand harsh environments 20. 
Protein engineering, or modification, is another application of synthetic biology. 
Natural proteins can be modified; for example, by performing changes to their 
DNA sequence and recording protein efficiency and function. These modifications 
can be specific or random, like for example directed evolution, which tries to 
perform natural selection on the proteins to make them evolve into a specific path 
for a specific goal. The changes performed will create a mutant protein library in 
which candidates can be selected through screening methods (Figure 1.C). But also 
just de novo proteins can be created for new, mimicked, or better functions 21,22. 
This is done mostly in the industry field, as companies look to produce industrial 
enzymes with high activity, to optimise the yield and make them more effective. 
These new versions of enzymes can help in making specific products, like lactose-
free milk 23, or just lower the prices of the final product 24. 
But the industry is not the only one taking advantage of recombinant proteins. 
Microreactors can be engineered to produce components in specific places at any 
given time. This can be done without the need for complex equipment and using 
simple elements. NASA recently started to research the prospect of astronauts 
producing resources where they are located to eliminate the need for shuttle 
delivery from Earth 25. On Mars, in particular, synthetic biology could lead to 
production processes based on local resources, making it a powerful tool in the 




development of manned outposts with less dependence on Earth. Work has gone 
into developing plant strains that can cope with the harsh Martian environment, 
using similar techniques to those employed to increase resilience to certain 
environmental factors in crops 26. 
When it comes to creating a new protein function or modifying existing ones, the 
process can be laborious and time-consuming. For this, computational techniques 
have started to be used, such as bioinformatics, mathematical models, databases 
and algorithms (Figure 1.C). When performed properly, the results can yield 
enzymes having an exponential increase in non-natural product specificity 27. 
Modifications can also be done to expand the natural elements used by organisms. 
For example, generally, only 20 amino acids are coded genetically to be used for 
protein production, but by modifying the genetic code, alternative unnatural 
amino acids can be present and used (like L-2-Aminobutyric acid ) 28,29. To do this, 
tRNAs and tRNA synthetases, from other organisms, are engineered into the host 
cell. Just as adding more amino acids to the genetic code is possible, the opposite 
also happens. By limiting the number or types of amino acids used by a certain 
organism, information can be gathered from certain proteins and enzymes and 










Figure 1.C: Two different approaches to protein engineering. Parting from an original gene 
and its protein, two different paths can be taken for the engineering of new features: (Left) Directed 
Evolution, in which a DNA library is made and screening of each protein is done individually to 
select a potential candidate; (Right) Computational Design, uses several computational tools to 
search in extensive DNA and protein databases and predicts a potential candidate.  
 
Just as proteins can be designed, so can nucleic acids. It is possible to insert 
information into the sequence of a synthetic DNA molecule 31. Usually, the use of 
certain algorithms enables the design of these types of genetic systems. As it 
happens with unnatural amino acids, the same is possible with unnatural nucleic 
acids 32. This is usually done by genetically modifying an organism to allow the 
absorption and integration of said nucleic acids. 
 




1.2.3 Synthetic Biology Applications: Biosensors 
A sensor is a device that detects events or changes in its environment and sends 
the information to other devices to process it. Sensors are used frequently 
everywhere; especially in biological organisms as they have a multitude of 
regulatory circuits for sensing and responding to environmental changes. By taking 
advantage of these characteristics, biosensors can be engineered. A biosensor is an 
engineered organism that can sense a certain phenomenon in their surroundings 
and respond accordingly. A basic example of this is the capability of the bacteria 
Aliivibrio fischeri to detect and regulate the production of the luciferin enzyme, 
which produces light (bioluminescence). A more advanced example is an 
engineered E.coli  bacteria that can detect TNT (trinitrotoluene ) and DNT 
(dinitro), and posteriorly produce GFP (green fluorescence protein) 33. When it 
comes to engineering organisms as biosensors, it can be done at the transcriptional, 
translational or post-translational level (Figure 1.D; A). The first stage in gene 
expression is the transcription, and all the elements involved in it can serve as 
biosensors. The main focus is on the promoters and their associated factors. This 
is mostly because there is already a great number of known promoters that respond 
to environmental changes, like for example, the lac operon. When done at the 
translational level, RNA molecules are the main target, especially non-coding RNA 
(Figure 1.D; B). These have a wide variety of important functions in the cell; like 
editing or cutting other RNA molecules or even regulating gene expression directly 
34. Since their ability to regulate depends on their particular sequence, they are 




highly flexible and can have a broad range of targets, therefore allowing for fine-
tuning of the biosensor system. Post-translational biosensing (Figure 1.D; C), is 
characterised by its high diversity and complexity. It depends on a high number of 
factors and interacting components, such as the connection between molecules or 
the ramifications of protein cascades. In this case, the main element to be used is 
protein receptors. While promoters and RNA molecules are mainly selected from 
naturally found ones, protein receptors can be designed de novo 18,33. 
When these genetic circuits are present in more intricate patterns, they can be 
used to build biological computers 35. These encircle a variety of genetic pathways 
with logical gates (e.g. AND, NOT, OR) that perform operations similar to those 
that computers do. Each pathway usually produces a molecule that induces or 
represses another pathway (activator, repressor sites), therefore creating an 
intricate web of systems interacting and working together. Studies have used this 
approach to make a proof-of-concept therapy that can detect and kill cancer cells 
36.  





Figure 1.D: Types of synthetic biosensors. (A) Transcriptional biosensors mainly focus on 
environment responsive promoters linked to genetic circuits. (B) Translational biosensors are 
typically built by linking RNA aptamers to regulatory domains. (C) Post-translational biosensors 
are done by using protein receptors (usually in the membrane) that trigger signal cascades. Image 
used is from Khalil et al. (Nature Reviews, 2010) 18. 
 
1.2.4 Synthetic Biology Applications: Artificial Life and Artificial Cells 
Another use of synthetic biology is the possibility to create artificial life. This is 
based on the in vitro creation of organisms from non-living biomolecules. The two 
pathways of synthetic life are: understanding the origins of life and what makes 
something “alive” 37 and to use them as engineered cells, for drug delivery 38, as 
bioreactors 39, pollution treatment organisms, etc 40. For the definition of what 
makes something “alive”, some characteristics have to be all present in an 




organism: 1. Presence of metabolic reactions that allow for all the other 
characteristics listed here to perform, 2. Organization and coordination of all the 
parts that constitute the organism, 3. Ability to perform regulated growth and 
therefore reproduction to create new organism, 4. The capability to sense and 
respond to signals and changes in the environment, and 5. Being able to undergo 
evolution.  
When it comes to creating synthetic cells that are “alive”, being able to sustain their 
metabolism on their own is essential. This can be done by up-taking elements 
found in their environment; creating ion gradients and recycling energy molecules. 
Additionally, the ability to store genetic information for all these processes is 
necessary along with the capability to mutate and reproduce. But so far this has 
not been possible 41. The closest anyone came to this, was by creating a full 
synthetic bacterial genome and introducing it to a bacterial host with no genome 
42. This experiment was aimed to reveal the minimal genes necessary for life. The 
resulting bacteria cells came were created by inserting and deleting genes until a 
viable genome was obtained. The bacteria was called Mycoplasma mycoides JCVI-
syn3.0 (Syn3.0), it had a total of 473 genes (Figure 1.E) 43 and was able to grow and 
reproduce itself (for comparison, E. coli has 4,500 genes). One peculiar aspect of 
this experiment is that only 80% of the original genes (from the donor) were 
essential. Apart from helping understand the minimal requirements for “life”, 
Syn3.0 became very practical for laboratory use since its small genome made it 
possible to grow and reproduce much faster than many laboratory strains. Due to 




its reduced genome, the time and nutrients the bacteria use to duplicate, and 
therefore reproduce, is lesser than the average bacterial strains, making it save time 
and resources when working with it. But most important, the creation of Syn3.0 
helped in propelling the research of artificial cells, along with its development and 
customisation. It showed that even the simplest of cells can still be quite complex 
in nature and that the current reach of synthetic biology is not enough yet and 





Figure 1.E: Pie chart of the different types of genes that encompass the first artificial species, 
Mycoplasma laboratorium. The organism, also called Syn3.0, had a total of 473 genes. The type 
of gene distribution is shown in the chart. It is important to note that a significant amount of genes 
are of unknown function. 
 




Another close call in creating artificial life was done when scientists managed to 
create a completely artificial genome for E. coli, in which they reduced the natural 
number of codons from 64 to 59 44. In most cases, when it comes to synthesising 
an artificial organism, Mycoplasma genitalium (the original organism used for 
Syn3.0) or Escherichia coli with reduced genes, are used as starting points. These 
bacteria already have reduced genomes and can be easily cultivated in laboratory 
conditions. 
So far all the examples explained were performed in vivo, using organisms as 
backbones for the synthetic genomes, so in other words, a top-down approach. 
When it comes to the bottom-up path, building a de novo artificial cell involves 
using non-living elements. The most basic cell model would involve: a 
phospholipid bilayer vesicle (lipid membrane), encapsulated synthetic DNA, and 
many biological systems to self-maintain and reproduce (Figure 1.F). When it 
comes to self-maintenance, active transport of energy molecules, cofactors and 
building blocks (nucleotides and amino acids) through the membrane from 
outside to the inside is necessary 45–47. The main challenge encountered has been 
the synthesis of a minimal genome that includes all necessary genes for the 
production of the components involved in the protocell’s development. Although 
it has not been possible yet, slowly these encountered issues are being mitigated 
48,49. One way to discover the minimum requirements for a protocell is to try and 
recreate the conditions believed to be present when the first cells arose. By re-
enacting prebiotic conditions, synthetic cells can be formed “naturally” on their 




own, for example, by allowing RNA polymers to be encapsulated by lipid vesicles 
through chemical reactions 50. 
 
Figure 1.F: Scheme of the minimum requirements of an artificial cell. The protocell, needs of 
a lipid membrane (dark yellow) encapsulating a cytosol (light yellow) and all the necessary 
elements. The cell needs to able to sustain a metabolism (1) of DNA replication; RNA, enzyme and 
metabolites production and their transportation. Also, a system of DNA encapsulation through 
lipid membrane growth (2) for cell division. Finally, an active transportation system (3) permits the 
movement of all crucial components inside the cell.  
 
Since artificial cells are minimal versions of organisms, it is quite possible to 
engineer them to eliminate all the drawbacks of using living organisms. For 
example, they can be used as bioreactors, biosensors and drug transporters at the 
same time. Since they are of biological origin, rejection risks if used on humans are 
reduced, as well as the production costs and time. Some studies have managed to 
engineer bacteria that, upon the detection of cancer cells (with protein to protein 
interaction) or the detection of a cancerous environment (for example, hypoxia), 
produce therapeutic molecules 51–53. But since the treatment of diseases with living 




organisms is not recommended for fear of infection and off-target side effects; 
researchers are trying to work more with more bottom-up approaches for artificial 
cells. Another way to avoid using foreign organisms is to engineer directly cells 





Figure 1.G: The two different ways artificial cells can be used for therapy. The first way (left) 
is to create de novo protocells with a piece of transcription-translation machinery and genetic code 
to create the appropriate proteins and enzymes for the detection and elimination of the target cell. 
The second method (right) is the removal, from the patient, of cells from the immune system (like 
T-cells) and engineer them to enhance their functionality. Whether they are de novo or engineered, 
both types of cells are applied to the patient for illness treatment.  
  




1.3 Cell-Free Protein Systems 
1.3.1 Properties and Characteristics 
Cell-free (CF) systems, also called transcription-translation (TX-TL) systems, are a 
type of in vitro mechanism. They are used to research and recreate a biological 
system that happens inside cells, but without using living organisms (Figure 1.H). 
They have been increasingly popular for synthetic biology and metabolic 
engineering applications in recent years 55–57. They bring certain advantages to 
reduce or eliminate issues that happen when working with complex living 
organisms. They prevail especially in the most influential fields of protein 
evolution and drug delivery therapy 58–64. Some of the benefits of CF synthetic 
biology are the decreased amount of total experimental time 65 since it does not 
require to grow and maintain live organisms. It also reduces the efforts on analysis 
and reaction optimisation, mainly as the reaction can be easily modified and 
monitored. Other positive aspects of CF systems are the ability to avoid the 
production of by-products or the presence of unwanted cell mass 66. One of the 
most appealing advantages is the ability to incorporate reactions that are not 
possible with living organisms, like, production of toxic compounds 67 or reactions 
in extreme conditions 68, which are conditions (temperature, pH, etc …)  which fall 
outside the range in which an organism can survive naturally.  
These systems often produce a substantial yield of protein products; however, 
some issues remain. One of them is the lack of an energy regeneration system. This 
leads to the use of expensive phosphoenolpyruvate (PEP) as a supplement for the 




reaction. Although PEP improves the ATP regeneration issue, the final costs of the 
reactions increase significantly. Due to this, a good amount of research is focusing 
on finding more affordable energy sources 69,70, such as glucose and glucose-6-
phosphate, while avoiding the decrease in protein yield. Even though several 
studies managed to achieve this 71, and decrease even further the cell-free reaction 
costs 72, PEP remains the most extensively used energy source. Apart from that, the 
quality of several reaction components is an issue. This happens due to their origin, 
mostly from prokaryote cell extracts. But this is also been researched and improved 
greatly with the use of recombinant purified components 59. While ongoing 
research continues to mitigate these issues and some others 73,74, cell-free systems 
using recombinant protein elements 59,75,76, offer a contaminant-free alternative 
with a final significant protein yield 77.  
One of the main and most important components of CF systems are the proteins 
and enzymes that carry out most reactions. They can be obtained through different 
types of methods, such as cell lysis to obtain cell extracts; or from purified 
components protein expression.  All these ways to obtain a CF system provide a 
wide assortment of experimental diversity and high reaction customisation. Also, 
CF reactions can be performed with basic affordable laboratory equipment. 
Whether it comes from cell extracts or purified components, obtaining the main 
proportion of enzymes and proteins takes up a high amount of time and cost, so 
this is another aspect being improved in CF systems 78. 






Figure 1.H: Scheme showing the necessary components for a cell-free expression system. 
There are three main factors for a CF reaction. A cell extract (or purified components) that contains 
the machinery necessary for TX-TL. A genetic component for the production of the desired product. 
And a reaction buffer containing cofactors, amino acids, salts, etc so the system can work properly 
and the enzymes have an energy source.  
 
1.3.2 Types of Cell-Free Systems: Cell-extract vs Purified Components 
The first CF systems were obtained through cell extract lysates. These lysates come 
from a living organism, such as bacteria, yeast, fall armyworm, wheat germ, 
tobacco, rabbit reticulocytes or HeLa cell line 79–85. These lysates are taken from 
their intracellular fluid (ICF), which contains water, ions and macromolecules. It 
is mainly the TX-TL molecules that are necessary, like RNA polymerase, ribosomes, 




tRNA synthetases, etc. All the other necessary components are usually added to 
the lysate, such as amino acids, nucleotides and buffers (Figure 1.H). These lysates, 
or subcellular fractions, can be obtained through several cell disruption methods 
(Figure 1.I) 86, like mechanical grinding 82, ultrasonic waves 87, high pressure88, 
thermal lysis 89, biochemical rupture 90, enzymatic disruption 91 etc.  
Some methods are dependent on what type of elements are being isolated, if they 
are temperature sensitive, thermal lysis is not adequate. Others might be used for 
very specific organisms, such as the enzymatic disruption using the chitinase 
enzyme for yeast cells. And some even use a mixture of several methods to 
overcome certain problems, such as the lower cell rupture efficiency by chemical 
methods, in which case, it is combined with a mechanical way 92. 
The CF systems that use cell lysates are more affected by certain problems, like 
degradation of DNA, RNA and proteins due to nucleases and proteases found in 
the extracts. Degradation is a controlled way used by organisms to maintain a 
balance, but outside the host, there is no control of this process and these enzymes 
degenerate their targets without any regulation. Because of these issues, some of 
the most modern CF systems do not use cell lysates, instead, they use purified 
components 75.  






Figure 1.I: Detailed overview of some types of cell lysis methods. The “Methods” column 
makes a distinction between techniques that rely or not on mechanical disruption. The “Sub-
method” column provides additional details whether the technique is physical, chemical or 
biological. The “Technique” column gives some examples of each category, and the “Advantages” 
(green) and “Disadvantages” (red) column explains some of the techniques’ benefits and restrains 
respectively.  
 
E. coli - based systems are the most well-established systems due to the high yield 
for protein expression. But they are still being actively improved to simplify the 




preparation methods 93–97 and obtain even better yield 69,98. Protein synthesis Using 
Recombinant Elements (PURE) system is another type of cell-free system 59,99. In 
contrast to the extract-based cell-free systems, purified components were 
reconstituted for protein synthesis (Figure 1.J). 
The PURE system 59,100 is made of several components that are used for 
transcription (e.g., MetRS), translation (e.g., IF3 factor), aminoacylation (e.g., 
amino acyl-tRNA synthetase), and energy regeneration (e.g., creatine phosphate). 
All factors are purified individually to a high degree and assembled with substrates 
in a buffer ready to use. Since all the components are produced and purified 
individually, only the ones involved in the transcription/translation system are 
included. This removes from the system unwanted components like proteases and 
nucleases. Furthermore, the system allows for adjustments to the composition of 
each reaction individually. PUREfrex 1.0 is the commercial version of the PURE 
system. Lately, more research has focused on simplification, robustness and low-
cost for reconstruction 101 as well as alternative energy sources 102 in the PURE 
system. As the concentrations of all the components in the PURE system are 
known, it is suitable for systematic studies of cell-free protein expression, such as 
optimisation of component concentrations for better yield 103.   





Figure 1.J: Comparison of three different ways for protein expression. The left column shows 
the in vivo way, in which organisms are transformed with a DNA molecule so it produces the desired 
protein, after the product can be obtained by cell lysis (optional if external protein) and purified. 
The middle column shows a cell extract-based cell-free system that takes advantage of a cell cytosol 
machinery to produce the desired product in vitro. The right column is also a cell-free system but 
based on purified components, that will also be used in vitro to obtain the desired product. 
 
A recent computational study pointed out that there are more than 240 
components and nearly 1000 reactions involved in the translation process of the 
PURE system 104. The complex cell-free expression dynamics can be an issue 
especially when multiple proteins are being expressed, such as the reconstitution 
of the Sec translocon 105 or ATP synthase 99. The correct balance of each synthesised 
proteins needs to be adjusted for the whole complex to be functional. Although 




this is usually done by titrating the amount of each DNA input, protein expression 
levels do not linearly correlate with the amount of DNA 106,107, especially when a 
strong promoter is used 108. Because of this nonlinear nature of cell-free protein 
expression, finding an optimal balance for multiple proteins can be a daunting 
challenge.  
1.3.3 Cell-Free Protein Systems Applications 
Using cell-free systems quickly gained popularity as it tackled constraints 
encountered when using living organisms,  like cellular toxicity or unnatural 
environment conditions 67,109,110. They are also starting to be used as a more 
economical way to synthesise biological elements instead of the traditional 
microbial fermentation 111. They have a wide range of applications (Figure 1.K) from 
the rapid characterisation of genetic constructs (typically linear DNA constructs) 
112 to protein expression in microcompartments for in vitro evolution 113,114. 
The most straightforward use for CF systems is protein synthesis. In vitro reactions 
can very easily be controlled and monitored since they are not enclosed by 
membranes. From the production of proteins with tagged amino acids 115 to 
establishing a stable protein production system with a continuous flow of 
resources and removal of products 116. Apart from these examples, fusion proteins 
made by CF systems are being an asset in the medicinal field to use as possible 
vaccines 117.  




Another use for CF systems is real-time monitoring and alteration of metabolic 
pathways and their components. By using certain enzymes in an in vitro 
environment, it is possible to track the synthesis of products, the depletion of 
resources and each elements concentration at any given moment. Furthermore, 
the reaction can be altered anytime by adding, removing or altering the 
components. This can be very useful to optimise metabolic pathways and product 
synthesis 118,119. 
As it was previously mentioned (Section 1.2.2) the incorporation of certain 
elements, like non-natural amino acids, is one of the uses for synthetic biology, but 
when working inside a cell it can be challenging. CF systems can be used when the 
amino acid metabolism is lacking or has been altered inside an organism. This way 
amino acids can be labelled for protein characterisation using NRM spectroscopy 
120. 
Directed evolution is another way CF systems come in handy. This method has 
been used for high throughput engineering, screening and selection of proteins. 
Using CF systems in this stance can be useful when dealing with difficult proteins 
(multimeric proteins, membrane proteins, and proteins with expanded amino 
acids) 121. One of the main advantages of using both cell-free systems and directed 
evolution are that it allows for the use of large libraries (up to 1013 variants to test) 
since there are limitations of transformation efficiency when using living 
organisms (around 109 variants). It also allows to control the conditions of the 
reaction. When it comes to membrane proteins, this combination, along with lipid 




vesicles, can be really useful as membrane proteins are quite difficult to 
characterise and screen since they are dependent on a membrane 122.  
 
Figure 1.K: Applications of cell-free protein system. Cell-free systems have a wide variety of 
uses. (Top-left) in vitro protein evolution, (top-middle) protein synthesis for industry and research, 
(top-right) real-time monitoring and alteration for optimisation of metabolic pathways, (bottom-
left) in situ drug delivery when encapsulated in lipid vesicles, (bottom-middle) as portable methods 
for illness diagnosis and, (bottom-right) for protein characterisation of membrane proteins. 
 
A major characteristic of cell-free systems is the lack of engineered organisms and 
all the difficulties working with them brings. As a result, these systems have started 
to be quite promising when it comes to performing experimental research and 
diagnosis in remote locations where delivery, manufacturing or handling of 
laboratory products is impossible. Still, some issues remain with reagents’ stability, 
durability and safety, requiring them to be in perpetual cold storage. Some studies 




have been focusing on making a cell-free system more durable and stable at 
elevated temperatures 123,124 so they could be used as portable diagnosis tools. 
Encapsulating CF systems inside lipid vesicles allows the creation of microreactors 
125,126. This method is being used frequently to study the origin of life since these 
artificial protocells could show how the first cells on Earth appeared 37. Also, these 
microreactors are useful as vehicles for specific targeted drug delivery 127–130. These 
liposome delivery systems are quite “trendy” as they overcome several problems 
found in delivery systems such as the possibility to deliver both hydrophobic and 
hydrophilic drugs and the insulation it provides to the encapsulated drug. They 
can prolong the drug’s lifetime and decreases the probability of degradation 131. 
Although liposomes seem like very suitable tools when delivering drugs, they still 
have their downsides like short half-life or premature rupture 131. To overcome 
these difficulties, studies have focused on making hybrid vesicles with lipids and 
polymers to improve their stability 132. 
 
  




1.4 In vitro and in vivo Display Techniques 
1.4.1 Properties and Drug Screening 
There has always been a high constant demand for the discovery and production 
of antibodies. One of the most established methods for antibody selection is 
hybridomas. This method produces a large number of antibodies by injecting 
mammals (usual mice) with a certain antigen that starts an immune response. 
Antibodies, produced by B lymphocytes, are then harvested from the animal and 
fused with B cell cancer cells. This new cell line, called hybridoma, can produce the 
monoclonal antibodies and be grown in the laboratory. But as it can be expected, 
this method is time-consuming, needs high resources, and is a disadvantage when 
it comes to animal ethics.  
A different approach to antibody screening and production are in vitro display 
techniques. This technology encompasses a multitude of different methods to 
screen, select and optimise many antibodies from large libraries. The core of the 
technique is based on the fact that for each different antibody (phenotype) there 
is a specific genetic sequence (genotype). So by testing the capabilities of one 
specific antibody, its genetic sequence can be known and even evolved to enhance 
its function. When compared to the conventional techniques (hybridomas), 
display techniques stand out in their ability to test new (de novo) sequences, which 
immediately brings a much wider diversity of candidates to select from 133. 
Furthermore, in vitro techniques are not restrained by the in vivo experimental 








Figure 1.L: In vitro and in vivo antibody screening and selection techniques. The left side of 
the image shows a general way to perform in vitro selection of antibodies. This starts with a library 
and through rounds of testing and selection, the desired antibody is found and its DNA sequence 
obtained to produce more of it. The right side of the image shows the traditional in vivo 
(hybridoma) method, in which mice are injected with a specific antigen and the antibodies they 
produce are harvested. These antibodies are fused with B cancer cells to make a new cell line that 
can be used to harvest antibodies.  
 




Different display techniques are available to choose from:  phage display 134, yeast 
display 135,136, ribosome display 137, liposome display 138, DNA display 139–141, cDNA 
display 142,143, mRNA display 144–146. Although the majority of them are performed in 
vitro, some still are performed by using microorganisms (yeast display, bacteria 
display, etc …). But even so, they all use different strategies for the same purpose: 
to couple genotype to phenotype; and therefore all have become indispensable 
tools for directed evolution. Among the display methods, in vitro approaches can 
screen the highest number of molecules, up to 1015  for mRNA, cDNA, and ribosome 
display. For both phage and bacterial display, the library size is around 1011 
sequences (yeast display is even smaller), since they are dependent on the 
transformation efficiency. Furthermore, cell-based display methods are restricted 
to the use of natural elements. Using bigger libraries helps with the probability to 
select rare and unusual sequences and improves the total diversity. Moreover, in 
vitro reactions can be easily modified to suit a specific environment for functional 
screening 147. Whether one or another display technique is used, if it very important 
to link one genotype to its one phenotype, otherwise, false positives could occur.  
1.4.2 mRNA Display and cDNA Display 
This method (Figure 1.M), is used primarily for in vitro protein, 
and/or peptide evolution. The main procedure starts with a DNA library for 
proteins or the peptide of interest. Depending on both the in vitro transcription 
and the translation systems to be used, the specific elements (promoter, RBS, etc 
…) need to be included in the DNA constructs. This library is first transcribed into 




an mRNA library and further purified with a gel to be later ligated to a puromycin 
molecule using a T4 ligase system.  
 
Figure 1.M: mRNA display overview. Parting from a DNA library, the molecules are transcribed 
into mRNA and then puromycin molecules attached to them. Later, the mRNA library is translated 
and the resulting product is a library of mRNA-protein conjugates. The proteins with the highest 
affinity, are selected and separated from the rest. The selected variants are reverse transcribed to 
cDNA and their numbers increased by PCR. Several further rounds of selection are performed to 
minimise the number of undesired proteins. Image used is from Blanco et al. (Physical Chemistry 
Chemical Physics, 2020) 148. 
 
These ligated mRNA molecules are then translated, and their resulting peptides 
(or proteins) become attached to their coding mRNA molecules, by a covalent link 
to the puromycin molecule. The mRNA-peptide complexes can be further 
immobilised through a selection step, such as affinity chromatography, in which 
the sample attaches itself to a column, a well plate or magnetic beads coated with 
the immobilized ligand.  The ones that do bind are then chosen to go through 
reverse transcription which gives a cDNA molecule sequence for each specific 




bound peptide. Error-prone PCR can be also performed to increase the diversity 
for posterior cycles. If several cycles of selection are performed, the number of 
molecules with a weak affinity can be minimised. Afterwards, by sequencing the 
obtained cDNA molecules, the sequences of the peptides with high affinity to a 
specific molecule can be known. 
Puromycin is the molecule used to bind the mRNA to the peptide. It is an antibiotic 
protein synthesis inhibitor that causes early translation termination. Puromycin is 
an analogue of the 3’ end of a tyrosyl-tRNA with a part of its structure similar 
to adenosine, and the other to tyrosine (Figure 1.N) As a result, it causes a 
premature release of translation products. Puromycin is connected to the 3’ end of 
each mRNA molecule after the transcription from DNA; so, when it comes to the 
translation step, once the ribosome reaches the 3’ end of the mRNA molecule, the 
fused puromycin will enter the ribosome’s A site and be incorporated into the 
peptide that is being formed. The mRNA-polypeptide conjugate is then released 
from the ribosome. The puromycin attachment in itself is usually not enough, and 
some other modifications are needed. Extra oligonucleotides and spacers are 
needed, in the DNA sequence, to provide flexibility and enough space for the 
puromycin to enter the A site of the ribosome 149. 
 
 






Figure 1.N: Molecular structure of the puromycin molecule. Puromycin is an analogue of the 
3’ end of a tyrosyl-tRNA with a part of its structure similar to adenosine, and the other to tyrosine. 
 
As mentioned in the previous section, there are other different display methods, 
but mRNA brings certain advantages in comparison to them 150,151. To start with, 
since it is an in vitro method, it already avoids the problems when working with 
yeast or bacteria cells, like reduced library size or increased method time and cost. 
When it comes to comparing mRNA display to other in vitro methods a unique 
advantage observed is the use of a covalent bond of the mRNA molecule and its 
peptide. For example, ribosome display has a non-covalent bond between the 
ribosome, the mRNA and the peptide, which hinders the complex stability and in 
return reduces the efficiency of the binding process. Apart from that, the mRNA-
peptide complex is much smaller than that of its ribosome display counterpart, 
which helps reduce greatly the probability of unwanted peptide interactions (like 




peptide to ribosome). So in this sense, mRNA display has the potential for fast 
evolution and selection of high-affinity diagnostic and therapeutic antibodies 152.  
Cell-free systems offer a great advantage when it comes to tight control over the 
reaction environment, so when coupled with display techniques, they are useful 
for high-throughput screening and directed evolution of peptide/proteins 122,153,154. 
But some problems arise due to the instability of the mRNA-protein conjugates, 
which makes cell lysate-based translation systems have limited utility for mRNA 
display 155–157. While this issue is usually addressed by using of RNAse inhibitors 
and nuclease-free chemicals, to minimise RNA degradation 144,158, advancements of 
reconstituted contaminant-free “PURE” translation system have made in vitro 
display methods more popular for screening antibodies 159,160 and functional 
peptidomimetics 161. Since the PURE system operates primarily with reconstituted 
components, it offers increased stability of mRNA-protein conjugates and also 
allows for greater flexibility in selection condition when combined with the mRNA 
display.  
In addition to the already mentioned ways to improve the stability of the mRNA 
molecule, a variation of the mRNA display can be used. The cDNA display method 
(Figure 1.O), converts unstable mRNA-peptide conjugates into mRNA/cDNA-
peptide conjugates. This new conjugate is advantageous under conditions where 
RNA instability is an issue during the selection step, such as targeting cell surface 
antigens under the presence of cellular ribonucleases 142,162.  






Figure 1.O: cDNA display overview. Almost identical to the mRNA display, this method helps 
with the stabilisation of the mRNA molecule by going through a reverse transcription step after the 
translation process. This mRNA/cDNA duplex is stronger to the formation of secondary structures 
and unwanted interactions with other elements. Image used is from Ong et al. (Current Topics in 
Medicinal Chemistry, 2020) 163. 
 
1.4.3 Ribosome Display 
Ribosome display (Figure 1.P) is an in vitro selection process for proteins and 
peptides. Much like mRNA display, it involves the translated peptide being bound 
to its mRNA molecule, but it does so through the ribosome. The mRNA-protein-
ribosome complex uses the ribosome as the connection molecule between the 
other two components. These complexes also go through a binding process in 
which those with high affinity are selected so that later the mRNA can be 




transformed into cDNA by reverse-transcription. The cDNA molecule is later 
amplified and sequenced to obtain the desired peptide sequence. Ribosome display 
is suitable for displaying big libraries and working with special requirements, such 
as amino acid modification, and unstable proteins.  
This method also begins with a library of DNA sequences, but the constructs have 
a spacer sequence lacking a stop codon at their 3’ end. The library then goes 
through transcription and translation, but the absence of a stop codon prevents 
the binding of release factors and therefore the mRNA-ribosome-peptide 
conjugate cannot be dismantled. The stability of the mRNA-ribosome-peptide is 
usually aided by lowering the temperature of the reaction and the addition of 
cations (like Mg2+). The spacer sequence in the mRNA molecule gets attached to 
the peptidyl tRNA allowing the peptide to go out of the ribosome and fold. 
Posteriorly, the complexes go through a binding process and once the peptides are 
attached to their ligands and restrained from movement, elution of the mRNA 
molecules is performed using high salt concentrations, chelating agents, or ligands. 
The mRNA is then reverse transcribed back into cDNA which goes through further 
selection cycles. 





Figure 1.P: Ribosome display overview. Starting from a DNA library, and after being transcribed 
and translated, an mRNA-ribosome-peptide complex is formed. This conjugate goes through a 
selection process in which the mRNA molecules of the bound peptides are eluted and reverse 
transcribed to obtain cDNA sequences. Image used is from www.creative-biolabs.com. 
 
Ribosome display provides a fast way to identify and produce the proteins that are 
selected, whether their sequence is known or not. Furthermore, as with all the in 
vitro methods, large pools of sequences can be made and analysed rapidly and the 
mRNA-ribosome-peptide complex keeps them from degrading or interacting with 
each other. Although it has a few drawbacks, like the lack of a stable enough link 
within the ribosomal complex or the higher probability of the peptides interacting 




with the ribosome, it is still widely used for antibody and protein engineering 
regarding therapeutic approaches 164. 
1.4.4 Phage Display 
Phage display (Figure 1.Q) is the most widely used in vivo display technique for 
protein-protein, protein-peptide, and protein-DNA interactions. It uses 
bacteriophage viruses as a way to create a link between the genetic information 
encoded inside them, and the proteins that they display. A specific target gene, 
that codes for a certain protein, is inserted inside the reading frame for the virus 
coat proteins. This results in the phage displaying on its surface the protein of 
interest while retaining the inserted gene inside. Since the displayed protein is on 
the outside of the phage, it can be easily used for binding and selection processes. 
Depending on the protein, peptide or antibody of interest, different phage viruses 
can be used, such as M13, T4, T7, and λ 165. 
Phage display starts with a DNA gene library which is cloned into the virus coat 
proteins. Different cloning sites are used at the same time to ensure the desired 
genes are inserted in all available reading frames and no problems arise during the 
translation process. This hybrid library (gene of interest and coat protein gene) is 
inserted inside bacteria cells, usually, E. coli, though transduction so the assembly 
of the hybrid DNA into the virus particles can be done. Sometimes, depending on 
the type of genetic construct made, a helper phage (or a bacterial packaging cell 
line) might be needed to aid with the assembly process. Once the viruses are 
assembled, they are released from the bacteria and can then be used for binding 




processes. Since the displayed protein is on the virus surface, they will bind to the 
protein target and stay immobilised, while the ones that do not bind, are washed 
away. Posteriorly, the selected viruses can be eluted using a low-pH 
elution buffer along with sonication and used to transfect bacteria cells again to 
produce more phage. In this case, performing several selection cycles is called 
“panning”. After several cycles of panning, the final phage can be used to recover 
the DNA sequence for sequencing and identification of the target protein.   
 
Figure 1.Q. Phage display overview. The process starts with a virus library in which the inserted 
gene encodes for a surface protein. Then through amplification of the virus numbers by bacteria 
transfection, posterior selection processes, and repetition through a round of selection, a protein 
candidate is selected and its encoding gene sequenced. Image used is from www.sinobiological.com. 
 
Applications of phage display are bound to the same principle of display methods, 
to create a link between the displayed protein (phenotype) and its encoding gene 
(genotype). This method is widely used for in vitro protein evolution and therefore 
a popular tool for finding new ligands to certain target proteins (drug discovery). 




It has been used to find, for example, antigens to tumours cells so that they can aid 
in diagnosis 166 but also antibodies for cancer treatment 167. The main reasons phage 
display became so popular for antibody screening, when compared to hybridomas, 
is the ability to do large scale production, the high speed and easiness of the 
method, but also the lack of animal use. Furthermore, it is also possible to screen 
for toxic antigens as the viability of the bacteria cells is only necessary for a short 
period.  
1.4.5 Cell Display: Bacterial and Yeast Display 
Organisms can be used to perform in vivo display. As all display techniques, it is 
used for the discovery and selection of peptides, proteins and antibodies. This 
process can mainly be separated into two types of cells used: yeast and bacteria. 
Yeast display (Figure 1.R), as its name suggests, uses yeast cells to display a library 
of recombinant proteins on the cell wall surface 168. The gene, of the protein of 
interest, is encoded with the Aga2p protein gene, so the result is a fusion protein. 
The Aga2p protein is used by yeast to interact with other cells during reproduction 
cycles, and as such, it is displayed on the cell surface and away from other proteins. 
The selection process is done mainly through magnetic-activated cell sorting 
(MACS) or fluorescence-activated cell sorting (FACS) techniques, which both are 
performed in real-time. When it comes to the advantages of yeast display, it is 
worth mentioning that since eukaryotic cells are being used, it is a more suitable 
environment for the folding, post-translational modification, and translocation of 
human proteins. But even if beneficial for human protein screening, this method 




has one of the lowest library sizes to work with (~108) and glycosylation of proteins 
is different in yeast and mammalian cells.  
 
 
Figure 1.R: Yeast display overview. This display method starts with the coding of the gene of 
interest with the gene of the Aga2p surface protein. As a fusion protein, it is directed to the cell 
surface where it can be screened and selected using cell sorting methods. Image used is from 
www.creative-biolabs.com. 
 
Bacterial display, on the other hand, uses bacteria cells instead of displaying 
engineered proteins. Much like yeast display, it starts with a DNA library, but in 
this case, the genes are coded with any surface protein (called a scaffold). These 
surface proteins are used for a wide range of functions, like cell recognition, 




interaction, and signalling; and as with all surface proteins, they are translocated 
from the cytoplasm to the membrane. Since gram-negative bacteria have a 
periplasmic space (not found in gram-positive bacteria), they have a more difficult 
time translocating proteins to the surface. Once the fusion protein is displayed on 
the bacterial surface, cell sorting methods can be used for the selection process 
(FACS or MACS). The bacterial display can be used for all the typical applications 
of display methods: antibody mapping, peptide, and protein screening, etc. But 
there is a specific application used with this method, called vaccine delivery, in 
which they use the bacteria cells (with the displayed surface protein) as a delivery 
system directly for the vaccine. To do this, the bacteria cell has to be weakened so 
it is no longer pathogenic, or safe bacteria are used instead (food-grade bacteria). 
This way of delivery brings some advantages, such as the use of other proteins 
expressed on the bacteria surface as adjuvants (an agent that improves the immune 
response of a vaccine).  
1.4.6 Liposome Display 
Liposome display (Figure 1.S) is a recently discovered in vitro technique that 
involves the use of liposome and cell-free systems for the screening and selection 
of membrane proteins. This approach uses the liposome and cell-free system 
combination to create a micro-reactor or an artificial cell. Inside the liposome, the 
gene of interest, such for example a DNA molecule, is transcribed and translated 
by a cell-free system. The produced membrane protein is translocated to the 
liposome membrane and displayed there. These liposomes, as with bacteria and 




yeast, can be screened and selected using cell sorting techniques (like FACS). The 
DNA encoding the membrane protein can be easily recovered from the liposomes 
to forgo more rounds of selection 122.  
 
Figure 1.S: Liposome display overview. A novel method based on the use of both liposomes and 
cell-free systems to create artificial cells so membrane proteins can be expressed and displayed on 
the surface of the liposome. TA647 is a fluorescent molecule used in the inner solution of the 
liposome as a volume marker to know the size of the liposomes. The sorting and collection 
processes are performed by FACS analysis. Image used is from Fujii et al.122. 
 
Although the number of the DNA library is not as big as other display methods 
(~108), this technique offers speed in the selection process and the benefits of both 
in vitro and in vivo processes. Since it is an in vitro process, it allows for a high 




degree of protein engineering and reaction environment control. But since the 
liposome mimics an artificial cell, it makes it possible to work with membrane 
proteins (and not only soluble globular proteins) and use cell-sorting methods for 
the screening and selection process. 
 
1.5 Artificial Lipid Membranes and Membrane Proteins 
1.5.1 Artificial Lipid Membranes Composition, Characteristics and Uses. 
Artificial lipid membranes, or model lipid bilayers, are composed of a double layer 
of lipid molecules, that were assembled in vitro, and that try to mimic the natural 
cell membranes found in cells 169. These synthetic membranes can be used to study 
the properties of biological membranes in a simple controlled in vitro environment 
170 or just to construct artificial cells 171. Furthermore, since they can be constructed 
with natural or synthetic elements, with one or several lipid mixtures, these 
membranes models are useful tools for the study and discovery of novel lipids. 
These advantages provide easier ways to improve the stability and fluidity of 
membranes. Furthermore, a wide range of model membranes can be constructed 
for different experimental demands. When these synthetic membranes are 
produced, they can stay in a soluble state or be anchored to a solid surface or 
substrate. If they are static, their stability increases making them more ideal to 
work with. 




The simplest model bilayer is called black lipid membrane (BLM). To make them, 
first, a small fissure is made in a layer of a hydrophobic material, then the area 
around this fissure is coated with a solution of lipids (in a hydrophobic solvent). 
After drying, a salt solution is added on both sides and another lipid solution is 
coated for a second time. Between the organic and the aqueous phase, two lipid 
monolayer form which ends up fusing creating a bilayer (Figure 1.T, A). This bilayer 
separates two opposite chambers, which makes it ideal to study membrane 
proteins like ion channels and transportation proteins 172. Membrane proteins can 
be spontaneously inserted into the bilayer by solubilising the protein into the 
aqueous solution. The main disadvantage of this membrane model is its short 
lifespan (measured in hours) and the contamination of the bilayer with unwanted 
solvents that can be trapped in-between the two monolayers.  
A variation of the BLM model is the tethered bilayer lipid membrane (t-BLM). This 
method uses a BLM and anchors it to a solid surface to increase the membrane 
stability. Since unwanted interactions between the membrane (or the membrane 
protein) and the surface are a possibility, a material with inert chemistry is usually 
used, for example, gold. For the binding between the surface material and the 
membrane, thiolipids (lipid derivatives) are used (Figure 1.T, B). The bilayer is 
formed after the lipid monolayer is tethered to the gold surface by exposing it to a 
lipid solution 173. The space between the hydrophobic head is usually bigger than 
in the BLM model, which makes it beneficial to work with bigger membrane 
proteins.  




When the synthetic membrane is not attached to a solid surface by thiolipids or 
any other components, and just by the hydrophobic heads of one of the layers, it 
is called supported lipid bilayers (SLB) 174. Due to the configuration of this model, 
only one of the monolayers is exposed. This characteristic brings enhanced 
stability to the membrane lasting weeks, which helps when using certain 
characterisation methods that use vibrations or movements that may break the 
bilayer.  
If the lipid bilayer closes around itself, creating a sphere, and leaving a solution 
inside, it is a vesicle. Since they mimic very well the physiology of a cell, vesicles 
have been used widely to study the dynamics of cell membranes. They are 
produced in a very easy straightforward way, by exposing dehydrated lipids to a 
polar solution, which in turn makes the lipids close around themselves by creating 
an orb (Figure 1.T, C). Since the creation of the vesicles happens spontaneously, 
these tend to be of various sizes and contain several monolayers, reason why they 
are called multilamellar vesicles (MLV). Different methods, such as sonication, can 
be used to break these initial vesicles (or liposomes) into smaller unilamellar ones 
(SUVs). Since they can be prepared economically and fast, they are preferred for 
bulk studies and long term storage. SUVs are sometimes too small for certain 
studies, such as detailed fluorescence microscope imaging, and as a result, bigger 
versions can also be created, called giant unilamellar vesicle (GUV). But GUVs do 
take more manufacturing time, are more fragile to work with, and produce fewer 
numbers of total vesicles than SUVs. Another possible way to obtain vesicles is to 




just isolate them from organisms or cells 175, but since they are of natural origin, 
they have pre-determined compositions and so this is not usually the preferred 
method. Since liposomes can be used to enclose markers or drugs inside 
themselves or to just express membrane proteins on their surfaces, they are widely 
used as tools for diagnosis and treatment 176. Vesicles can help in the correct 
temporal delivery of drugs (chemicals, oligonucleotides, genes, and recombinant 
proteins) without compromising their quality, and providing reduced toxicity to 
the host. Another practical use for these liposome microreactors is to take 
advantage of their lipid bilayer as a location for membrane proteins to get attached 
to. This method is mainly used as a way to study membrane proteins and their 
properties 177. Studying this type of proteins has proven to be challenging, mainly 
due to the difficulty in trying to find optimal conditions in vitro that would allow 
membrane proteins to keep their original correct conformation and functionality 
178. Liposomes provide an enclosed environment for the membrane protein to be 
produced and, at the same time, allow for its insertion and correct conformation 
into the liposome membrane. The liposomes’ membrane offers a natural 
environment for the membrane proteins to be studied in terms of their structure 
and functionality 179. The correct composition of the liposome’s lipid bilayer is 
fundamental for the membrane protein and therefore the optimisation of this 
process is necessary for each different membrane protein produced 180. Although 
liposome-based vesicles seem like a favourable drug delivery method and an easy 
and fast way to study membrane proteins, they have some fundamental issues due 




to the heterogenous multilamellar condition of the liposomes. This issue can lead 
to different heterogeneous conformations of the same proteins and when it comes 
to oligomer proteins, differences in their monomers 181.  
 
Figure 1.T: Types of synthetic lipid bilayers. (A) The simplest model bilayer, black lipid 
membrane (BLM); (B) an anchored version of a synthetic lipid membrane, tethered bilayer lipid 
membrane (t-BLM); (C) a liposome or vesicle; and (D) a figure of an empty nanodisc and one with 
an embedded membrane protein. Images used are from: (A) Hąc-Wydro et al.182, (B) Andersson et 
al.173, (C) Lee 183, and (D) Zoghbi et al.184. 
 
As an alternative, nanometric lipid bilayers, or nanodiscs, have started to gain 
popularity to perform in vitro experiments of membrane proteins 185. These 
nanodiscs are also synthetic model membranes composed of a phospholipid 
bilayer and two membrane scaffold proteins (MSP) surrounding the hydrophobic 
region of the phospholipids (Figure 1.T, D). The popularity of these nanodiscs 




comes from the fact that they offer a favourable and flexible way to study 
membrane proteins (MP) as the size and lipid composition can be easily adjusted. 
But also due to the increased stability which allows for elongated storage and 
analysis of the MP-nanodisc complex 181. Another convenience is that, because of 
the aforementioned advantages, it is possible to regulate the oligomerisation of 
oligomeric proteins 185. The membrane proteins produced in nanodiscs have shown 
to be quite stable for further analysis such as Nuclear Magnetic Resonance (NMR) 
185–187. Small drawbacks when working with nanodiscs can be some issues with loss 
of lipids when compared to liposomes, 188 and the time-consuming process of 
producing the MSP and finding the optimal lipid composition. But once these 
issues are dealt with, the nanodiscs can be produced in big quantities and stored 
for very long periods which makes them eventually very convenient in saving time. 
1.5.2 Membrane Proteins: G-Protein Coupled Receptors (GPCRs) and their 
Applications for Drug Screening. 
When a protein interacts or is part of a biological membrane, it falls into the 
membrane protein category. Almost 1/3 of all the human proteins are membrane 
proteins, so they play an important role in drug targeting. These proteins are quite 
difficult to characterise since they always depend on a lipid bilayer to properly 
localise to, and therefore determining the optimal conditions to ensure the correct 
conformation of the membrane proteins is a challenge. These membrane proteins 
play important roles for the cell 189. One of their main functions is to serve as 
receptors, they help cells communicate between themselves and identify each 




other, but also respond to external signals. Another function is that they help 
transport molecules and ions through the membrane in either direction. Apart 
from those two main roles of being receptors and transporters, membrane proteins 
can carry out a variety of other activities (enzymes, connectors, anchors, etc). 
Independently of their functions, they also fall into two categories according to 
their localisation on the cell membrane: Integral and peripheral. Both types usually 
go through post-translation modifications so that they can bind to the lipid 
membrane. 
Integral membrane proteins are always located on the membrane and they tend to 
cross the whole membrane from one side to the other (Figure 1.V). Since they are 
fully integrated in the membrane, it is quite difficult to isolate them, as it would 
require to free them from the membrane using detergents or nonpolar solvents, 
which tends to damage the protein. If they cross more than once the membrane, 
they are called polytopic, and if they only cross it once they are called bitopic. Some 
do not fully cross the membrane all the way and are only attached to one of the 
monolayers, these are called monotopic. Another way to classify integral 
membrane proteins is depending on the motifs found in their secondary structure 
and how they assemble in their tertiary structure: alpha-helical (single or as a 
bundle) and beta-barrels (Figure 1.U). They can also be classified depending on 
which side of the membrane their C- and N- terminus ends up.  





Figure 1.U. Types of membrane proteins. The main division of membrane protein is whether 
they are integral or peripheral. Inside the integral proteins, depending on the conformation they 
take, they can be part of the alpha-helix (single or bundle) or the beta-barrel. All membrane 
proteins have a wide verity of different functions. Image used is from www.ib.bioninja.com 
 
Peripheral membrane proteins are only temporarily attached to one end of the 
lipid membrane or they are attached to integral proteins (Figure 1.U). Since they 
are not embedded in the membrane, they are much easier to isolate, only requiring 
treatment with a polar solution.  They attach themselves to the lipid membrane 
through a mixture of hydrophobic, electrostatic, and other non-covalent links. Just 
as with the integral membrane proteins, they have a wide variety of functions, from 
transporters to acting as enzymes. 
One of the main reasons membrane proteins are so important to study is that they 
are optimal targets for clinical and drug treatments of various diseases, especially 
for cancer, since they tend to overexpress themselves 190 and/or alter their post-




translational modifications 191 in cancerous cells. Also, they are easy targets as they 
are found in the surface of every cell which makes them accessible from the outside, 
but also because they have numerous antibodies as targets 192. The family of 
membrane proteins most important as pharmaceutical targets are the G protein-
coupled receptors (GPCR). The GPCR family of receptors is found in the surface of 
the lipid membrane of eukaryotic cells. They have specific roles to sense external 
stimuli and send an internal cascade of signals that will alter the gene expression 
of the cell (Figure 1.V).  These proteins, the largest membrane receptors family, can 
recognise a huge variety of different ligands: neurotransmitters, mediators, 
hormones, peptides, lipids, amino acids and nucleic acids, as well as being able to 
respond to light. All these ligands can either way bind to the extracellular loops 
and N-terminus end, or the intramembrane helices. Since they cross the lipid 
membrane seven times, they are also known as seven-transmembrane receptors. 
As the name suggests, they are coupled to G proteins (signal transmitters). Once a 
ligand binds to the GPCR, it causes a conformational change which in return 
activates the G protein. Since they are receptors to so many different types of 
ligands and they are involved in many of the cell’s signaling pathways, they tend 
to be highly involved in many diseases (cancerous, endocrinal, immunological, etc) 
when they suffer mutations or polymorphisms 193. Around half of the commercial 
drugs in the market act as targets of GPCRs.  





Figure 1.V. Different signalling pathways of GPCRs. The image shows details of the GPCRs 
reacting to external stimuli and all the possible ways they induce a cascade of signals inside the cell 
which has the ultimate goal of altering gene expression to adapt to the new signal. Image used is 
from www. gpcr.co.kr. 
 
GPCRs are of great importance due to their involvement in human 
pathophysiology and because they are easily handled in the pharmaceutical 
industry 194. Their genetic variation, along with the fact that they are attractive 
targets for pharmaceutical drugs, leads to a constant necessity to find new possible 
antibodies and proteins to target GPCRs.  




1.6 Thesis Aims  
The main aim of this thesis is to understand in vitro cell-free systems and display 
techniques that could help create a novel interaction of both methods to screen 
and select from a wide library of peptides so that possible drug targets against 
GPCRs protein (expressed in synthetic membranes) could be found. In order to 
carry out this, several objectives were followed. 
 
Chapter 3 starts by performing a study of two different types of cell-free systems: 
based on cell extracts and based on purified components. This study was done to 
understand the dynamics behind each system and how they behave with a library 
of different samples, as well as to find ways to improve their weak spots. From this 
chapter, an optimal cell-free system (PURE system) was selected to work with for 
the rest of the chapters. For this chapter, two objectives were in mind: 
 
1. Data analysis and modelling of the performance of two cell-free protein 
expression systems by using a promoter mutant library, for the optimization 
of product yield and minimization of degradation. 
 
Cell-free protein expression systems are widely used for many applications 
regarding synthetic biology and metabolic engineering. More information was 
gathered from the dynamics of protein expression within these systems, including 




on the impact of feedback loops and possible bottlenecks. A systems approach was 
used to uncover the underlying dynamics of protein expression in cell-free systems.  
 
2. Design and analysis of mutant libraries in cell-free systems, to better 
understand relevant interacting nucleotides or sections within the 
promoter and identify beneficial mutants. 
 
Coupled with the previous objective, a mutant library of a promoter displayed a 
range of protein level expression. This information could be valuable for 
performing cell-free system reactions in which individual tuning of protein 
expression is needed due to the presence of several genetic circuits. Also, beneficial 
mutants could enhance the final protein yield. The results obtained could also 
feedback into the first objective by feeding the model information about changes 
during transcription. Further exploration of the interactions of each mutant 
nucleotide (single nucleotide changes within the promoter) with the polymerase 
protein provided a starting point for the discovery of enhanced promoter 
sequences.  
 
Continuing, chapter 4 shows a possible method for the screening and selection of 
peptides using the cell-free system chosen in chapter 3, the PURE system, and two 
different in vitro display methods, mRNA and cDNA display. The main objective 
was: 





3. Determination of a methodology that could be used for clean and efficient 
sequence screening of candidates for drug screening using in vitro display 
techniques with cell-free systems (objective 1) and mutant libraries 
(objective 2). 
 
The use of an appropriate cell-free system improved the efficiency of in vitro 
display techniques to prolong the stability of peptide conjugates. Also, it 
diminished the presence of components that could create undesired interactions 
with the ligand candidates. These advantages could provide a faster enrichment 
rate and a higher number of selected peptide candidates than traditional 
methodologies. These two aspects may prove useful when working with time-
constraints of difficult proteins (like membrane proteins). 
 
Chapter 5 is aimed at exploring synthetic lipid membranes and cell-free systems, 
for the production of G-protein-coupled receptors (GPCRs) membrane protein, a 
receptor from the G protein-coupled receptors (GPCRs) family, which are highly 
researched targets for drug screening in medical therapy. By using the PURE 
system, the CX3CR1 membrane protein receptor was produced in their natural 
conformation in vitro, in two types of synthetic membranes: liposomes and 
nanodiscs. This chapter also proposes a type of DNA library that could be used to 




screen for possible candidates for CX3CR1 when using an in vitro display method. 
The main objective of this chapter was: 
 
4. Expression of membrane proteins with the PURE cell-free system using two 
different types of synthetic membranes: liposomes and nanodiscs.  
 
Synthesis and purification of membrane proteins using different synthetic 
membranes provided insight into the difficulties encountered when working with 
membrane proteins and how to overcome them. The use of an appropriate cell-
free system could enhance the protein yield, stability of the membrane-protein 
complex and efficiency of the purification steps.   
 
In summary, this thesis presents research made in-depth to analyse the dynamics 
of cell-free systems and screening selection methods. The combination of a 
transcription-translation system from purified components with in vitro selection 
allowed the production of highly stable peptide conjugates from a DNA library. All 
the proposed objectives could further be combined into an efficient and rapid 
method to screen and select for possible drug targets against membrane proteins.  
This could overcome the difficulties found in high throughput screening of these 
types of proteins. 
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Chapter 2. Materials and Methodology 
 
2.1 Experiments for Chapter 3 
2.1.1 General Materials and Verification Procedures 
Unless otherwise specified, all the reagents, bacterial growth mediums, nucleotides 
sequences, primers and constructs, were acquired from Thermo Fisher Scientific. 
The PUREfrex 1.0 cell-free system was purchased from GeneFrontier and the 
Expressway system (Expressway™ Maxi Cell-Free E. coli Expression System) from 
Thermo Fisher Scientific. The Zyppy Plasmid Miniprep and ZymoPURE Plasmid 
Midiprep kits were acquired from Zymo Research; the Wizard SV Gel and PCR 
Clean-Up System were bought from Promega, and the (5Z)-5-[(3,5-Difluoro-4-
hydroxyphenyl)methylene]-3,5-dihydro-2,3-dimethyl-4H-Imidazol-4-one 
(DFHBI) fluorophore from Sigma Aldrich. The competent bacteria cells used were 
E. coli BL21-CodonPlus (DE3)-RIPL, from Agilent Technologies. All the PCR 
reactions were performed using KOD Hot Start Master Mix, by EMD Millipore. 
A thermocycler (T100 Thermocycler, BioRad) was used for the incubation of all 
PCR reactions, which were subsequently verified for size in a 1.5% agarose Tris-
Acetate-EDTA (TAE) gel (UltraPure Agarose), with a constant voltage of 100V. For 
staining DNA products in the agarose gels, SYBR Gold Nucleic Acid Stain was used 
along with 1 kb DNA Ladder (NEB) for size comparison. 
DNA quantification was performed by UV-Vis spectrophotometry (Nanodrop 
2000c, Thermo Fisher Scientific). All the cell-free reactions were incubated in a 




plate reader (Infinite 200 PRO, Tecan) and the incubation steps for the competent 
bacteria cells were performed in an incubator (BioShaker BR-43FL, Taitec). 
Centrifugation steps were performed in a microcentrifuge (model 5415 R, 
Eppendorf), with different tubes adaptors depending on the size of the tubes used.  
2.1.2 Plasmid Stock and Production 
The plasmid sfGFP-pET32b (supplied by Yoshihiro Shimizu’s laboratory group, 
RIKEN) containing sfGFP (Superfolder Green Fluorescent Protein) as the reporter 
gene, was used as the template to create all the genetic constructs. E. coli BL21-
CodonPlus(DE3)-RIPL competent cells were transformed with the plasmid sfGFP-
pET32b following the manufacturer protocol, and after, grown overnight at 37°C in 
LB (Lysogeny Broth) agar plates with 50 µg/ml of ampicillin, for colony selection. 
The positive colonies were incubated in 10 ml of 2xYT medium, with 50 µg/ml of 
ampicillin, overnight at 37°C and 200 rpm. The plasmid, sfGFP-pET32b, was 
extracted from the bacterial colonies using the Zyppy Plasmid Miniprep and 
ZymoPURE Plasmid Midiprep Kits, and the remaining bacterial culture used as a 
plasmid stock by storing the cells with 70% glycerol at -80C.  
 2.1.3 Linear DNA Constructs 
The plasmid obtained was used to make a linear construct using the sfGFP gene 
along with an RBS (Ribosome Binding Site) and a T7 promoter. This was done by 
two-step PCR. The first one performed used the obtained sfGFP-pET32b plasmid 
as the DNA template, to add the RBS region using the primers RBS-sfGFP-F and sf-
GFP-R (Table 2.A). The PCR conditions were as follows: Initial Denaturation (94°C, 




120 sec), 35 cycles of denaturation (98°C, 10 sec) and annealing/extension (68°C, 30 
sec), and Final Extension (68°C, 120 sec). The result constructs, called RBS-sfGFP, 
was then used as the DNA template for the second round of PCR using the primers 
T7-RBS-sfGFP-F and sfGFP-R (Table 2.A) with the following conditions: Initial 
denaturation (94°C, 120 sec), 35 cycles of denaturation (98°C, 10 sec), annealing 
(30°C, 30 sec) and extension (70°C, 30 sec), and final extension (70°C, 120 sec). The 
construct from this final PCR, T7-RBS-sfGFP, which contains the consensus T7 
promoter sequence, was used throughout the experiments as the reference 
sequence (also named as “WT” for Wild Type). 
Other linear DNA constructs containing variants of only the T7 promoter, along 
with consensus RBS and sfGFP gene sequences, were constructed using also a two-
step PCR by following the protocol for the cell-free system, PUREfrex 1.0: The first 
PCR, used the already obtained WT construct as the template DNA. A different 
forward primer was used for each variant (Table 2.A) but the reverse primer, sfGFP-
R, was common for them all. For making all the variants, the PCR conditions were: 
Initial denaturation (95°C, 120 sec), 35 cycles of denaturation (95°C, 20 sec), 
annealing (67°C, 10 sec) and extension (70°C, 15 sec), and final extension (70°C, 120 











Table 2.A: Sequences and names of the oligo primers used for creating the WT consensus and the 










































Using the original WT DNA construct, along with all its variations, extra bases were 
added at both the 5’ end and the 3’ end. The sequence attached at the 5’ end was a 
non-coding random sequence, and that at the 3’ end contained a T7 terminator 
sequence. Specific forward primers for each variant were used along with a 
common reverse primer, 5p3p_Common_R (Table 2.B). The PCR conditions were: 
































annealing (56°C, 10 sec) and extension (70°C, 30 sec), and final extension (70°C, 10 
min). For the WT sample with extra bases only at the 5’ end, its specific forward 
primer was used as described above with the difference of the reverse primer, 
which was 5p_Common2_R (Table 2.B). The PCR conditions were the same as 
those for the 5’ and 3’ extra bases sequences.  
 
Table 2.B: Sequences and names of the oligo primers used for creating the WT consensus and the 
promoter variants construct with additional bases at 3’ and 5’ and the ones with only additional 
































2.1.4 Spinach RNA Aptamer Constructs 
Several linear DNA templates, containing the spinach aptamer, were constructed. 
A first PCR was performed using four primers at the same time: Aptamer1-F, 
Aptamer2-F, Aptamer3-R and Aptamer4-R (Table 2.B), to create the RNA aptamer 
and tRNA scaffold sequence. The PCR conditions were: Initial denaturation (95°C, 
120 sec), 40 cycles of denaturation (95°C, 20 sec), annealing phase (62°C, 10 sec) 
and extension (70°C, 5 sec), and final extension (70°C, 10 min). 
The PCR product obtained was purified and immediately used as a template for a 
second PCR to attach to it the promoter region of some of the constructs. The 
forward primers that were used to make the initial set of constructs (Table 1) and 
a common reverse primer, Aptamer4-R (Table 2), were used for this second PCR. 




















of denaturation (95°C, 20 sec), annealing phase (57°C, 10 sec) and extension (70°C, 
5 sec), and final extension (70°C, 10 min). The forward primers used were the ones 
for the WT construct and for the 17A, 17C, 16C, 16T and 11A variants.  
2.1.5 Cell-Free Transcription-Translation Reaction 
Unless otherwise indicated, all the reactions using the PURE system were 
performed with a final volume of 20 µl and using 24 ng (1 µl) of each linear DNA 
construct. For the reactions using the Expressway system, the total volume of each 
reaction was 26.6 µl with 235 ng (5 µl) of linear DNA. Stocks of DNA samples were 
made for accurate reproducibility and all experiments were performed in 
duplicate. The reaction components for both systems were assembled in a master 
mix for each one and then the specifically required volume added to the wells of a 
black flat-bottom 384 well-plate (Nunc 384 black well-plate) along with their 
corresponding amount of linear DNA template. The well-plates were covered with 
a transparent sealing membrane (Breath-Easy, Sigma-Aldrich) to avoid 
evaporation and afterwards incubated in a plate reader at 37°C for 12-20 h. During 
the incubation period, GFP fluorescence was measured and recorded every 15 min 
(excitation: 395 nm; emission: 509 nm). 
2.1.6 RNA Spinach Aptamer Cell-Free Transcription Reaction 
For the RNA spinach aptamer experiments, the reactions with the PURE and 
Expressway systems were performed the same as stipulated before and following 
the same conditions, but DFHBI fluorophore was added to each reaction to a final 




concentration of 20 µM and its fluorescence measured instead (excitation: 460 nm; 
emission: 502 nm).  
2.1.7 Mathematical Analysis and Modelling  
A computer simulation was performed using custom programs written in Python 
and R1. For numerical simulation of differential equations, SciPy module2 was used. 
Nonlinear fitting of experimental data for the estimation of system parameters in 
the differential equations was performed by least-square fitting using leastsq 
function in the SciPy module. The rate of reaction and the maximum expression 
level for each time-course fluorescence data were calculated in R using 
growthcurver package 3.  
 
2.2 Experiments for Chapter 4 
2.2.1 General Materials and Verification Procedures 
Unless otherwise specified, all the reagents were acquired from Thermo Fisher 
Scientific. All the oligonucleotide sequences were ordered from FASMAC Inc., 
(Table 2.C). The DNA Polymerase I, Klenow Fragment (Large Fragment of the E. 
coli DNA Polymerase I) and PrimeScript One Step RT-PCR Kit Ver.2, were bought 
from Takara Bio; the Wizard SV Gel and PCR Clean-Up System from Promega; the 
HiScribe™ T7 Quick High Yield RNA Synthesis Kit and all the T4 DNA Ligase 
products from New England Biolabs (NEB); and both the NucleoSpin® RNA Clean-
up and the NucleoSpin RNA Clean-up XS kits, from Macherey-Nagel. The 
PUREfrex 1.0 cell-free system was purchased from GeneFrontier. 




All DNA library samples transcribed mRNA libraries and their FITC-puromycin-
FITC DNA tag ligated products (mRNA-tag) were confirmed for the correct size 
before proceeding to the next steps. Unless otherwise stated, the DNA samples 
were run on a 2% agarose Tris-Acetate-EDTA gel (UltraPure Agarose), with a 
constant voltage of 100V; the transcribed mRNA (and mRNA-tag) samples were 
resolved using a mini size (8 ml) 8 M Urea 6% polyacrylamide Tris-borate-EDTA 
(TBE) gel at constant 50 mA; and the translated mRNA-peptide conjugate samples 
in a polyacrylamide SDS-PAGE gel, with a 3.5% stacking gel and a 10% resolving 
gel containing 8 M urea, at a constant 50 mA. For detecting both DNA and mRNA 
products, SYBR Gold Nucleic Acid Stain was used and the gels were visualised in a 
transilluminator (FUJIFILM Wako Pure Chemical). The electroelution processes 
were performed in an Electro-Eluter by Bio-Rad (model 422) along with all its 
components.  
The Western-blot reactions performed were done using polyvinylidene fluoride 
(PVDF) membranes (Bio-Rad), and a Trans-Blot SD Cell (Bio-Rad) apparatus in 
semi-dry conditions at 110 mA for 60 minutes. The blocking solution used was 
PVDF Blocking Reagent for Can Get Signal (Toyobo), and the incubation reagent 
was Can Get Signal, solution 2 (Toyobo). The membrane was revealed with 
chemiluminescence using ECL Select Western Blotting Detection Reagent (GE 
Healthcare). 
The peptide conjugate selection process was performed using Anti-FLAG M2 
Magnetic Beads and a DynaMag-2 magnetic stand, bought from Sigma-Aldrich and 




Thermo Fisher Scientific respectively. All the incubation procedures were done in 
a circular rotator (Labinco L28, Salford Scientific Supplies). 
For next-generation sequencing (NGS), Illumina MiSeq was used. Quantification 
for sequencing was carried out using Qubit 2.0 Fluorometer and Qubit 1X dsDNA 
HS Assay Kit (Thermo Fisher Scientific). The sequencing products used were 
NEBNext Ultra II DNA Library Prep with Sample Purification Beads and NEBNext 
Multiplex Oligos for Illumina (Index Primers Set 1) (NEB). Agilent 2100 Bioanalyzer 
(Agilent Technologies) was used for length verification and the final samples run 
with the Miseq Reagent Kit v3 600 cycles. 
 
Table 2.C: Sequences and names of all the oligonucleotides for the DNA libraries’ construction, 
DNA-tag ligation, reverse transcription and real-time PCR procedures. Nomenclature is as follows: 
N = A, C, G and T; B = C, G and T; R = A and G; Y = C and T; p = 5'-phosphorylation; Spacer 18 = 
















Puromycin-DNA tag pCCCTTCACCTGATCCGCTGAAAAAAAAAAAAAAAAAA(Spacer 18) 
(Spacer 18) (F-dT) (Spacer 18) CC (Puro)




DNA quantification was performed by UV-Vis spectrophotometry (Nanodrop 
2000c, Thermo Fisher Scientific). All the cell-free reactions were incubated in a 
thermomixer (Eppendorf Thermomixer R, Eppendorf). Centrifugation steps were 
performed in a microcentrifuge (model 5415 R, Eppendorf), with different tubes 
adaptors depending on the size of the tubes used.  
2.2.2 Linear DNA Library Construction 
Linear DNA libraries were constructed by annealing and extension using the DNA 
Polymerase I, Klenow Fragment Kit and 3 μMof each of two single-stranded DNA 
(ssDNA) oligonucleotides. In the making of the two original libraries, the Display-
F and Display-FLAG-random-R oligos were used for the FLAG-random library 
while Display-F and Display-10aa-random-R oligos were used for the 10aa-random 
library. To make the fixed FLAG (DYKDDDDK) sequence, the oligos used were 
Display-F and FLAG-control-R. For all these reactions, each oligo pair was mixed 
with a final concentration of 200 μM dNTPs in Klenow buffer, and annealed by 
heating at 92℃ for 30 seconds followed by cooling to room temperature. Then 10U 
of the Klenow Fragment was added to the reaction mix and an extension step was 
performed at 37℃ for 1 hour, followed by inactivation of the enzyme at 50℃ for 15 
min. Both DNA libraries (FLAG-random and 10aa-random) were further purified 








2.2.3 In vitro Transcription and DNA-tag Ligation 
In vitro transcription was performed using HiScribe™ T7 Quick High Yield RNA 
Synthesis Kit with approximately 500 ng (11 pmol, 6.6 x 1012 molecules) of each 
linear DNA library at 37℃ for 6 h according to the kit’s protocol. The transcribed 
product was cleaned up afterwards using the NucleoSpin® RNA Clean-up kit and 
measured with Nanodrop. To anneal the transcribed mRNA library with a 
puromycin-FITC DNA tag, first, a 100 µL reaction was set up consisting of final 
concentrations of 4 μM transcribed mRNA, 6 µM puromycin-FITC DNA tag (Table 
2.C) and 1 mM ATP in T4 ligation buffer. Second, the reaction was incubated at 
90℃ for 30 sec and cooled to room temperature with a 1℃/sec decline rate to 
correctly anneal the mRNA library with the puromycin-FITC DNA tag. And third, 
3U of T4 PNK and 20U of T4 RNA ligase were added to the reaction mixture and 
further incubated at 25℃ for 30 min. 
2.2.4 Sample Product Purification: Electroelution and Ethanol 
Precipitation 
The ligation product, mRNA-puromycin-FITC (mRNA-tag), was run on a 40 ml 
(8M Urea 6% polyacrylamide) TBE gel for purification before being used for in vitro 
translation. Using a clean scalpel and under a blue light LED transilluminator, the 
strips containing the mRNA-tag were cut from the Urea-TBE gel and followed by 
standard electroelution gel purification. First, the cut gel’s strips were crushed into 
small pieces and placed inside the Electro-Eluter tubes (Bio-Rad) with a membrane 
cap (12kDa cut-off) attached to the tubes. The tubes were filled with 1x TBE buffer 




and run at 10 mA/tube for 30 min. Then, the polarity was reversed for 1 min to 
release the mRNA-tag from the membrane. The eluted sample solution was 
recovered and subjected to downstream ethanol precipitation, in which 10% 
sample volume of 3 M sodium acetate was added to the eluted sample solution, 
and after 3 volumes of 99.5% ethanol (FUJIFILM Wako Pure Chemical). The final 
solution was incubated overnight at -20℃ for increased yield and subsequently 
centrifuged at 4℃, 20,000 RCF for 60 min. The supernatant was carefully 
discarded, and 1 ml of 70% ethanol was added to the white pellet. A second 
centrifugation step was performed at 4℃, 20,000 x g for 15 min. The supernatant 
was again carefully discarded and the pellet was air-dried at room temperature for 
30 min. Finally, the pellet was re-suspended in RNase free water and quantified by 
Nanodrop.  
2.2.5 In vitro Translation Using Cell-free System for mRNA Display 
From the recovered mRNA-tag samples, a total of 2 μg was used for in vitro 
translation using PUREfrex 1.0 in a 100 µl final volume reaction mix. The optimised 
conditions for efficient mRNA-peptide conjugate formation are as follows: initial 
translation at 37℃ for 30 min, followed by addition of a salt mix to a final 
concentration of 32.5 mM MgCl2 and 375 mMKCl, and then a second incubation at 
37℃ for 60 min. After this step, an equal volume of 2x Laemmli sample buffer (Bio-
Rad) was added, mixed and centrifuged at 10,000 x g, 1 min and room temperature 
to remove the salt precipitant. The supernatant, containing the translated product 
(mRNA-peptide), was recovered and further resolved on a polyacrylamide SDS-




PAGE gel (3.5% stacking gel and 8 M urea 10% resolving gel). Afterwards, the gel 
bands corresponding to mRNA-peptide conjugate were excised and purified by 
electroelution and ethanol precipitation. 
2.2.6 Optimisation of mRNA-peptide Conjugate Formation 
The formation of the mRNA-peptide conjugate using PUREfrex1.0 described in the 
paragraph 2.2.5, was firstly optimised through experimentation of three different 
reaction conditions: translation time, salt mix concentration, and incubation time 
after salt mix addition. All test reactions were performed at a 10 μl scale. For the 
translation time, 0, 5, 15, 30 and 60 minutes at 37℃ were tested, before the addition 
of a specific salt mix (final concentration, 32.5 mM MgCl2 and 375 mM KCl) 
followed by 60 minutes of incubation. For the optimisation of the salt mix 
concentration, firstly a 30 minutes translation was performed at 37℃, then either 
no salt or 1x, 1/2x, 1/4x, 1/8x concentrations of 65 mM MgCl2 and 750 mM KCl salt 
mixed added. These salt concentration parameters (65 mM MgCl2 and 750 mM 
KCl) were originally reported to promote a covalent bond between puromycin and 
polypeptide chain 4,5. For the incubation time after salt addition, a 30 minutes 
translation was initially performed, and then salt added to final 32.5 mM MgCl2, 
375 mM KCl concentration, then 0, 10, 30, 60 and 90 minutes of posterior 
incubation tested. 
2.2.7 Trypsin Digestion 
Trypsin digestion was carried out by using 75 ng mRNA-tag sample (with and 
without translation under optimal condition), 1 mM CaCl2, 50 mM ammonium 




bicarbonate, and 0.5 µg of Trypsin Gold (Promega). Each reaction was incubated 
at 37℃ for 30 min and resolved on a polyacrylamide SDS-PAGE gel (3.5% stacking 
gel and 8 M urea 10% resolving gel). 
2.2.8 Reverse Transcription for cDNA Synthesis 
Reverse transcription (RT) was performed against purified mRNA-peptide 
conjugates to obtain mRNA/cDNA duplexes for cDNA display using PrimeScript 
One Step RT-PCR Kit Ver.2. The initial peptide library (0th round) was prepared 
by mixing both FLAG-random and 10aa-random mRNA-peptide conjugate samples 
on a 1:10,000 molar ratio respectively. Approximately 200 ng (~2 x 1012 molecules) 
of this initial peptide library was reverse transcribed in a 50 µl reaction with a final 
concentration of 0.4 µM of RTPCR-R primer (Table 2.C) in 1 step buffer. Tubes were 
incubated at 80℃ for 30 seconds, then cooled down to 4℃ for primer annealing. 
After, the PrimeScript 1 step Enzyme Mix was added and incubated at 48℃ for 20 
min. An “RT–“tube was also prepared as a negative control, without adding the 
enzyme mix. After the incubation, both samples (RT-: mRNA-peptide and RT+: 
mRNA/cDNA-peptide) were purified using the NucleoSpin RNA Clean-up XS kit 
and quantified by Nanodrop. 
2.2.9 Western Blot Analysis 
Western blot analysis was performed to confirm the physical bond between the 
peptide and their mRNA sequences in the mRNA-peptide or mRNA/cDNA-peptide 
conjugates. A control mRNA sequence (Table 2.C) encoding the FLAG epitope 
(DYKDDDDK) was ligated with the puromycin-FITC DNA tag and translated 




under optimised conditions. Samples were run on a 10-20% polyacrylamide SDS-
PAGE gel (SuperSep Ace, FUJIFILM Wako) at constant 30 mA until the samples 
stack and reach the separating gel, and after at constant 50 mA for additional 40 
minutes. The samples in the gel were semi-dry transferred to a PDVF membrane, 
blocking was carried out using the PVDF Blocking Reagent for Can Get Signal and, 
the membrane was incubated using Anti DYKDDDDK tag monoclonal antibody 
peroxidase-conjugated (FUJIFILM Wako Pure Chemical) and Can Get Signal, 
solution 2 with a 1: 12,000 ratio, respectively. The membrane was then revealed with 
chemiluminescence using ECL Select Western Blotting Detection Reagent. 
2.2.10 Selection Using Anti-FLAG M2 Antibody 
First, the Anti-FLAG M2 Magnetic Beads needed to be washed, so 40 µl of beads 
were mixed with 1 ml of TBS-T buffer (50 mM Tris-HCl, pH 7.4, with 150 mM NaCl, 
1 mM EDTA, 0.2% Tween 20), incubated in a circular rotor for 5 min and then the 
supernatant extracted using the DynaMag-2 magnetic stand. This process was 
repeated two times. Afterwards, as two different samples, 100 ng of each initial 
library, the mRNA-peptide and the mRNA/cDNA-peptide, were diluted with 500 
µl of TBS-T buffer. These diluted samples were mixed with the already washed 
beads and incubated with gentle mixing in the circular rotator for 1 hour to allow 
strong binding. After the incubation process, the supernatant was removed again 
with the magnetic stand, and the beads were further washed first three times with 
TBS-T and then another three times with TBS buffer. The incubation time for each 
washing step in the circular rotor was 5 min each. Through the 1st to 3rd rounds, 




beads were re-suspended in 50 µl of TBS buffer and solutions were directly applied 
to the RT-PCR reaction (see 2.2.11 section) to generate a double-strand DNA library 
for the next selection round and sequencing. For the 4th round samples though, 
the elution phase was performed in several steps using a FLAG Peptide (Sigma-
Aldrich) to compete and remove the conjugates, by increasing the FLAG Peptide 
concentrations from 4 μg/ml to 20 μg/ml and 100 μg/ml. Each of the eluted 
fractions, along with the remaining beads, were subjected to RT-PCR. 
2.2.11 RT-PCR for Amplifying Selected Sequences 
A total of 10 µl of re-suspended magnetic beads with bound mRNA-, mRNA/cDNA-
peptide conjugates (from round 1 to 3)were used as a substrate for a 50 µl RT-PCR 
reaction using PrimeScript One Step RT-PCR Kit Ver.2 with 0.4 µM of each RTPCR-
F and RTPCR-R primers (Table 2.C). The reaction mix was incubated at 80℃ for 30 
seconds, then cooled down to 4℃ for primer annealing, and afterwards followed 
by the addition of the PrimeScript enzyme with incubation at 48℃ for 20 min to 
complete the reverse transcription reaction. The reaction mixture was then split 
into a total 8 tubes to be able to recover the samples at different PCR cycles (0, 5, 
10, 15, 20, 25, 30 and 35 to be more specific), and this way, check the amplification 
efficiency and optimal numbers of cycles needed so over-amplification of the DNA 
could be avoided. PCR conditions were: initial denaturation at 94℃ for 60 seconds, 
followed by 30 cycles of 94℃ for 15 seconds, 62℃ for 30 seconds and 72℃ for 25 
seconds, then final extension at 68℃ for 30 seconds. The samples were run on a 2% 
TAE agarose gel stained by SYBR Gold and the optimal number of cycles was 




determined based on the band intensity and the absence of extra bands which are 
caused by non-specific amplified products. Finally, 50 µl of the RT-PCR reaction 
was once again conducted with optimal PCR cycles (20 cycles for rounds 1 and 2, 
and 15 cycles for round 3) and the product was purified using Wizard SV Gel and 
PCR Clean-Up System for the next round of selection and posterior sequencing. 
2.2.12 Next-Generation Sequencing 
Sequencing was performed for every round of DNA library (0 to 4 rounds). Firstly, 
quantification of the samples was carried out using Qubit 2.0 Fluorometer and 
Qubit 1X dsDNA HS Assay Kit. A total of 50 ng of each DNA library sample was 
used as an input for the NEBNext Ultra II DNA Library Prep with Sample 
Purification Beads and also the NEBNext Multiplex Oligos for Illumina (Index 
Primers Set 1) were used to multiplex the samples. The length of the ready DNA 
Library samples was determined with Agilent 2100 Bioanalyzer, then quantified by 
Qubit 2.0 Fluorometer and finally run on the MiSeqillumina platform using the 
Miseq Reagent Kit v3 600 cycles. 
2.2.13 Sequence Analysis  
The sequence information, from the MiSeqillumina platform, was retrieved as raw 
FASTQ files. The sequencing part corresponding to the coding regions was 
extracted using a pattern search program written by Perl script and only the 
sequences with an 8 nucleotide perfect match upstream of the start codon and 
downstream of the random region, were considered for downstream analysis. The 
selected sequences, still in FASTQ format, were further processed using 




FASTAptamer-count6 to rank sort the sequences based on their read counts. 
Consensus sequence logos were created using WebLogo 37 based on the top 50 
reads with specific conditions (fixed letter and position). 
 
2.3 Experiments for Chapter 5 
2.3.1 General Materials and Verification Procedures 
Unless otherwise specified, all the reagents, chemicals and vials were acquired 
from Thermo Fisher Scientific. The lipids were bought from Avanti Polar Lipids 
Inc; the PUREfrex systems (version 2.0, 2.1 and DS supplements) from Gene 
Frontiers. The Wizard Plus SV Minipreps DNA Purification System from Promega, 
the BL21 (DE3) Competent E. Coli cells and the Bio-Beads SM-2 Resin from New 
England Biolabs.  
Unless otherwise stated, size verification of DNA samples was performed on a 1.5% 
agarose Tris-Acetate-EDTA gel (UltraPure Agarose), with a constant voltage of 
100V; while for peptide and protein samples it was in a pre-cast 10-20% 
polyacrylamide SDS-PAGE gel (SuperSep Ace, FUJIFILM Wako) at constant 30 mA 
until the samples were stacked and reached the separating gel, and after that, at 
constant 50 mA for an additional 40 minutes. For detecting DNA products, SYBR 
Gold Nucleic Acid Stain was used and for proteins, the staining used was Oriole 
Fluorescent Gel Staining (Bio-Rad). DNA markers used for the agarose gel were 1 
kb DNA Ladder (NEB) and the protein ladder for the SDS-PAGE gel was Precision 
Plus Protein Dual ColorStandards (Bio-Rad). 




DNA constructs were done using the KOD -Plus- Neo PCR Kit (Toyobo). All the 
primer sequences were ordered from FASMAC Inc., (Table 2.D).  
Visualisation of vesicles was done by fluorescence microscopy using an Aarson 40x 
- 1000x Fluorescence Microscope (RSB-14, Aarson Scientific), and also by 
Fluorescence-Activated Cell Sorting (FACS) using a BD FACS Aria II (BD 
Biosciences). 
The protein purification process was performed using either MagneHIS Ni-
Particles (Promega) or Anti-HA-tag mAb-Magnetic Beads Monoclonal Antibody 
(MBL). Also, DynaMag-2 magnetic stand (Thermo Fisher Scientific) was used. All 
the incubation procedures were done in a circular rotator (Labinco L28, Salford 
Scientific Supplies). 
DNA quantification was performed by UV-Vis spectrophotometry (Nanodrop 
2000c, Thermo Fisher Scientific). All the cell-free reactions were incubated in a 
thermomixer (Eppendorf Thermomixer R, Eppendorf). Centrifugation steps were 
performed in a microcentrifuge (model 5415 R, Eppendorf), with different tubes 
adaptors depending on the size of the tubes used.  
2.3.2 DNA Constructs, Primers and PCR 
The plasmid for MSP1D1 protein was obtained from Addgene (#20061) and used as 
a circular construct for protein expression. The plasmid for the CX3CR1 receptor 
(pCX3CR1) was obtained from the Takuya Ueda Laboratory (University of Tokyo) 
8. The plasmid for sfGFP (psfGFP) was obtained from a colleague in the same 
laboratory (Earth-Life Science Institute). The CX3CR1 samples were used as linear 




DNA templates for protein expression. The first fragment used a forward primer 
containing a T7 promoter (with a 17A mutation) and RBS sequence and a reverse 
primer with an HA-tag. For this, two-step PCR was performed using the plasmid, 
pCX3CR1, the forward primer T7_CX3CR1_HA_F1 and the reverse primers 
T7_CX3CR1_HA_R (Table 2.D) were used with the following the first PCR 
conditions: Initial Denaturation (94°C, 120 sec), 35 cycles of denaturation (98°C, 10 
sec) and annealing/extension (68°C, 40 sec), and Final Extension (68°C, 120 sec). 
The result constructs, called RBS-CX3CR1_HA, was then used as the DNA template 
for the second round of PCR using the primers T7_CX3CR1_HA_F2 and 
T7_CX3CR1_HA_R (Table 2.D) with the following second PCR conditions: Initial 
denaturation (94°C, 120 sec), 35 cycles of denaturation (98°C, 10 sec), annealing 
(58°C, 30 sec) and extension (68°C, 40 sec), and final extension (68°C, 120 sec). The 
construct from this final PCR was referred to as T7-CX3CR1_HA. 
The second fragment, CX3CR1-sfGFP was constructed by overlap PCR. It fused an 
sfGFP sequence to the C-terminus of a CX3CR1 fragment. The sfGFP fragment was 
done using the psfGFP plasmid, the sfGFP_F forward primer and the sfGFP_R 
reverse primer (Table 2.D) with the following PCR conditions: Initial denaturation 
(94°C, 120 sec), 35 cycles of denaturation (98°C, 10 sec), annealing (67°C, 30 sec) 
and extension (68°C, 27 sec), and final extension (68°C, 120 sec). The CX3CR1 
fragment was done using a DNA template, the RBS-CX3CR1_HA fragment 
mentioned above. A T7 promoter was added and the HA tag replaced with the 
overlapping sequence. The primers used were T7_CX3CR1_HA_F1 and 




T7_CX3CR1_R (Table 2.D) with the following PCR conditions: Initial denaturation 
(94°C, 120 sec), 35 cycles of denaturation (98°C, 10 sec), annealing (58°C, 30 sec) 
and extension (68°C, 36 sec), and final extension (68°C, 120 sec). For the final 
overlapping PCR reaction, both sfGFP and CX3CR1 fragments were annealed with 
the following CPR conditions: Initial denaturation (94°C, 120 sec), 35 cycles of 
denaturation (98°C, 10 sec), annealing (63°C, 30 sec) and extension (68°C, 60 sec), 
and final extension (68°C, 120 sec). The construct from this final PCR was referred 
to as T7-CX3CR1_sfGFP. 
 





2.3.3 Giant Unilamellar Vesicles (GUVs) Preparation 
Liposomes were, produced by water-in-oil (w/o) emulsion transfer 9. The lipid 
mixture used was POPC: Cholesterol (1: 1). First, a 6 cubic ml vial is cleaned 
thoroughly and all traces of dust inside it are removed with pressure air. Once 
completed, dry lipids and paraffin oil are put inside following the calculations for 
the desired molarity. On top of that, a small stirrer is introduced with a pincer to 
Name Sequence (5' to 3')
T7_CX3CR1_HA_F1 5’- TTTAAGAAGGAGATATACCAATGGATCAGTTCCCG – 3’







sfGFP_F 5’- ACGGTCTCTGCGATCTCCCAATGAGTAAAGGAGAA – 3’
sfGFP_R 5’- GCGCCAGTGCGACGCTATTATTTGTAGAGCTCATC – 3’
T7_CX3CR1_R 5’- GCACTGCTGCTGCTGTGGGAGATCGCAGAGACCGT – 3’




avoid dust going inside. The solution is then mixed at room temperature and 1,000 
rpm for 2-3 h (or overnight at 4°C) in a magnetic stirrer (BT Lab Systems). In the 
meantime, the inner and outer solution of the liposomes is made. When testing 
new molarity, ratio or new lipids themselves, 200 mM of Glucose and 200 mM of 
Sucrose are used for the outer and inner solution respectively. Once good 
conditions are found, the PUREfrex system is used instead. For this, the inner 
solution is the normal PURE mixture as it is stipulated in the protocol, while the 
outer solution consists of the non-protein components of the PURE system, minus 
also the tRNAs, and complemented with 200 mM of Glucose.  
In an Eppendorf tube, first 200 µl of the outer solution is set at the bottom of the 
tube, then directly on top of it, 100 µl of the mixed lipid solution is poured slowly. 
In another Eppendorf tube, 200 µl of the lipid solution along 5 µl of the Inner 
solution is mixed by flicking the tube hard with a finger until the colour goes from 
transparent to slightly white. This lipid-inner solution mixture is slowly mixed 
inside the top layer of lipid solution from the first Eppendorf with a pipette. Once 
finished, the Eppendorf tube is centrifuged 300 g for 10 minutes, and then at 2,500 
g for another 10 minutes. After this step, a visible white pellet at the bottom of the 
tube appears. With the help of a pipette, the top layer of the lipid solution is slowly 
removed out of the tube and discarded until only the outer solution and the white 
pellet remain. From this point onwards, the white pellet can be slowly and carefully 
removed with a pipette and poured into another clean Eppendorf, or a small hole 
can be made at the bottom of the Eppendorf, where the while pellet is, with the 




help of a needle, to let a couple of droplets containing the freshly made vesicles out 
of the tube with pressure by closing the lid. Whether one or the other procedure is 
performed, a clean tube will be containing the new vesicles with the as little 
amount of outer solution as possible, to dissolve the sample as little as possible.  
To check the vesicles by fluorescence microscope, a tape separator with a hole in 
the middle was put between the two glass slides, and 2 µl of vesicles sample were 
placed in the middle of the hole.  
2.3.4 Fluorescence-Activated Cell Sorting (FACS) 
For vesicle visualisation using FACS, around 50-100 µl of vesicles at a 1:10 dilution 
rate was used each time. The experiment was carried out at room temperature 
when testing the vesicles and at 4°C when using the PURE system to avoid more 
product being produced. The flow rate was set to 1.0 and the FSC (Forward 
Scattering) and SSC (Side Scattering) thresholds to 200 both (all arbitrary units). 
The voltage was set to variable values that would allow for vesicles’ visualisation in 
the plot graph.  
2.3.5 Membrane Scaffold Protein (MSP) Production, PUREfrex2.0 
For the making of the membrane scaffold protein, MSP1D1, some already stipulated 
protocols were followed 8,10 with some slight modifications. 
The DH5α E. coli bacteria containing the plasmid with the MSP1D1 gene (Addgene, 
#20061) was first grown in 10 ml of LB medium containing Kanamycin (50 µg/ ml) 
overnight at 37°C with moderate shaking. The plasmid was extracted using the 
Wizard Plus SV Minipreps DNA Purification System and quantified with 




Nanodrop.  For storing and further plasmid expression purposes, the plasmid was 
transformed into E. coli BL21 (DE3) cells following the transformation protocol and 
the following day, selected colonies stored with 70% Glycerol at -80°C, while other 
colonies were grown in another 10 ml of LB medium containing Kanamycin (50 µg/ 
ml) for 6 h at 37°C with moderate shaking. The plasmid was again extruded using 
the aforementioned miniprep kit.  
The MSP1D1 proteins were expressed in PUREfrex 2.0 since it yields a higher 
protein output. The reaction was carried out in a final volume of 100 µl, using 10 ng 
of the MSP1D1 plasmid and following the company’s protocol by incubating the 
reaction at 37°C for 6 h.  
2.3.6 Membrane Scaffold Protein (MSP) Purification, MagneHis Ni-
Particles 
The MagneHis Ni-Particles were used to purify the MSP1D1 since these proteins 
have a 7-His tag at their N terminal. First, 50 µl of the beads were cleaned 
thoroughly two times with Lysis Buffer (50 mMTris HCl pH 8.07, 300 mM NaCl, 5 
mM MgCl2) by washing them with the mentioned buffer in a circular rotator for 5 
min each at room temperature.  
Parting from 100 µl of the PUREfrex 2.0 reaction, 5 µl of it were taken as the “PURE” 
fraction, for posterior analysis. The remaining 95 µl were mixed with 400 µl of Lysis 
Buffer and the 50 µl of the washed beads (with no liquid) in a circular rotator for 
30 min at room temperature, or overnight at 4°C. The tube was then placed in the 
Magnetic Stand for 2 min, and after the liquid taken out and put inside an 




Eppendorf tube as the “Flow-Through” fraction. To the remaining beads, 500 µl of 
Lysis Buffer with 20 mM Imidazole was added and the sample further incubated in 
a circular rotor for 10 min. After placing the tube in the magnetic stand, the liquid 
was transferred to an Eppendorf tube as “Wash 1”. The washing process was 
repeated and a second fraction, “Wash 2” was obtained. The process was finalised 
by adding to the beads another 500 µl of Lysis Buffer but this time with 500 mM 
Imidazole. The mixture was incubated for the last time in the circular rotor for 
another 10 minutes and then placed in the magnetic stand where the liquid was 
taken as the “Elution” fraction. All the fractions were flash-frozen and stored at -
80°C. 
The “Elution” fraction was later used for dialysis to remove the imidazole. The 
sample was put inside a dialysis cassette (Micro Float-A-Lyzer, Repligen) which 
was left inside a tank filled with 1 L of Lysis Buffer, overnight at 4°C with mild 
rotation.  
2.3.7 Membrane Scaffold Protein (MSP) Concentration and Verification 
After the dialysis of the MSP1D1 sample (section 2.3.5), 5 µl were stored on ice. 
Buffer exchange was performed with PBS using Amicon Ultra Centrifugal Filters 
(Merck Millipore) and the sample was also concentrated to a total volume of 50 µl.  
All the fractions, along with the dialysis and buffer exchange samples were 
analysed on two different 10–20% SDS-PAGE gels, for the correct size verification, 
at constant 30 mA until the samples stack and reach the separating gel, and after 
at constant 50 mA for additional 40 minutes. One gel was stained with Oriole 




Fluorescente Gel Stain for immediate visualisation and the other was subjected to 
semi-dry conditions and transferred to a PDVF membrane. Blocking was carried 
out using the PVDF Blocking Reagent for Can Get Signal and, the membrane was 
incubated using Anti 6xHistidine monoclonal antibody (9C11), Peroxidase-
conjugated (FUJIFILM Wako Chemicals) and Can Get Signal, solution 2 with a 1: 
10,000 ratio, respectively. The membrane was then revealed with 
chemiluminescence using ECL Select Western Blotting Detection Reagent. 
The sample was posteriorly flash-frozen for -80°C storage. The protein 
concentration for the MSP1D1 was calculated by Nanodrop.  
2.3.8 Nanodiscs Production, Bio-Beads  
The whole procedure was done following already stipulated protocols 11–14 with 
some modifications. When syringes were needed, metallic and glass ones were 
selected, instead of plastic, due to the use of chloroform. Syringes were pre-rinsed 
with chloroform and vials cleaned from dust with pressured air. The lipids used for 
the construction of the nanodiscs were POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine), POPS (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine) and 
Cholesterol in a 72: 20: 8 proportion respectively. The ratio of membrane scaffold 
protein to lipid mixture was 1: 60 (MSP1D1: lipid mixture). All the lipids were 
dissolved in Chloroform. 
First, the calculated volume of lipid mixture (POPC: POPS: Cholesterol) was 
poured into a 6 cc crystal vial and N2 gas was forced inside to dry the mixture, 
creating this way a dry film. The vial was then covered in aluminium foil and 




further dried overnight by leaving it at room temperature in a vacuum so that all 
the humidity is removed. The next day, the dry film was hydrated with 
NanodiscBuffer (20 mMTris/HCl, pH 7.4 and 100 mM NaCl) containing 100 mM Na 
cholate. During the hydration process, the glass vial was put into a water bath at 
60°C with sonication to ensure all the lipid dry films are fully dissolved. The process 
was aided by vortexing and/or flicking. Once dissolved, the whole volume was 
passed into a 2 ml tube and the MSP1D1 proteins were added. The sample was 
further incubated at 4°C for 1 h and kept in ice afterwards.  
In the meantime, the Bio-Beads SM-2 Resin was prepared to be used with the 
sample. First, the top 5 cm of a 25 ml pipette was cut off with a saw and the tube 
cleaned well with pressured air. Cotton was then pushed down the cut pipette, to 
where the tip is. The cut pipette was supported vertically with a holder and 25 ml 
of MiliQ water was run through it. Then around 2.5 gr of beads (4-5 ml) was put 
inside the cut pipette with 25 ml of 100% methanol. Before all the liquid came out 
of the cut pipette, the beads were pipetted up and down the tube to wash them 
thoroughly. Posteriorly, the beads were further washed 3 times with MiliQ water 
and finally another 3 times with Nanodisc Buffer (without the detergent). During 
the last wash, again before all the liquid came out the bottom, the flow was stopped 
with paraffin wax paper and the beads in the Nanodisc Buffer (around 15 ml) were 
collected into a Falcon tube.  
For every microliter of sample 1 mg of dry beads (no liquid) is necessary. To the 
lipid-detergent-MSP1D1 sample, the dry bio-beads were added and the mixture was 




mixed overnight at 4°C in a circular rotator. The following day, the mixed sample 
was centrifuged at 4°C for 10 minutes and 12,000 rpm. The supernatant was 
transferred into another Eppendorf tube and kept at 4°C.  
2.3.9 Nanodiscs Purification and Concentration, AKTA Chromatography 
Further purification of the nanodiscs was performed using AKTA chromatography 
(ÄKTA pure 25L, Cytiva) to separate the correctly assembled nanodiscs samples 
from the aberrant ones. The column used was HiLoad 16/600 Superdex 200 pg. 
The machine was cleaned and flushed with Nanodisc Buffer (20 mMTris/HCl, pH 
7.4 and 100 mMNaCl) before injecting the sample. The 500 µl tube line was used 
for running the sample through it and a flow rate of 0.2 ml/min was selected. The 
entire run lasted for 2h and a total of 24 fractions were collected, each one with 1 
ml of volume. A total of 10 fractions were selected to determine if they contain the 
purified nanodiscs from the AKTA plot. The gel was run with 5 µl from each 
selected fraction.  
A total of 5 fractions containing most of the purified nanodiscs were selected for 
concentration using Amicon Ultra-15 Centrifugal Filter (Merck). A final volume of 
1.3 ml was collected and stored at -80°C by flash freezing in 5 µl and 10 µl aliquots. 
The concentration of the Nanodiscs was determined by Nanodrop at 131 µM.  
2.3.10 G Protein-Coupled Receptors (GPCR) Production, PUREfrex 2.1 and 
DS Supplement 
The PUREfrex 2.1 version was selected first for its increase in product yield but 
more so, for the compatibility with the DS Supplement, which aids in the post-




transcriptional formation of sulphur bonds between proteins or subsections to 
secure the protein functionality. In the case CX3CR1 (C-C Chemokine receptor), 
this supplement was necessary. The reducing agent used was reduced glutathione 
(GSH). For this reaction, the nanodiscs previously produced (section 2.4.8) were 
supplemented at a final concentration of 10 µM and the template DNA, T7-CX3CR1-
HA at a final concentration of 5 nM. The final volume of the reaction was 100 µl 
and it was incubated for 6 h at 37°C.  
2.3.11 G Protein-Coupled Receptors (GPCR) Purification, Anti-HA-tag 
mAb-Magnetic Beads. 
The Anti-HA-tag mAb-Magnetic Beads were used to purify the CX3CR1 receptors 
that assembled correctly, from the empty nanodiscs. First, 50 µl of the beads were 
cleaned thoroughly 2 times with PBS buffer by washing them in a circular rotator 
for 5 min each at room temperature. Parting from 100 µl of the PUREfrex 2.1 DS 
Supplement reaction, 5 µl of it were stored as the “PURE” fraction. The remaining 
95 µl were mixed with 400 µl of PBS Buffer and the 50 µl of the washed beads (with 
no liquid) in a circular rotator for 30 min at room temperature, or overnight at 4°C. 
The tube was then placed in a Magnetic Stand for 2 min. The liquid was taken out 
and put inside an Eppendorf tube as the “Flow-Through” fraction. To the beads, 
500 µl of PBS Buffer was added and the solution mixed in a circular rotor for 10 
min. After placing the tube in the magnetic stand, the liquid was then transferred 
to an Eppendorf tube as the “Wash 1” fraction. The washing process was repeated 
and a second fraction, “Wash 2” obtained. The process was finalised by adding to 




the beads 200 µl of HA-peptide. The mixture was incubated in the rotor for another 
30 minutes and then placed in the magnetic stand where the liquid was removed 
and taken as the “Elution” fraction. All the fractions were flash-frozen and stored 
at -80°C. 
All the fractions were analysed on a 10–20% SDS-PAGE gel, for correct size 
verification, at constant 30 mA until the samples stack and reach the separating 
gel, and after at constant 50 mA for additional 40 minutes. The gel was stained 
with Oriole Fluorescent Gel Stain for immediate visualisation. 
2.3.12 Radiolabelling 
Radiolabelling was used to determine the concentration of CX3CR1 produced and 
the efficiency of the purification process. The radioactive amino acid used in this 
case was Methionine [S35] (Methionine L-[S35], PerkinElmer). 
Parting from 49 µl of PUREfrex 2.1 DS Supplement reaction, 1 µl of Methionine S35 
was added. The reaction was incubated at 37°C for 3 h. Afterwards, the samples 
were purified as stipulated in section 2.3.11.  
All the fractions obtained during the purification process were run in a pre-cast 10–
20% SDS-PAGE gel and run at constant 120 V for 60 min and then at 200 V for 
another 45 min. The gel was then incubated in Fixing Solution (30% Methanol and 
10% Acetic Acid) for 30 min with mild shaking. After the fixing step, the gel was 
dried to remove all radioactive water and humidity from it. Using a gel dryer (AE-
3711RapiDry mini, Atto), the gel was dehydrated at 80°C during 1 h.  




In the meantime, several dilutions of the Methionine [S35] were made for a standard 
curve. The labelled amino acid was diluted with 50 mM HEPES pH 7.5 in the 
following dilutions: 1/500, 1/1,000, ½,000, 1/5,000, 1/10,000, 1/50,000, 1/100,000 and 
1/200,000. A total of 10 µl of each dilution was spotted onto a rectangular piece of 
filter paper and each dilution spots labelled. The spotted samples were then left to 
dry.  
Once the dilutions and the samples were dried in their respective filter papers, they 
were put inside an autoradiography cassette (Fisher Scientific) along with an 
intensifying screen (Fisher Scientific) and incubated in the dark for 2 days. After 
this period, the intensifying screen was revealed using a phosphorimager (Typhoon 
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Chapter 3. Cell-free protein expression systems and 
promoter library mutants: uncovering their dynamics and 
tackling optimization processes 
 
 
3.1 Chapter 3 Aims and Summary 
Cell-free protein expression systems have been widely used for applications such 
as synthetic biology and metabolic engineering. But even if broadly used, little is 
known about how protein expression works in cell-free systems. Furthermore, 
there are gaps in understanding the molecular interactions taking place, their 
dynamics, and how these can contribute to bottlenecks in the process. This chapter 
describes a systems approach to uncovering the underlying dynamics of protein 
expression in cell-free systems.  
A set of T7 promoter variants was constructed to express superfolder GFP (sfGFP) 
in two different cell-free systems: one with reconstituted purified elements and the 
other based on E. coli extracts. The maximum expression level and the rate of 
protein synthesis as responses to the transcription rate change were different in 
the two cell-free systems, suggesting they could be driven by different expression 
dynamics. This observation was confirmed by a mathematical model for each cell-
free system. It revealed negative feedback in the mRNA-protein translation by the 
PURE system and also identified limiting factors that could be optimised to 
enhance protein expression in the two cell-free systems (Fig.3.A). For the PURE 
system, these dynamics can be extrapolated to other types of systems based on 




purified components as long as they maintain the same level of contaminant-free 
environment. Differences could occur if different proteins and components were 
to be used. That is why the results obtained in this chapter would probably not 
match many other types of extract-based system. These systems differ much since 




Figure 3.A: Summary of the experimental approach carried out for Chapter 3. From left to 
right, first, a series of T7 promoter variants are created and tested in two different cell-free systems. 
The protein expression of sfGFP is measured in both and mathematical models are run with the 
information gathered to reveal the dynamics of both systems.  
  




3.2 Preparation of T7 Promoter Library Variants Constructs 
The T7 promoter has been universally used for in vitro and in vivo experiments 1,2, 
mostly due to the high promoter-specific strength of the T7 RNA Polymerase 
(RNAP).  
To gather information about its performance in cell-free systems, screens of the 
promoter sequence against transcription rates and translated product yield have 
been performed [3]. However such studies have focused on multiple mutations and 
high throughput screening, which prevented a systematic analysis that could 
generate rational understanding of the bottlenecks.  Here we used single mutations 
and studied the dynamics of two very different cell-free systems. 
Alterations were made to the 17 base-pair long recognition site of the T7 promoter 
sequence (TAATACGACTCACTATA) and a library constructed of T7 promoter 
variants, that encompassed all possible single base-pair alterations (Fig.3.B), 
yielding a total of 51 variants. Each of these variants was ligated downstream to a 
common ribosome binding site (RBS) and sfGFP. The original T7 promoter 
sequence will be referred in this chapter as the "core sequence" or “WT” from now 
on for easier referral.  
 





Figure 3.B: Schematic of the linear DNA templates used for protein expression in this 
chapter. Each DNA sequence contains the consensus core sequence (or one of its 51 variants) 
(white), a ribosome binding site (RBS) (blue) and an sfGFP gene (green). Single base-pair 
substitutions in the T7 promoter variants are highlighted in red. 
 
3.3 The PURE System vs. the Expressway System 
To investigate the expression levels of sfGFP in each DNA construct, they needed 
to be tested in a cell-free system. The cell-free systems to be used with the 
constructs had to include the T7 RNA Polymerase protein as all of the DNA 
constructs use the T7 promoter (or variations of it). The cell-free systems, also 
called in vitro transcription-translation systems, were selected to represent the two 
competing approaches currently used in the field, namely either purified 
components (PURE system (PUREfrex 1.0, GeneFrontier)4) or cell extracts (E.coli 
extract-based cell-free system (Expressway™ Cell-Free E. coli Expression System, 
Thermo Fisher Scientific)) (Fig.3.C).  






Figure 3.C: Schematics of both the PUREfrex 1.0 Cell-free System and the Expressway Cell-
free system. The PURE system (left) contains all the minimum necessary components to perform 
a transcription-translation reaction. All its protein and enzymatic components are recombinant 
and were produced in vitro to be later purified by chromatography. It is composed of three 
solutions: the protein mix contain all the proteins and enzymes necessary (minus the ribosomes); 
the energy mix contains all the chemical components, factors and co-factors and buffers for the 
proteins and enzymes to work; and the ribosome mix contains the purified ribosomes. The 
Expressway system (right) is based on an E. coli cell extract which contains a mixture of protein and 
enzymes, which is supplemented by buffers, amino acids and the T7 RNA Polymerase.  
 
 




3.4 mRNA and Protein Degradation  
To measure the protein yield for all constructs and both cell-free systems, each 
sample was incubated with either PUREfrex 1.0 and Expressway and the sfGFP 
fluorescence measured every 15 min for at least for 12 h. All the experiments were 
performed at least in duplicate.  
A few constructs were selected to represent the wide variation of sfGFP 
fluorescence obtained from the DNA library. The results can be seen in Figure 3.D 
(A and B), where a time-course of the sfGFP fluorescence is plotted (the core 
sequence is denominated as “WT”). Results for all variants are provided in 




Figure 3.D: Protein expression in the PURE and extract-based cell-free system using T7 
promoter variants. (A) PUREfrex System and (B) Expressway System. Fluorescence 
measurements of sfGFP expression were made every 15 min with the consensus promoter sequence 
(denoted as WT) and three variants.  




In the PURE system, the reaction took an average of 7.5 h (± 1.5 h) for saturation, 
while for the extract-based system it took an average of 3.5 h (± 0.5 h) to saturate. 
The first thing to mention about the plots is the difference in sfGFP fluorescence 
achieved from each variant. This shows that each mutation performed in the T7 
promoter affected the final levels of protein expression. When looking at each plot, 
they all have the same shape. This includes a first exponential phase in which 
protein production is happening. But as resources are used and they eventually ran 
out, the plot comes to a saturation point in which the protein production halts.  
A possible reason for the difference between both systems can be the rate of both 
DNA and RNA degradation. Since the PURE system is made from recombinant 
elements, the reaction is expected to last longer as it is free from DNase and RNase5 
elements; without having into consideration possible contaminants that could fall 
into the reaction while performing it. This feature would allow the reaction to last 
longer as the substrates for both the T7 RNA polymerase and ribosome (DNA and 
mRNA respectively) would degrade at a much slower pace. On the other hand, 
since the majority of the extract-based system proteins and enzymes come from 
the E. coli cytoplasm (except for the T7 RNAP), it could also include components 
that are part of the bacteria metabolism. Some of those elements could be 
nucleases that degrade mRNA and DNA, which in return would cause early 
termination of the protein synthesis due to lack of the two main substrates. Also, 
as the sequences have only five additional base-pairs upstream of the T7 promoter 




sequence, these linear DNA templates were probably digested by nucleases and 
lost the promoter sequence faster in the Expressway system. 
Furthermore, some promoter variants had higher final expression levels than those 
of the core sequence (e.g. 13G in PURE and 12A in Expressway). These 
improvements were not as common in previous studies with T7 promoter variants, 
whether in linear 6 or plasmid form 7.  
To better compare different variants and their expression levels, the final 
fluorescence numbers were normalized to that of the core sequence. This was done 
by averaging the two values obtained from each variant (duplicate experiment) and 
then dividing that value to that of the wild type. A value similar to 1 indicates a 
similar level of protein expression than that of the core sequence. A value above 1 
indicates a higher level of protein expression when compared to the wild type 
version and so on. When visualizing these normalized number in descending order 
(Figure 3.E, A and B), a spectrum of protein expression levels can be seen in both 
cases. This trait is ideal when trying to perform high throughput screening in a 
library of samples and for identifying an optimal candidate. Out of all the 51 
variants, some showed an improvement in expression levels, compared to the core 
sequence. In the PURE system, 12 of them did while in the extract-based system, 9 
did. The highest yield change averaged at a 1.5-fold increase for the PURE system 
(1.4 and 1.6 for each duplicate), while in the extract-based system it was a 3.6-fold 
increase (3.4 and 3.8 for each duplicate). 




Although the protein expression increment in some variants in the extract-based 
system was high, the absolute expression level in the extract-based system was 
lower when compared to that in the PURE system (Figure 3.J). For example, using 
the core “WT” sequence in the PURE system led to fluorescence levels 3 times 
higher than in the extract (Figure 3.D). This could be due to proteases, mainly 
absent in the PURE system, but not specifically removed in the extract. These 
proteases degrade proteins, including the newly synthesized sfGFP, and therefore 










Figure 3.E: Relative sfGFP fluorescence with 51 T7 promoter variants, normalized to that with the 
consensus sequence (indicated by the red line) for the PUREfrex System (A) and the Expressway 
System (B). Each variant was identified by the position and substituted base. For example, “17A” 
indicates a base at position -17 was substituted to adenine. The black bars represent the upper and 








3.5 Reproducibility  
To test the reproducibility level of both system, two sets of values were obtained 
from experiments performed on two different days. This reproducibility level was 
calculated by plotting both normalized values against each other. The R-squared 
value (R2), represents how close the data are to the fitted regression line. This line 
represents the relationship between the x-scale value and the y-scale value. The 
closer the R2 value is to 1, the more similar both values are and the more 
reproducible the data is. The regression line does not necessarily have to pass 
through the 0-0 origin value. This is due to the fact that this line tries to 
accommodate as much as possible passing through all the data points, and since 
the blank was already subtracted from each point, there is not a 0-0 value.  
The extract-based system had higher reproducibility levels (R2=0.97) between the 
two experiments than the PURE system (R2=0.74). (Figure 3.F, A and B).  
In the PURE system, proteins are often partially translated and consequently 
functionally inactive due to ribosome stalling on the mRNA 8. On the other hand, 
the Expressway system is made from bacterial extracts and therefore it contains 
additional elements that can rescue stalled ribosomes; such as the alternative 
ribosome-rescue factor A (ArfA), release factor 2 (RF-2) 9 and the elongation factor 
P (EF-P) 10,11. These factors, among others, could help increase the quality of the 











Figure 3.F: Scatter plots of the relative sfGFP fluorescence for each of the variants. (A and 
B) Scatter plots of duplicated experimental data for the PURE and extract-based systems, 
respectively. (C) Scatter plot of the averaged values (of both days) obtained with the PURE system 
against those of the extract-based system. The coefficient of determination R2 was shown in the 
upper left part of the plots. The blue line indicates the regression line.  
 
A previous study 5 pointed out that the PURE system could produce ~4-fold more 
protein than an E. coli extract-based system. Since some proteins in the PURE 
system were very likely incompletely translated or even non-functional and the 




reproducibility levels were not very high, our data shows consistency with the 
previous study by displaying approximately a 3-fold increase in protein expression 
levels compared to that with the extract-based system (Figure 3.J).  
These results also show that there is not much correlation between each variant’s 
promoter strength of both systems (Figure 3.F, C; R2=0.23), confirming our 
previous observation linked to the different compositions of each system. 
Although some outliers’ samples can be seen in the plot (more easily seen in Figure 
3.I), omitting these values will most likely result in different values for R2. In order 
to identify better if the outliers should be omitted or not, further experimental data 
should be obtained first, to confirm the reproducibility values obtained and to 
determine why they are outliers in the first place.  
 
3.6 Substitution Location within the Promoter Region 
To study the effect of the position of the substitutions in the variants, the data is 
also displayed as heat maps of relative protein expressions (Figure 3.G, A and B). 
This representation shows that most of the variants that show improvement in the 
levels of protein expression (higher levels than the core sequence) are the ones 
located in the upper region of the promoter. This region corresponds to the 
polymerase binding domain, where the T7 RNAP makes its first contact with the 
promoter sequence (position -17 to -13) 12. In contrast, substitutions that follow this 
mentioned region (-9 and -5 for PURE and -11 and -4 for the extract-based), 
significantly reduce the protein expression level. This is consistent with previous 




studies that show that bases around the -12 to -5 region, are crucial for the T7 RNAP 
to recognize the promoter sequence 7,13, and thus, substitutions introduced around 
this area are prone to interfere negatively with the protein-promoter recognition. 
Even further downstream of the regions already mentioned, substitutions affected 
more negatively to protein expression in both cell-free systems, but substantially 
more in the Expressway System.  
 
 
Figure 3.G: Heat maps of the relative sfGFP fluorescence of the 51 T7 promoter variants. In 
the PURE (A) and extract-based systems (B). The normalized data is also presented in Figure 3.E (A 
and B). Colours represent fold change in the final expression level relative to that of the consensus 
promoter.  
 
3.7 Effects of Extended Sequence Length  
As mentioned in Section 3.3, one of the reasons believed to affect the lower general 
yield of the extract-based system, along with the shorter time it takes to saturate; 




might be the presence of nucleases that could degrade the DNA (and mRNA) 
quickly by attacking the 5’ end where the promoter is located.  
To test this hypothesis further and investigate the behaviours of the variants, a new 
different type of DNA construct was produced. This new version included an 
additional 20 base-pair random sequence located upstream of the T7 promoter (at 
the 5’ end); and additional bases downstream the sfGFP gene (at the 3’ end). The 
sequence added at the 3’ end is that of the T7 promoter, to test if its presence can 
affect the overall protein yield. From this point, these new sequences will be 
referred to as “extended sequence” (Figure 3. H).  
Since the variants located in the regions -17 to -10 seemed to be more significant to 
the final protein expression levels (whether beneficial or deleterious), it was 
decided to only construct the extended versions of those variants.  
As done before with the non-extended sequences, a heat map of the normalized 
values of the new extended constructs was made (Figure 3.H). Overall, the 
fluorescence values of the variants decreased in most of the cases when being 
compared to the values of the core sequence.  
 






Figure 3.H: Schematic of the extended linear DNA templates and heat maps of the relative 
GFP fluorescence of 21 T7 promoter variants with extended base pairs at 5’ and 3’ ends. 
(A)The extended version features the core sequence (Figure 3.B) with extra only bases at the 5’-end 
(red); or with those plus extra bases at the 3’-end (dark blue). The sequence attached at the 3’-end 
contains a T7 terminator sequence. Each DNA sequence contains the consensus core sequence (or 
one of its 51 variants) (white), a ribosome binding site (RBS) (light blue) and an sfGFP gene (green). 
(B) For the PURE system (upper) and extract-based system (lower). Colours represent fold change 








This data shows that the extra bases had a more positive outcome for the core 
sequence (10-fold increase) that it had for the rest of the variants (average 4-fold 
increase) (Appendix, Section A.1, Table A.1.1.), therefore making the normalized 
values lower than those of the sequences without extra bases. A possibility for the 
decrease in these values would be a more stable binding of the T7 RNAP to the 
linear DNA due to the extra bases. As mentioned in Section 3.3, most substitutions 
located in the -17 to -10 region in the T7 promoter could have helped the T7 TNAP 
attach itself more securely to the DNA; so, it could be that the extra bases added 
at the 5’-end also had a similar, but lower, effect on the T7 RNAP, therefore 
cancelling the greater beneficial effects of the base substitution. However, the 
correlation between extended and non-extended sequences showed good values 
when it comes to the protein expression levels for both cell-free systems 
(Appendix, Section A.1., Figure A.1.3). This suggests that the gene expression levels 
by the T7 variants are consistent overall. In general, the regression line value shows 
a positive correlation between protected and unprotected samples, therefore 
proving that the extra bases protection was universal for all variants. 
 
3.8 Absolute Fluorescence Levels and Rate of Reaction  
Even though each extended sequence variant’s normalized fluorescence levels 
decreased, in general, when comparing the absolute expression levels between 
protected and unprotected samples, the fluorescence values increased more than 
4-fold on average for the extract-based system when having extra bases (Figure 3.I, 




A) (Appendix, Section A.1, Table A.1.1.). But for the PURE system, the sfGFP levels 
for the extended sequences were similar to those with no extra bases (Appendix, 
Section A.1, Table A.1.2.).  
 
 
Figure 3.I: (A) Boxplot of absolute sfGFP fluorescence for the normal and extended DNA constructs 
in the PURE and extract-based systems. (B) Boxplot of the rate of reaction from all DNA constructs. 
The rate was calculated as the slope of a logistic curve fitted to individual fluorescence time-course 
data. The black thick line represents the median, and the box shows the first and third quartile. 
The upper and lower whiskers indicate 50% of the values higher or lower than the median, 
respectively. Black dots are outliers. Notes: (A) fluorescence expression levels (a.u.) are the 
fluorescence levels (numbers) detected from the sfGFP protein. This correlates to the amount of 
mRNA being transcribed and therefore, to the strength of the promoter which participates in said 
transcription. (B) rate of reaction is the speed at which a reaction takes place, in this case, the speed 
at which the sfGFP protein is being produced. This is calculated by dividing the change in 
fluorescence values in a specific amount of time. The faster a protein is being produced, the higher 
this number will be.  
 




Additional bases on each end of the extended sequenced could help to postpone 
the degradation by nucleases of the T7 promoter sequence as well as some coding 
regions of the sfGFP gene in the Expressway system. Since the PURE system does 
not contain DNases as it is made out of purified components, the added bases do 
not provide significant extra protection and therefore the expression levels remain 
the same. One way to test this theory could be to intentionally add nucleases to 
the PURE system and text whether the extended sequences do help in this case.  
Second, the T7 terminator introduced on the 3'-end of the extended sequence 
could have also helped in the increase of protein yield. It has already been reported 
that the T7 terminator improves the stability of transcribed mRNA in the E. coli-
based cell-free system by improving the expression yield more than 3-fold 14. To 
determine if the T7 terminator did influence the increase in protein expression, 
another construct was made with only extra added bases at the 5’-end. For the 
extract-based system, the results showed a small increase in protein expression 
(Figure 3.J, A), suggesting that even though the T7 promoter might help with the 
mRNA stabilization in this system, it is less significant than the extended random 
sequence at the 5’-end. In the case of the PURE system, the effect of T7 terminator 










Figure 3.J: Time-course of GFP fluorescence over a period of 12 h using the T7 consensus 
sequence. Three different linear constructions, the core sequence (red squares), core sequence 
with extra bases at 5’-end (green diamonds) and core with extra bases at 5’ and 3’-ends (blue 
triangles). (A) GFP expression in the extract-based system, and (B) the PURE system. 
 
 
When looking at the rate of protein expression (Figure 3.I, B) of the normal and 
extended constructs in both cell-free systems, the extended sequence in the 
extract-based system showed a major increase compared to the non-extended 
sequence (1.3/h and 0.3/h respectively). In the PURE system, only a small increase 
was observed (0.8/h for extended and 0.6/h for non-extended).  
When the rate and absolute expression levels (Figure 3.I) are plotted against each 
other, they show different modes of protein expression dynamics (Figure 3.K, A 
and B). In the case of the PURE system, the plot shows an exponential-like profile; 
in the low expression region (weak promoter variants) whereas, in the high 
expression region (strong promoter variants), the variants showed a wide range of 




expression rates, although it appeared to have a limit of maximum expression level 
around at 12,500. On the other hand, when it comes to the extract-based system, 
the plot shows a diagonally-rotated profile. That is, if we take the plot from the 
PURE system and rotate in a diagonal (from lower left to upper right), the plot 
from the Expressway System appears. The rate of reaction seems to have a limit 
around 2/h while several variants were showing no fluorescence and thus very low 




Figure 3.K: Scatter plots of the rate of protein expression against the absolute GFP 
fluorescence for the PURE (A) and extract-based systems (B). The same data as Figure 3.J. was 
used for the plots. Blue and red circles indicate the data for T7 promoter variants with the core and 
extended sequences, respectively. 
 
 




To summarize the results obtained during the experimental part of the chapter: 
- T7 promoter variants were tested in two different cell-free systems: extract-
based and from purified components. The results showed a wide range of 
protein expression levels. Some of them showing higher levels than the core 
sequence, 1.5-fold and 3.6-fold increase in the PURE and Expressway system 
respectively.  
- The reproducibility level of both systems was quite different. The extract-
based system showed an R2 value of 0.97 while the PURE system had a value 
of 0.74. This is probably due to the lack of ribosome rescue systems in the 
PURE system, as opposed to the extract-based one. This causes early 
termination of proteins and decreases the reproducibility rate.  
- The mutations located around the -17 to -13 promoter region were most 
beneficial. This region is the polymerase binding site to the promoter. While 
mutations around the -11 to -4 region were mostly detrimental. This region 
is the polymerase recognition site of the promoter.  
- Extension of the DNA constructs was performed and their protein levels 
tested. In the PURE system, the fluorescence levels stayed mostly the same 
and so did the rate of reaction (from 0.6/h to 0.8/h). But in the Expressway 
system, there was a 4-fold increment in the fluorescence level and the 
reaction rate raised from 0.3/h to 1.3/h on average. The extended sequence 
most likely helps delay the degradation of the DNA and mRNA by nucleases 
found in the cell-extracts, which are not present in the PURE system. 




3.9 Cell-Free Systems Mathematical Models  
Each sfGFP measurement time-course curve was fitted with model equations and 
the parameter values, 𝑘𝑘𝑇𝑇𝑇𝑇,𝑘𝑘𝑇𝑇𝑇𝑇,𝑑𝑑𝐷𝐷 ,𝑑𝑑𝑅𝑅  and 𝑑𝑑𝑃𝑃  estimated. This systems approach 
was performed to better understand the dynamics of protein expression in cell-free 
systems. Cell-free systems are considered a grey-box model, there is previous 
knowledge to feed the model.  A model of protein expression in a cell-free system 
can be described with the following equations (Equation 3.A, 1-3) 15–17. A modified 
equation (Equation 3.A, 3* instead of 3), was used instead, to fit the PURE system 




=  −𝒅𝒅𝑫𝑫[𝑫𝑫𝑫𝑫𝑫𝑫] 
(2) 𝐝𝐝[𝐦𝐦𝐦𝐦𝐃𝐃𝐃𝐃]
𝐝𝐝𝐝𝐝
= 𝒌𝒌𝑻𝑻𝑻𝑻[𝑫𝑫𝑫𝑫𝑫𝑫] − 𝒅𝒅𝑹𝑹[𝒎𝒎𝑹𝑹𝑫𝑫𝑫𝑫] 
(3) 𝐝𝐝[𝐏𝐏𝐏𝐏𝐏𝐏𝐝𝐝𝐏𝐏𝐏𝐏𝐏𝐏]
𝐝𝐝𝐝𝐝






) − 𝒅𝒅𝑷𝑷[𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷𝑷] 
 
Equation 3.A: Equations used for the mathematical models of protein expression for both 
cell-free systems. For the extract-based system, the equations used were 1 through 3; but for the 
PURE system the equations used were: 1, 2 and 3*. 
 
In these equations, [DNA], [mRNA] and [Protein] are the concentrations of DNA, 
mRNA, and protein in the cell-free reaction. kTX and kTL are reaction constants for 
transcription and translation, respectively. dD, dR, and dP are degradation constants 




for DNA, mRNA, and protein, respectively. To estimate the system parameters, the 
inputs (concentration of template DNA) were varied and changes in protein 
expression levels were measured 16. However, it is also possible to modify other 
parameters by adding/removing system components. For example, the addition of 
GamS (RecBCD nuclease inhibitor) to a crude extract-based cell-free system 
prevents DNA degradation 18, which corresponds to decreasing 𝑑𝑑𝐷𝐷 in the equation 
(1) above (Equation 3.A). In this model, the transcription rate 𝑘𝑘𝑇𝑇𝑇𝑇 was modified 
and changes in protein expression levels measured. It is known that alterations to 
the consensus promoter sequence affect the binding affinity of T7 RNA polymerase 
(RNAP) to the promoter and thus changes the protein expression level 7,19,20. 
Protein expression dynamics of these two types of cell-free systems are considered 
to be different owing to the lack of supplementary components in the PURE system 
4,8,21. So it is possible that the two cell-free systems would give different protein 
expression patterns in response to the varied transcription rates 𝑘𝑘𝑇𝑇𝑇𝑇.  
 






 Figure 3.L: Histograms of estimated parameter values. (A) Transcription constant 𝑘𝑘𝑇𝑇𝑇𝑇, (B) 
translation constant  𝑘𝑘𝑇𝑇𝑇𝑇 , (C-E) degradation constants for DNA  𝑑𝑑𝐷𝐷 , mRNA  𝑑𝑑𝑅𝑅 , and protein  𝑑𝑑𝑃𝑃 , 
respectively. Note that different models were used to fit the parameters for the PURE and extract-
based cell-free systems.  
 
The fitted parameter values were consistent with the possible mechanisms behind 
the observed protein expression discussed in previous sections. The transcription 
parameter 𝑘𝑘𝑇𝑇𝑇𝑇  showed a wide distribution (over three orders of magnitude) 
(Figure 3.L, A) since each substituted base in the T7 promoter sequence changes 
the binding affinity of the T7 RNAP. On the opposite side, most of the translation 
parameter 𝑘𝑘𝑇𝑇𝑇𝑇  (Figure 3.M, B) fit within the same order of magnitude. The 
DNA/mRNA degradation parameters, 𝑑𝑑𝐷𝐷  and  𝑑𝑑𝑅𝑅 , between the two cell-free 
systems are different (Figure 3.L, C and D). The extract-based system shows a wider 
distribution than the PURE system, which had only one single peak. This could 
indicate that both the DNA and mRNA degrade very slowly in the PURE system, 




as it lacks nucleases; but since they are present in the extract-based system, both 
DNA and mRNA are quickly digested. In both systems, the protein degradation 
value 𝑑𝑑𝑃𝑃 (Figure 3.L, E) was close to zero. This is consistent with the experimental 
data as the measured GFP fluorescent signal did not decrease over a long period 
(Figure 3.D and Appendix, Section A.1, Figure A.1.1.).   
When looking at the histograms of figure 3.L, few parameter values, especially 
those of degradations are in the negative range. Since the mathematical model 
tends to change the parameters linearly, it is possible that if some of experimental 
observed values are quite close to 0, the error range of the model can go into 
negative values, even though it is not biologically possible. The presence of outliers 
also makes the error range bigger. Due to the simplicity of the, modifications are 
needed to include the characteristics of complex non-linear system and also setting 
up rational upper and lower limits. 
Altering the promoter sequence should correspond to modifying the transcription 
parameter 𝑘𝑘𝑇𝑇𝑇𝑇, since the substitution in bases of the promoter affects directly the 
binding affinity of the T7 polymerase to the promoter, and therefore the 
transcription process gets influenced. Consequently, to simulate the different 
protein expressions levels by all the promoter variants, the parameter values were 
fitted for the consensus promoter sequence and only 𝑘𝑘𝑇𝑇𝑇𝑇 was changed from zero 
to the maximum fitted value.  
The simulated protein expression in both systems is shown in Figure 3.M (left 
column for the extract-based system and the right column for the PURE system). 




The simulation reproduces the behaviour of the protein expression in both 
systems; such as the halting of protein expression after 3-4 h in the extract-based 
system (Figure 3.M, A). For figure 3.M, the parameter Ktx was varied while the other 
remained fixed, since the Ktx represents the transcription constant and therefore is 
the value that most directly represent the effect the mutations on the T7 promoters 
had. The other parameters, can only be estimated and would have to be 
experimentally obtained to be able to vary then in the model more accurately.  
When calculations were made for the rate of reaction and the maximum protein 
expression level (Figure 3.N), by fitting the simulated data to a logistic curve, it 
displayed a similar profile as shown in Figure 3.K. 
The simulation which was performed for the PUREfrex system data was done with 
a modified version of the equation (Equation 3.A; 1, 2 and 3*) instead. When 
performed using the same equations used for the extract-based system (Appendix, 
Section A.1, Figure A.1.4), the temporal expression patterns obtained matched the 
observed temporal expression profiles, but it did not reproduce the unique scatter 
pattern in Figure 3.K, A. This result implied that some factors were not being taken 
into consideration in the already mentioned theoretical model.  
 






Figure 3.M: Simulated cell-free protein expression. Simulated cell-free protein expression of 
the extract-based system (A) and the PURE system (B). DNA concentration (top), mRNA 
concentration (middle), and protein expression (bottom) were shown. The parameter 𝑘𝑘𝑇𝑇𝑇𝑇  was 
varied (colours) while the other parameters were fixed. A modified equation (see text for details) 
was used to simulate protein expression for the PURE system. 
 
As mentioned in Chapter 1, the main limitation concerning cell-free systems is the 
limited amount of energy sources and the accumulation of inhibitory by-products 
5. As further proof of this issue, when a cell-free reaction is being fed energy 
molecules and by-products are eliminated through dialysis, the final protein yield 
can increase up to 72-fold 22. Also, recycling of inorganic phosphate can improve 
the total protein yield 23. All these issues should be considered as negative feedback 




to the protein production, so to incorporate this factor, the last equation was 
modified so that the term (1 − [𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃]/𝐾𝐾) represents the negative feedback. The 
proteins stop being produced as the protein expression level reaches the maximum 
defined by the carrying capacity constant 𝐾𝐾. Using the equations (1), (2), and (3*), 
the model was refitted for the experimental data to estimate the system 
parameters 𝑘𝑘𝑇𝑇𝑇𝑇,𝑘𝑘𝑇𝑇𝑇𝑇,𝑑𝑑𝐷𝐷 ,𝑑𝑑𝑅𝑅 ,𝑑𝑑𝑃𝑃, and the carrying capacity 𝐾𝐾. Figure 3.N (B) shows 
the simulation results performed with equation 3* for PURE and 3 for Expressway, 
for the rate of reaction against the maximum expression level.  
In the extract-based system, mRNA was produced very rapidly and peaked around 
at 30 min after the start of the reaction and then decreased exponentially since the 
template DNA was degraded by nucleases present in the reaction mixture, and 
eventually reached to the base level at around 4 h. Whereas in the PURE system, 
the template DNA gets degraded at a much slower rate, resulting in the rate of 
mRNA production to be slower. Most of transcribed mRNA was still present even 
after 12 h.  
 






Figure 3.N: Scatter plots of the rate of protein expression against the maximum protein 
expression. The values were obtained by fitting the simulated data in Figure 3.N. (A and B) to a 
logistic curve. 
 
When the parameter 𝑘𝑘𝑇𝑇𝑇𝑇 was linearly varied, the protein expression yield in the 
extract-based system also changed linearly because there were no nonlinear terms 
in the model equation. In the PURE system though, the response to this linear 
change was nonlinear because of the negative feedback already explained. This 
makes the system very sensitive to small changes in parameter values, which 
implies that the maximum expression levels could be biased to the higher region. 
Combined time-course plots for both cell-free systems (Appendix, Section A.1, 
Figure A.1.2) show similar patterns as the simulated cases in Figure 3.M, especially 
the cases with the extended sequences. Although it was not possible to 
experimentally measure 𝑘𝑘𝑇𝑇𝑇𝑇  (the binding affinity of T7 RNAP to each promoter 
variant sequence), these results may also validate the models. 




3.10 RNA Spinach Aptamer 
To look more deeply into the temporal dynamics of the mRNA, a final DNA 
construct was made. This consisted of two of the typical components, T7 promoter 
and RBS, but with an added Spinach aptamer (Figure 3.O), providing green 
fluorescence in the presence of a specific fluorophore, such as 3,5-difluoro-4-
hydroxybenzylidene imidazolinone (DFHBI) 24,25. Due to the green fluorescence of 
the aptamer, it was not possible to include the sfGFP gene in the DNA template as 
both peaks of emission wavelength overlap. Only a few constructs were selected 
for this experiment: the consensus T7 promoter sequence, two strong variants (17A 





Figure 3.O: Linear DNA template with Spinach aptamer. The sequence contains the T7 
promoter or its variant, RBS, and Spinach aptamer. It does not contain any genes to be expressed.  
 
The measured mRNA concentration profile (Figure 3.P) was similar to the 
simulated mRNA concentration in both cell-free systems. It should be noted that 
no experimental information about mRNA concentration was included when 




fitting the differential equations to the protein expression data. Nevertheless, the 
time-courses of mRNA concentration in the simulation reproduced those in the 
experiments. This result validates the theoretical models as a representation of the 
dynamics behind the cell-free protein expression.  
Although it is known that the fluorescence of DFHBI molecules are sensitive to pH 
changed in the reaction, the pH was not monitored in this case. Therefore, the 
fluorescence levels obtained might not be fully representative of the mRNA levels.  
But since cell-free system try to mimic reactions that take place inside a cell, it is 
probable that the pH of the reaction did not vary too much outside a considerable 
range.  
 
Figure 3.P: Fluorescence measurements of Spinach aptamer with the consensus promoter 










In this chapter, the behaviour of single base-pair substituted variants of the T7 
promoter in two different cell-free systems was characterized. Although further 
understanding of cell-free protein expression mechanism at the molecular level is 
required to fully explain the complex expression patterns observed here, the 
experiments revealed different modes of protein expression dynamics in the PURE 
and extract-based systems, which were confirmed by analytical models. It was 
shown that even simple time-course measurement data of cell-free systems 
contains rich information and the combination with systems approach helps 
uncover the dynamics behind it.  
These observations illustrate that the two cell-free systems have different limiting 
factors for improved protein expression. In the extract-based system, the protein 
expression was primarily limited by the availability of template DNA and 
transcribed mRNA. As they were quickly digested by nucleases in the reaction 
mixture, any method to prevent or slow down the degradation would improve the 
yield. For example, the addition of salmon sperm DNA could “occupy” the 
nucleases and slow down the degradation of the DNA as an easier and maybe more 
affordable way. But whenever possible, it is always better to keep the experimental 
reactions a simple as possible.  
This is consistent with the experimental results in previous sections that the 
extended sequence showed significantly improved yield. In the PURE system, the 
limiting factors lie within the mRNA-protein translation. In the current form, the 




negative feedback term in the model is still ambiguous and needs further biological 
elaboration. However, it has been shown that supplementing certain components 
like amino acids, tRNAs, magnesium, and proteins involved in ribosome recycling 
to the PURE system improves the final yield 5. This is consistent with our model 
prediction.   
As it has been shown before by previous studies, the systems approach has proven 
effective for engineering synthetic genetic circuits in the cell-free system 16,26. This 
approach can also be effective to disentangle the complex dynamically-interacting 
factors in the cell-free systems and obtain deeper insights that are otherwise 
difficult to capture.  
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Chapter 4. In vitro display techniques and cell-free 
systems: a refined and clean method for in vitro selection 
of drug targeted peptides 
 
4.1 Chapter 4 Aims and Summary 
Cell-free transcription-translation systems are excellent tools for protein 
expression. The PURE system, based on recombinant elements, has been shown to 
present high purity and high yield, and therefore it has been used for expression of 
both native and de novo proteins, as well as in experiments involving various 
display methods to select for functional polypeptides 1–3. This chapter builds upon 
the knowledge gained in Chapter 3 to extend the use of cell-free systems with high-
throughput screening methods. 
A refined method was developed that involved the use of the PURE cell-free system 
and a display methodology for the preparation of stable mRNA and cDNA-peptide 
conjugates. The method was further validated for its use for in vitro selection 
processes. The conjugates of peptide-mRNA/cDNA obtained reached a formation 
efficiency of 40% (conjugation efficiency range is between 5% to 40% 4). This was 
followed by precise gel purification to minimize the existence of carry-over of 
components, from the translation system, in the conjugate samples. Strict 
purification steps allowed for posterior clean and efficient sequence screening of 
the random peptide library. To test the efficiency of the method, the anti-FLAG M2 
antibody was selected as a target for process validation. With a starting library of 
approximately 1.7 x 1012 random sequences and after 4 rounds of selection with two 




defined display methods: mRNA and cDNA display; high-throughput sequencing 
showed enrichment of the FLAG epitope DYKDDD as well as a consensus FLAG 
epitope motif DYK(D/L/N)(L/Y/D/N/F)D. Furthermore, both mRNA and cDNA 




Figure 4.A: Summary of the experimental approach carried out for Chapter 4. From the 
bottom left corner, the 1st round of selection starts the experiment and it ends with the 4th round. 
Each round uses the PURE system for the translation step, meticulous cleaning of the constructs 
and two different display methods: mRNA and cDNA display. The selection process is performed 
using Anti-FLAG antibody beads. The final samples are sent for MiSeq sequencing and the results 
analysed. 
  




4.2 Method Overview 
The experiments carried out encompassed the development and optimization of 
two display methods: mRNA and cDNA display; utilizing a commercial version of 
the PURE protein expression system (PUREfrex 1.0) 5,6. During each round of 
selection, approximately 1,000 peptides were sequenced.  
One of the important features of this method is the stability and high purity of 
both the mRNA-tag and mRNA/cDNA-peptide constructs, mainly due both the 
use of the PURE system during the translation step (as it is a nuclease- and 
protease-free environment) and the two-step gel purification performed (as it 
eliminates the majority of by-products).  
The elimination of specific components and by-products (RNA, enzymes, 
polyamines, cofactors, and ions) from the samples during the selection rounds 
minimized non-specific interactions; with either the mRNA and cDNA-peptide 
conjugates or with other components; especially during the binding assay steps. 
To test the validity of the method, a short FLAG epitope (DYKDDDDK) was 
selected due to its already known crystal structure 7. Several display methods 
(phage, DNA and ribosome display) have already been successful in enriching the 
FLAG epitope motif 8–11. One round of selection takes a minimum of 1 day (24 h) 
(Figure 4.B), which means the whole procedure can be completed in 1 week. 
Usually, for mRNA display, one round of selection takes around 2-7 days depending 
on the type of target. The high-throughput sequencing was performed after 




collecting the DNA library samples from each round, to characterize the sequence 




Figure 4.B: Schematic overview of one round of selection and the estimated time of each 
step. The initial round starts with a DNA library (designed with randomized sequences) that 
includes a T7 promoter upstream and a leader sequence (complementary to the puromycin-FITC-
DNA tag) downstream. The DNA library is in vitro transcribed to an mRNA library and later ligated 
to the puromycin-FITC DNA tag. The resulting product purified with a gel and translated using the 
PUREfrex 1.0 System. The resulting mRNA-peptide conjugate is purified a second time again by gel 
electrophoresis. The purified product could be used as it is (mRNA Display) or reverse transcribed 
(cDNA Display). Both products forego a binding assay against anti-FLAG M2 magnetic beads and 
the selected conjugates are further reverse transcribed to go into another round and later on, 
sequenced using the Illumina MiSeq system. Preparation time (hours) for each step is shown in red 
with exception of MiSeq sequencing (5 days) carried out only after all samples from all round were 
obtained. 




4.3 DNA Library Design with Random Sequences  
To oversee the trajectory of various sequences in each round, two different DNA 
libraries were designed. The ‘FLAG-random library’ contained a fixed sequence for 
the first five amino acids of the FLAG epitope (DYKDDDDK); followed by three 
consecutive degenerate “RRN” codons corresponding to seven amino acids (Asn, 
Lys, Asp, Glu, Ser, Arg and Gly) (Appendix, Section A.2, Figure A.2.1). The ‘10aa-
random library’ contained ten degenerate codons (“VNN” and “NNY”) which 
corresponded to 16 and 17 different amino acids, respectively (Appendix, Section 
A.2, Figure A.2.1). The number of different sequences in both FLAG-random and 
10aa-random libraries was 343 and 1.7 x 1012, respectively. The FLAG-random library 
was used as a positive control to confirm the enrichment of the full FLAG epitope 
sequence in the early rounds. On the other hand, the 10aa-random library was used 
to validate the performance of the display method by exploring a wide range of 
random sequences to find several suitable ones that could bind to the anti-FLAG 
M2 antibody.  
Since this method was used with the PURE system, both DNA libraries contained 
upstream a T7 promoter and ribosome binding site (RBS). The leader sequence at 
the 3’ region was complementary to the puromycin-FITC DNA tag for an efficient 
ligation. The only difference between the two libraries was the randomized 
sequence regions.  
  




4.4. T7 RNAP In vitro Transcription and T4 RNA Ligation 
Following the construction of both DNA libraries, in vitro transcription with T7 
RNA Polymerase was performed. After a purification step, the mRNA construct 
was ligated to the puromycin-FITC DNA tag with T4 Ligase enzyme. The ligation 
was carried out by the Y-ligation method 12 to connect the 3’ end from the single-
stranded mRNA construct to the phosphorylated 5’ end of the DNA tag (Appendix, 
Section A.2, Figure A.2.2). The ligation procedure was confirmed by running the 
ligated products on 6 % polyacrylamide TBE gel with 8 M Urea and visualizing the 
band shift using SYBR Gold staining for the mRNA molecule and FITC fluorescence 
detection of the puromycin-FITC DNA tag (Figure 4.C).  
After the ligation procedure, around 50% of the mRNA molecules were attached to 
the Puromycin-FITC DNA. The final product mRNA-tag product was further 
purified by gel using electroelution and ethanol precipitation to eliminate 
unligated products. The elimination of free non-ligated Puromycin-FITC DNA tag 
was important for the posterior translation of the mRNA-tag product since 
puromycin can interfere with the ribosomes.  





Figure 4.C: Puromycin-FITC DNA tag ligation gel images. Image of ligated samples resolved in 
6 % polyacrylamide TBE with 8 M Urea gels with both SYBR GOLD staining and isothiocyanate 
fluorescence (FITC). The gels show both the FLAG-random and 10aa-random libraries samples with 
and without (negative control) the ligation process.  
 
4.5 PURE system in vitro Translation Optimization 
The recovered mRNA-tag from section 4.4 was posteriorly subjected to in vitro 
translation, to form mRNA-peptide conjugate constructs, using the commercial 
version of the cell-free PURE system, PUREfrex 1.0. The PUREfrex kit is known, as 
discussed in chapter 3, for its high purity as it does not contain nucleases and 
proteases and therefore is adapted for any display methods. The lack of nucleases 
already gives an important advantage for mRNA and cDNA display methods as it 




allows for strong stability of the conjugates since their degradation in the reaction 
mixture is minimal. Since display methods and selection processes occur during 
the span of several days, the elimination of degradation, whether it is for 
nucleotides or peptides, is of high importance. Another important aspect of the 
PURE system is the high protein yield even if the rate of product formation 
depends greatly on other aspects, like incubation time and co-factors 
concentration. These conditions, if optimized, could help promote the efficient 
incorporation of the puromycin into the stalled ribosome at the mRNA-DNA 
border. Previous studies have tackled this by introducing rare codons at the 3’ end 
2 or by using long linkers in the puromycin-DNA tag 13. So in this study, a rare GGA 
codon was placed at the 3’ end and a polyA (18 nt) included in the puromycin-FITC 
DNA tag (Appendix, Section A.2, Figure A.2.2).  
But even with these optimizations, as already mentioned, more can be done in 
terms of the incubation conditions. So before continuing with the selection round, 
a series of experiments were performed to optimize this process by testing 3 sets of 
different conditions in the translation reaction with the PURE system. The sample 
used for the optimization was the purified 10aa-random library mRNA-tag, and the 
parameters tested were: translation time, salt mix concentration (KCl and MgCl2), 
and incubation time after salt addition.  
The total incubation (translation) time reflects the time for the ribosomes to 
prepare and perform the translation of the coding region, which since it lacks a 
STOP codon, makes the ribosome stall at the 3’ end of the mRNA. Since the optimal 




incubation temperature for the PUREfrex 1.0 System is 37 °C, that parameter was 
not changed and stayed the same. What was first tested was the initial incubation 
time before the addition of the salt mixture; from 0 to 60 minutes. It was found 
that after just 5 min, already 40% of the samples were translated; and further 
incubation did not increase significantly this number (Figure 4.D; A).  
 
 
Figure 4.D: Gel images of the mRNA-peptide conjugate formation under various 
translation conditions. (A) The difference in length of translation before salt addition. The 
numbers indicate different incubation time (in minutes) carried out at 37 degrees Celsius.  (B) The 
difference in salt concentrations with original concentration (100%) as 750 mM KCl, 65 mM MgCl2 
used in previous studies 13,14 (C) Difference in lengths of incubation time (in minutes) after salt 
addition. 
 
The second thing that was tested was the concentration of salt mix to be added to 
the reaction after the initial incubation. Previous studies showed that high 
concentration of KCl improved the accessibility of the peptidyl-tRNA (bound to 
the ribosome) to the puromycin 15, and so this salt addition step has been adopted 
in recent mRNA and cDNA display methods 13,16,17. If the salt mixture is not added, 




conjugate formation is less than 10%, however, adding 32.5 mM MgCl2 and 375 mM 
KCl to the mixture increases the formation rate to above 40% (Figure 4.D; B). 
Finally, the last parameter tested was the incubation time post-salt addition, as it 
helps the puromycin to react with the peptidyl-tRNA to form a covalent link 
between mRNA and peptide. A total of 60 minutes of incubation at 37℃ after 
adding the already mentioned salt mixture, yielded a conjugate formation rate of 
48.5% (Figure 4.D; C).  
After the optimized conditions were tested and confirmed, the mRNA-peptide 
conjugates were synthesized from both libraries mRNA-tag samples. Gel 
purification followed with an SDS-Urea polyacrylamide gel.  
 
4.6 Reverse Transcription for cDNA Display and Verification of 
mRNA-peptide and mRNA/cDNA-peptide Conjugates  
With the purified mRNA-peptide conjugates, reverse transcription (RT) was 
performed to obtain mRNA/cDNA-peptide conjugates, for cDNA Display. 
Purification was also performed on the resulted samples.  
Verification for both mRNA-peptide and mRNA/cDNA-peptide samples was done 
in two different ways: trypsin digestion and western blot. Trypsin digestion was 
performed since it targets lysine (Lys) and arginine (Arg) residues, and all peptides 
have 3 Lys resides close to the C-terminus region, where the DNA tag is (Appendix, 
Section A.2, Figure A.2.1). Therefore, after the digestion, the peptide is cut from the 
nucleotide part of the conjugate and a band shift in a Urea-SDS PAGE gel should 




be visible. The digestion was applied for the 10aa-random mRNA-tag and mRNA-
tag-peptide products.  
After the digestion was performed for 30 min on the translated product, the upper 
band on the gel disappeared, indicating that the band corresponded to the mRNA-
tag-peptide conjugate (Figure 4.E; A).  
As for the western-blot, it was performed on the products (with and without RT) 
derived from the fixed FLAG-control library (Figure 4.E; B). FITC fluorescence 
signal was observed from the membrane transferred samples and the 
chemiluminescence signal was detected using an anti-FLAG-HRP antibody. Both 
signals overlap at the same position indicating the formation of peptides and their 
attachments to both mRNA-tag and mRNA/cDNA-tag samples. Under SDS-PAGE 
conditions, translated samples migrate more slowly (upper bands) than mRNA-tag 
products, as the peptide attachments make them heavier and bigger; but double-
stranded mRNA/cDNA-peptide conjugates migrate faster than the single-stranded 
mRNA-peptide conjugate, due to the double charge from the phosphate backbone 
(two nucleotide strands). 
 





Figure 4.E: Confirmation of mRNA/cDNA-peptide conjugates. (A) Trypsin digestion of 10aa-
random library mRNA-tag and mRNA-peptide conjugate products. (B) Western blotting of FLAG-
random library mRNA-tag, mRNA-peptide and mRNA/cDNA-peptide conjugate products. For the 
western blot, the detection was done using FITC fluorescence for the DNA-tag located in all 
conjugate products (left); and chemiluminescent signal for the FLAG epitope. 
 
4.7 In vitro Selection Assay and Reverse Transcription PCR 
To validate the performance of both mRNA and cDNA display methods, a selection 
assay was conducted using anti-FLAG M2 antibody magnetic beads.  
To further test the selection ability of both methods, the two libraries (FLAG-
random and 10aa-random) conjugate peptide samples were mixed with a 1:10,000 
molar ratio respectively. After the binding selection process was finished and 
several washing steps were carried out, the recovered beads were directly subjected 
to reverse transcription PCR (RT-PCR) to produce cDNA sequences of the selected 
samples in the binding assay. Before this though, a test was done to determine the 
optimal number of cycles of the RT-PCR to avoid over-amplification of the 




samples. For each round of selection, the amplified product was checked every 5 
cycles (from 0 to 35 cycles) (Appendix, Section A.2, Figure A.2.3).  
Amplified DNA products, from both display methods, started being seen at the 
15th cycle and were saturated at the 20th cycle. When looking at the band intensity 
of the 15th RT-PCR cycle, the final rounds showed a higher intensity, proving that 
the quantity of sample attached to the beads was higher as the rounds progressed. 
A non-specific band, probably from non-specific binding of primers, appeared in 
every lane at around 200 bp, but since it remained weak in intensity throughout 
multiple rounds, the rounds of selection were continued. The optimal number of 
cycles (for both display methods) for rounds 1 and 2 were settled at 20 cycles and 
for the 3 rd round, 16 cycles.  
 
4.8 High-throughput MiSeq Sequencing Analysis 
All the sequencing data from the MiSeq system (performed by the sequencing 
department of the Tokyo Institute of Technology) were collected and analysed 
with a Perl script to extract the coding regions. The extracted sequences were 
further evaluated by the FastAptamer software 18, to count and rank the unique 
sequences based on their total number of reads. The top 50 most abundant 
sequences from each round, of mRNA display, were further explored to confirm 
the enrichment of FLAG epitope during the selection. Sequences from the FLAG-
random library resulted in a fixed aspartic acid (D) amino acid residue at the 6th 
position just after the first round of selection; followed by two positively charged 




arginine (R) and lysine (K) residues at the variables 7th and 8th positions 
respectively (Figure 4.F; A). For the 10aa-random library, after three rounds of 
selection, the sequences settled on a conserved core FLAG motif (DYKxxD) in two 
different positions: one starting at position 2 and the other at position 5 (Figure 
4.D; B). This binding motif has been reported previously to have a strong affinity 
to anti-FLAG M2 antibodies 8–11. Further analysis was put into those two conserved 
motifs and a few features were found; namely a weakly conserved glutamic acid (E) 
immediately before the FLAG motif, (D/L/N) and (D/F/L/N/Y) located between 
the conserved lysine (K) and aspartic acid (D) with over 80% probability followed 
by a downstream proline (P) residue (Figure 4.F; C and D).  
The next analysis performed was the enrichment rate of various FLAG motifs 
detected through both displays methods and their comparison. This step is 
important to determine the efficiency of both display methods.  
Although from the 1st round to the 3rd, the samples sequenced were obtained 
directly from the magnetic beads, for the final round, the 4th, a competitive elution 
with a FLAG peptide (DYKDDDDK) was done by increasing the concentration 
during the elution process, and the samples obtained sequenced as normal. 
 




Figure 4.F: Consensus logo of top 50 abundant sequences from each selection round of 
mRNA display. A round-by-round consensus logo was created using Weblogo3 19 using the top 50 
most abundant sequences based on their RPM. Sequence logos derived from FLAG-random library 
(A), 10aa-random library (B), core FLAG motif bearing sequences within the 10aa-random library 
(C and D) are colour-coded based on their charge (negatively charged: red, positively charged: blue 
and others: black). For the 4th round, consensus logo was created using the sequences eluted with 
highest FLAG epitope tag concentration (100 μg/ml). 
 
The expected frequency for the full FLAG epitope sequence (DYKDDDDK) in the 
initial library (zero round) was 0.29 reads per million and it was indeed not 
detected (1,768,526 sequences). But as the rounds advanced, the observed 
frequency went up, to 1,479 and 198 reads per million (3rd round) for mRNA and 
cDNA display, respectively (Figure 4.G; A). When focused on the consensus FLAG 
motif (DYKDDDxx) with a fixed aspartic acid (D) at the sixth position, the 




enrichment numbers were 261,982 and 31,689 reads per million (for mRNA and 
cDNA display, respectively) (Figure 4.G; B).  
 
 
Figure 4.G: Round-by-round read counts for the enriched FLAG motifs. Sequence reads from 
initial library (0th) to 3rd round selection, 4th round with competitive elution with FLAG epitope 
tag at 4, 20, 100 μg/ml concentration and remaining beads are counted for (A) DYKDDDDK, (B) 
DYKDDDxx, (C) xDYK(D/L/N)(D/F/L/N/Y)Dxxx and (D) xxxxDYK(D/L/N)(D/F/L/N/Y)D 
sequences. For each round, read counts for mRNA display method (orange) and cDNA display (dark 
blue) are presented side-by-side. 
 
This suggests that the 6th position is important as it enhances the binding of the 
sequence to the anti-FLAG M2 antibody. A majority of the sequences that were 
collected derived from the 10aa-random library, especially one type of consensus 
FLAG motifs: DYK(D/L/N)(D/F/L/N/Y)D, located at two different positions 
(Figure 4.G; C and D).  




The highest enrichment of FLAG motifs was not seen from the sequences on the 
beads but from the elution done with the competitor FLAG peptide (20 or 100 
μg/ml), reaching total 325,917 and 135,913 RPM for mRNA and cDNA display, 
respectively (Table 4.A; B). With the selection conditions chosen, mRNA display 
shows a higher enrichment rate of the consensus FLAG motif over cDNA display 
(Table 4.A; C). Additionally, with mRNA display, the number of FLAG motifs in 
the sequences that remain bound to the beads, after the highest elution was done, 
was greater than with cDNA display (Figure 4.G and Table 4.A; A and B). These 
results suggest that the mRNA/cDNA conjugate is more easily eluted from the 
beads.  
  




Table 4.A: Read per million (RPM) counts of sequence motifs for each selection round. 
 
 




A final analysis of the sequences was done to see how much importance some 
amino acids residues, from the FLAG motif, have over the binding strength to the 
anti-FLAG M2 antibody. Comparison of sequences lacking one of the four residues 
of the core FLAG motif (DYKxxD) was done (Figure 4.H). The lacking tyrosine (Y) 
or lysine (K) residues showed negative enrichment in the first round, indicating 
the importance of these residues for primary recognition of the anti-FLAG M2 
antibody and posterior binding. The observed result is consistent with the previous 
selections 8–10 and the obtained M2 antibody structural data 7. 
 
 
Figure 4.H: Round-by-round enrichment of the motifs lacking a single key residue from the 
core FLAG motif. Sequence reads for partial FLAG motif lacking each of the four key residues first 
D (yellow), Y (blue), K (green) and second D (dark red) are shown for each round during the (A) 
mRNA display and (B) cDNA display selection. 
  





In this chapter, two display methods (mRNA and cDNA) were tested using the 
commercially available PUREfrex 1.0 cell-free protein system. This purified cell-free 
system was chosen over cell-free systems based on cell lysates. This method proved 
efficient and stable in the synthesis and selection of mRNA and mRNA/cDNA-
peptide conjugate. The PURE systems lack of contaminants allowed for minimal 
degradation of the sample as it was shown by the high conjugation efficiency 
(40%). In existing methodologies, degradation causes the conjugation efficiency to 
range between 5-40% 4. Unwanted components during the cleaning steps were 
limited using electroelution to ensure the purity of the peptide conjugates and 
ethanol precipitation to secure as much sample recovery as possible. Although 
these latter two steps are common purification techniques, they could be 
important when selecting for a component of the PURE system such as 
components involved in the transcription and translations processes.  
mRNA and cDNA display methods were also compared. The overall performance 
was validated by searching for epitopes, from approximately 1,012 sequences, using 
the anti-FLAG M2 antibody 7. Posterior high-throughput sequencing, after three 
rounds of selection, led to the identification of the FLAG epitope (DYKDDDxx) and 
consensus FLAG motif sequences [DYK(DLN)(DFLNY)D]. This specific motif 
appeared in the only two sites where it could appear (if the restrictions imposed in 
the original library are taken into consideration) since only three sites in the 
mentioned library had degenerate codon sequences that can code for tyrosine, and 




one of those three sites is too close to the C-terminal end of the random region and 
therefore cannot be part of the FLAG motif. 
When comparing the performance of both methods, similar results were obtained, 
with the mRNA display having slightly higher enrichment than the cDNA display 
(Figure 4.H). Although this has only been performed once, and repetition should 
be done to confirm this statement, this could prove the consistency of the method 
which will be useful for future studies to explore the sequence and functional space 
of diverse polypeptides. 
 One difference found was the elution speed of both FLAG motif sequences 
conjugates, mRNA-peptide and mRNA/cDNA-peptide, with the latter being eluted 
slower from the magnetic beads. One possible reason could be that the mRNA-
peptide conjugate is smaller in size (around 135 bp of cDNA lighter depending on 
the DNA library) and thus allows it to be more accessible to binding sites on the 
beads than the larger mRNA/cDNA-peptide conjugates. Also, the sequences from 
the cDNA display method appear to have more non-specific binding on the 
remaining beads after the elution process.  
By showing that through a round-by-round sequencing process and a stepwise 
competitive elution with FLAG peptide (at the final 4th round), the consensus 
FLAG motif prevailed over other sequence variants; the method gained a strong 
point in favour since high-throughput sequencing is being used more and more as 
a powerful approach for various in vitro selection and evolution experiments. 
Additional enrichment of several amino acids adjacent to the FLAG motif in a 




library dependent manner (FLAG-random vs 10aa-random) were also observed. 
This suggests a mutual interaction between residues so an optimal binding 
conformation can be formed. Furthermore, by comparing the enrichment patterns 
of sequences with a single residue difference, it was possible to highlight the 
residues with the most influence with regards to the anti-FLAG M2 antibody 
recognition process. Enrichment of core FLAG motifs lacking one of the four key 
residues (DYKxxD) indicates that tyrosine (Y) and lysine (K) appear as the two key 
residues essential for binding. Although this has been studied before, it has been 
done on phage display 9. This pattern can be useful to further explore high-affinity 
epitope candidates and even discover “super epitopes variants”, based on recent 
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Chapter 5: Production of Lipid Vesicles and Nanodiscs 
Synthetic Membranes and G-protein-coupled receptors 
(GPCRs) using the PURE Cell-free System 
 
5.1 Chapter 5 Aims and Summary 
Chapter 3 presented studies focused on cell-free system’s dynamics whilst Chapter 
4 used this information to select a cell-free system from purified components to 
test two different display methods: mRNA and cDNA display.  
This Chapter focusses on using the PURE system within two different types of 
synthetic lipid membranes for the production of G-protein-coupled receptors 
(GPCRs). These types of membrane protein are attractive targets for drug screening 
since they are found in most cells. They perform a wide variety of functions and 
their localization, on the cell’s surface, provides easy access. But they are more 
challenging to study than soluble proteins since they are dependent on lipid 
membranes to fold and settle properly. The main elements of this chapter include 
the use of a cell-free system, the PURE system; the selection of a type GPCR 
membrane protein, CX3CR1; and the use of two different synthetic lipid 
membranes, vesicles and nanodiscs. The CX3CR1 protein (from the human GPCR 
family) was selected as a target because it is involved in a wide range of 
inflammatory diseases 1, which makes it a potential target for cancer therapy 2. It 
also has a known specific ligand, CX3CL1 3. This information could help check the 
veracity of the proposed method or design a peptide target library more readily. 




CX3CR1 also has shown polymorphism, which offers targeted therapeutic options 
4.  
The chapter details the synthesis of the CX3CR1 protein in both lipid vesicles and 
nanodiscs (Figure 5.A). The design and production of a random peptide library will 
then be described to find suitable targets for the GPCR. This last section is the first 
step in performing screening and selection of peptide targets for GPCRs samples 
using display methods. The details of this will be outlined and expanded in Chapter 
6 (Future Work Section).   





Figure 5.A: Summary of the experimental approach for Chapter 5. Experimental procedures 
carried out during this chapter. (A) Expression of GPCR in nanodiscs. The first step (1) used the 
PURE system to produce the MSP1D1 proteins, which are necessary to create nanodiscs, with a His-
tag for future selection and purification. The second step (2) involves the full creation of the 
nanodiscs using the MSP1D1 protein and a lipid mixture. The third step (3) uses the nanodiscs and 
again the PURE system to produce GPCRs. (B) Expression of GPCR in liposomes. The first step (1) 
encapsulates the cell-free system and GPCR DNA inside the liposome. The second step (2) 
incubates the liposomes so the GPCR is produced and automatically inserted in the membrane.  




5.2 Liposomes as Synthetic Membranes for GPCRs Production 
and Assembly: Microscope Visualisation and FACS Analysis. 
The first lipid membrane model used for the production of GPCRs was liposomes 
and Giant unilamellar vesicles, (GUVs). Vesicles are usually more economical to 
produce and large quantities can be obtained in a single preparation process, and 
even stored for future use. The water-in-oil (w/o) emulsion transfer method 5–7 
(Figure 5.B) was chosen to produce the lipid vesicles since the liposomes produced 
with this method have already been studied and their stability optimized for 
protein production 8. The DNA of the product being synthesised, in this case, the 
GPCR membrane protein CX3CR1, is located in the inner solution, along with the 
PURE system. So when the liposomes are assembled, the membrane protein 
production occurs inside the liposome. It has been found that even though there 
are no translocon proteins located inside the liposome to carry the GPCRs to the 
membrane, membrane proteins can spontaneously integrate themselves on the 
liposome’s membrane 9,10. To visualize the GPCRs, these were cloned downstream 
with an sfGFP gene, so as a fusion protein when the GPCRs travels and assembles 
in the membrane, the sfGFP fluorescence should be visible on the liposome’s 
surface, instead of inside where some of the proteins that fail to interact with the 
membrane remain. Furthermore, when creating the DNA construct, the T7 
promoter had a mutation at the position 17, adenine (A) for tyrosine (T), since it 
was proven in chapter 3 that a few mutations in the T7 promoter enhance the final 
protein production. 














Figure 5.B: Schematic of the water in oil (w/o) emulsion-transfer method for GUV 
production. The method starts with a water droplet suspended in the upper oil phase while being 
protected by a lipid monolayer, which later will become the inner monolayer of the vesicle. By 
performing centrifugation, the w/o droplet sinks further and settles in the lower aqueous phase, 
which is the outer solution in which the GUVs will be suspended. When the liposome passes from 
the oil phase to the aqueous phase, it crosses a layer of lipids which quickly link themselves to the 
droplet forming a lipid bilayer. Image used is from Tsuji et al. (Journal of Bioscience and 
Bioengineering, 2018) 7. 
 
To determine the optimal composition for the lipid, inner and outer solutions for 
the vesicles, a first test was performed. This consisted of producing vesicles 
according to Fujii et al. 6. The lipid composition used was POPC: Cholesterol (1: 1). 
The inner solution consisted of the PURE system and a DNA sequence for sfGFP 




(the WT construction from Chapter 3), to confirm the proper functioning of the 
transcription-translation system (Appendix, Section A.3, Figure A.3.1). The outer 
solution is composed of the non-protein elements of the PURE system but also 
without the tRNAs. This outer solution is also complemented with 200 mM glucose 
to maintain an osmosis balance. sfGFP was produced and visualized by microscope 
(Appendix, Figure A.3.1).  
The next step involved the direct production of the hybrid GPCR protein, CX3CR1-
sfGFP inside the vesicles and posterior analysis. The hybrid protein was seen on 
the surface of the vesicles under the microscope (Figure 5.C; A). The vesicles were 
also run through fluorescence-activated cell sorting (FACS) to analyse better the 
total population of the vesicles, along with their conformation and fluorescence 
level. FACS analysis was chosen to explore the characteristics of the whole 
population of liposomes. When plotting the liposomes, calculations can be 
performed to analyse the percentage of liposomes with certain characteristics and 
collect them to separate them from the rest of the population.  This is useful when 
performing further experiments with the liposomes in order to have a more 
homogenous population with high number of the protein of interest.  
When plotting the forward (FSC-A) and side (SSC-A) scattering values of each 
vesicle against each other, there is a certain region of the plot that corresponds to 
the unilamellar liposomes (Figure 5.C; B). These liposomes are usually of various 
sizes (wide range of FSC-A values) but with low SSC-A values since several 
monolayers divert the laser more and therefore increment the side scattering of 




the vesicle, as it was shown in the Fujii et. al paper 6. Furthermore, when comparing 
the sfGFP fluorescence levels (FITC-A) of the vesicles with ones with no DNA, the 
plot shifted (Figure 5.C; B). It can be seen that the lower plots (negative control) 
show no fluorescence further than the 102, being this the background noise. While 
the upper graphs (those of the sample) show population of vesicles with FITC 
signal (to the right of the 102 mark). However, less than 25% of the total vesicle 
population showed sfGFP fluorescence in the FACS analysis. This could be due to 
the limited concentration of the inner phase when manufacturing the vesicles, 
resulting in depleted liposomes. Studies have also shown that the PURE system is 
prone to generate partially translated proteins or functionally inactive, due to 











Figure 5.C: Lipid vesicles analysis using the PURE system and CX3CR1-sfGFP fusion protein. 
(A) Microscope images of vesicles with a lipid composition of POPC: Cholesterol (1: 1). The inner 
solution contains the PUREfrex 1.0 system and CX3CR1-sfGFP DNA. The images on the left column 
correspond to phase contrast and the ones on the right column to the green fluorescence of 
CX3CR1-sfGFP migrating to the liposome membrane. The bar size, on the right upper corners of 
the images, is 25 µm. (B) Plots in 2D of the lipid vesicles population when run through FACS. The 
upper graphs represent the CX3CR1-sfGFP sample while the bottom graphs represent a negative 
control (PURE system with no DNA). The forward scattering value is represented by FSC-A and the 
side scattering value by SSC-A. The sfGFP fluorescence is represented by FITC-A. The total number 
of vesicles plotted in each graph is 100,000.  
 
  




5.3 Nanodiscs as Synthetic Membranes for GPCRs Production 
and Assembly: MagneHis Purification and Western Blot Analysis. 
Another lipid model chosen for the production of GPCRs was nanodiscs 12,13. These 
are smaller than vesicles, and GPCRs inserted in them are accessible from both 
ends. This provides a significant advantage when performing selection methods as 
there is limited concern over the correct insertion of the protein in the membrane. 
Furthermore, detection can be easily be carried out by SDS-PAGE gel and western 
blot. Nanodiscs, like vesicles, remain stable when kept at low temperatures (4 to -
20 degree Celsius), so they are useful for long experiments.  
The first step in making nanodiscs is the expression and purification of the 
membrane scaffold proteins (MSP). In this case, the human MSP1D1 amphipathic 
protein was used since it has been shown to enable nanodiscs stabilization 14. The 
plasmid pMSP1D1, contains the MSP1D1 gene, a His-tag on the N-terminus and a 
T7 promoter. Using the PUREfrex 1.0 system, the proteins were produced. 
Purification was achieved using magnetic nickel particles attached to His-tag 
antibodies. Recovered MSP1D1-HisTag samples were then concentrated and stored. 
Quantification was determined by absorbance at 280 nm using a calculated 
coefficient of extinction of 21,430 (mg/ml)-1 cm-1, obtaining 3.8 mg/ml of purified 
product.  
Nanodiscs were prepared with a lipid mixture consisting of POPC, POPS and 
Cholesterol in a 72: 20: 8 ratio respectively. The lipid mixture was incubated with 
purified MSP1D1 protein in a 1: 60 ratio. The chosen ratios for the lipids and 




proteins have been reported to form stable nanodiscs for GPCR insertion 12. 
Elimination of remaining detergent in the mixture (which is the Na cholate from 
the Nanodisc buffer), to aid correct nanodisc assembly, was achieved by SM2 bio 
beads. A two-step purification process was performed on the recovered nanodiscs 
samples to eliminate aggregation and aberrant nanodiscs. The first one was done 
by ultra-centrifugation for big lipid and protein aggregations, since the precipitate 
faster and at lower speed. The second one by AKTA Chromatography for better 
sample recovery and concentration. Bigger particles and aggregations elute faster 
from the column than single nanodiscs. From the chromatography peak obtained 
(Figure 5.D; A), 10 fractions were run on an SDS-PAGE gel for sample size 
verification (Figure 5.D; B). 5 fractions were selected for sample concentration, and 
when finished, another SDS-PAGE gel run was performed (Figure 5.D; C). 
 






Figure 5.D: Nanodisc purification and verification. (A) Plot graph of the nanodisc sample as it 
passes through the AKTA chromatography channels. The red and blue lines represent the 
absorbance at 260 and 280 nm respectively. The x-axis represents the millilitres of sample/buffer 
that have passed through the column and just on top of it, the number of each fraction collected. 
The y-axis represents the mili-absorbance units. The blue and red peaks both show the nanodiscs. 
(B) SDS-PAGE gel of the selected fractions from the AKTA chromatography purification step. A 
total of 10 fractions were run on the gel. The nanodiscs band can be appreciated at 26 kDa. From 
these fractions, only 5 were selected for sample concentration. (C) A second SDS-PAGE gel shows 
the final purified and concentrated nanodisc sample. 
 
  




For the final step, nanodiscs will be used along with the PURE system to produce 
CX3CR1. The DNA construct that encodes this protein gene, also contains a 
HaloTag sequence downstream the CX3CR1 gene. This tag will allow purification 
of the protein-nanodiscs complexes from those nanodiscs that are empty. The cell-
free system selected was PUREfrex 2.1 DS supplemented. This version differs from 
the basic PURE system in that it helps in the formation of disulphide bonds in the 
protein by replacing DTT for glutathione reduced (GSH). After the transcription-
translation reaction with nanodiscs, the sample was purified using magnetic nickel 
particles attached to HA-tag antibodies. This ensured only the CX3CR1 samples 
were selected and the empty nanodiscs left behind. The collected fractions were 
run on an SDS-PAGE gel for visualization (Figure 5.E; B). The samples visualized 
in the SDS-PAGE gel also included the PURE system components. It was 
challenging to estimate the purification efficiency since some bands were 
superposed over the CX3CR1 band in the PURE fraction lane (Figure 5.E; A). The 
process was repeated but with Methionine [S35] in the PURE system, (Figure 5E; B). 
The results showed that 0.021 mg of final purified CX3CR1 was obtained per ml of 
the PURE system. The purification efficiency was 63%. One important aspect to 
have in mind during the experiment is that the obtained bands in the gels 
corresponding to the CX3CR1 sample were lower than expected. The CX3CR1 
protein has a molecular weight of 41 kDa. But the obtained bands in both gels were 
in the 34 kDa mark. A possible explanation comes from the studies performed by 
Rath et al. 15. They showed that membrane proteins do not migrate in SDS-PAGE 




gels accordingly to their molecular weight. Numerical factors have to be taken into 
consideration when calculating the molecular weight band on the gel. For proteins 
migrating faster, like CX3CR1, a correction factor of 0.82 has to be applied. In this 
case, the molecular weight of the observed band was divided by this factor, 




Figure 5.E: CX3CR1 purification and verification. Each lane represents a fraction from the 
purification process. From left to right: PURE fraction, flow-through fraction, 1st wash fraction, 2nd 
wash fraction, and elution fraction. (A) SDS-PAGE gel of the fractions from the HA-tag magnetic 
particles purification step. (B) SDS-PAGE gel of the fractions from the HA-tag magnetic 
particles purification step. The gel went through fixing and drying processes for posterior 
visualization of Methionine [S35] signal in the bands. 
  




When analysing the efficiency of the HA-tag magnetic purification process, the 
majority of the sample that was not purified was located in the flow-through 
fraction, around 35%. This indicated that this purification process needs to be 
optimized, as a big portion of the sample does not bind to the HA-tagged particles 
during the incubation period. This can be solved by finding out the optimal 
number of magnetic particles needed and incubation time and temperature. 
Another possible cause could be the HA-tag located in the CX3CR1 proteins. If the 
tag is not available, due to a short linker sequence, it will not be able to find and 
bind to the anti-HA tag from the magnetic beads. Furthermore, if the HA-tag has 
a considerable amount of hydrophobic amino acids, it is more likely to interact and 
bind to the nanodiscs, making it unavailable for binding to the beads.  
The amount of CX3CR1 sample obtained, 0.021 mg, per ml of the PURE system is 
low when comparing to results obtained from previous studies, but still within an 
expected range (0.05 – 0.01 mg) 12. Nanodiscs play an important role when it comes 
to protein yield. Their final concentration and size can affect the right 
incorporation and stability of membrane proteins. Thus, this factor is to be taken 
into consideration when making improvements to this aspect of the reaction.  
  




5.4 DNA Library Design for Screening and Selection of Peptides 
as Drug Targets for GPCRs.  
Following the successful production of CX3CR1 in both lipid vesicles and nanodiscs, 
these samples could be used for screening of peptide targets for GPCR interactions 
(important as drug targets).  
Using the designs introduced in Chapter 4 as a backbone, a new method could be 
made for peptide testing on CX3CR1 (expressed in both vesicles and nanodiscs). 
The first step in this process is the creation of a random peptide library that will 
provide targets for the protein of interest. Since the PURE system is the preferred 
cell-free system, the use of the T7 promoter is mandatory. Even more, from chapter 
2 several mutations on this promoter enhanced the product yield. A leader region 
on the 3’ end, which complements the puromycin-FITC-DNA tag, is also one of the 
components of the library, for posterior puromycin ligation to the mRNA molecule 
(for both mRNA and cDNA display). For the design of the random peptide part, it 
is important to understand the natural ligands of CX3CR1 and their properties and 
conformations. The chemokine protein CX3CL1 (FKN) is a ligand of the CX3CR1 
receptor. This ligand is around 400 amino acids long in humans, making it a long 
protein and not suitable for designing any random library. But the chemokine 
domain (FKN-CD) of CX3CL1 that binds to CX3CR1 16, with a length of 76 amino 
acids 17,18, can be used for the library design. This domain binds to the extracellular 
loops of the receptor 17. Even if the FKN-CD section of CX3CL1 is much shorter than 
the whole protein, it is still long if a full random library is to be made. The limit of 




the number of sequences in vitro display methods can screen and select is around 
1015. This number corresponds to around a peptide 12 amino acids long, if all 
possible natural amino acids can be located in each spot. In the case of FKN-CD, 
this could be done by parts. Changing certain regions of the FKN-CD domain one 
at a time and analysing the dominant motifs in each region of the sequence (Figure 
5.F; middle). A final optimized ligand can be designed by using the top motifs. 
Another way could be to just create a random peptide library that is around 10 
amino acids long (Figure 5.F; bottom). Although the whole 76 amino acids FKN-
CD attaches to CX3CR1, shorter peptides could reveal important binding regions 
and sequences. This option also allows to produce the random library more 
economically using long primers and PCR. Long sequences, otherwise, have to be 
ordered. 
One last possibility could be to decrease the possible number of amino acids that 
can be inserted in each spot. By allowing, for example, 10 possible amino acids per 
spot, the maximum length of the random peptides increases to 15 amino acids. This 
could help save resources if some option is already known not to work for certain 
positions in the peptide. Whether one or another type of library is chosen, it is 
important to have a positive control (Figure 5.F; top). The untouched sequence of 
FKN-CD binds fully to CX3CR1. This can be used to test the veracity of the method 
like it was done in chapter 4.  
 






Figure 5.F: Possible DNA libraries for the screening and selection of peptides targets for the 
CX3CR1 receptor. All libraries contain a T7 promoter, a ribosome binding site (RBS) and a leader 
region at the 3’ end that complements the puromycin-FITC-DNA tag. (Top) The control DNA 
library encodes the gene for the chemokine domain (FKN-CD) of the CX3CL1 ligand. This is the 
naturally found ligand of the CX3CR1 membrane protein. (Middle) The long version of the random 
peptide library. Only the first 12 amino acids are randomized to limit the total number of possible 
sequences. (Bottom) The short version of the random peptide library. This only contains 12 
randomized amino acids without the rest of the FKN-CD.  
  




5.5 Outline and Conclusions 
In this chapter, a first experiment involved the production of the CX3CR1 receptor, 
a GPCR membrane protein, in lipid vesicles. Liposomes were chosen as the first 
model of synthetic lipid membranes. The receptor production was carried out 
inside the liposome using the PURE system. This system is based on purified 
components and includes only the minimum necessary components for 
transcription-translation. This helps increase the stability of liposomes as it keeps 
the concentration of the inner solution elements low, therefore minimizing the 
change of bursting due to pressure. The visualization of the protein on the 
liposome surface was done by fusing CX3CR1 to sfGFP. The use of liposome for 
expression of membrane proteins is widely used. Liposomes are produced quickly 
and economically. They can also be stored for future uses. The main issue 
encountered is the lack of knowledge on the membrane protein inclusion 
direction. In the case of GPCRs, most ligands interact with the extracellular loops. 
If the loops are found inside the vesicle, the ligands cannot reach them.  
The second synthetic membrane model used for CX3CR1 was nanodiscs. These 
have longer production time and require more laboratory equipment, so they may 
not be always affordable. But they are small which makes it possible to analyse 
them using methods as simple as an SDS-PAGE gel. They also permit the 
membrane protein to be reached by both sides. Storage for longer experimental 
periods is also possible. Although the efficiency of CX3CR1 production and 
purification was satisfactory, it can still be improved. For example by allowing 




more free access to the HA-tag in the protein. Or by selecting a less hydrophobic 
tag to minimize interaction with the nanodisc. The amount of total protein 
produced, 0.021 mg/ml of PURE system, was on the low range. This issue is 
probably caused by several factors: the condition of the PURE system, the amount 
and size of the nanodiscs, and the design of the DNA construct used. All these 
parameters have room for optimization.  
CX3CR1 was chosen as the GPCR candidate for this chapter. This protein is related 
to several types of diseases, and mutations found in it can cause cell mortality 19.  
Since CX3CR1 shows polymorphisms, future treatments involving this protein 
could focus on individual targeted therapy. This membrane protein has a known 
natural ligand, CX3CL1. This knowledge comes in handy to design more specific 
sequences, or libraries, of possible targets for CX3CR1.  
The design of a random peptide library for CX3CR1 was hindered due to the size of 
its known ligand, CX3CL1. The chemokine domain of the ligand that binds to the 
target protein is quite long. This reduces the number of amino acids that can be 
randomized in the sequence as in vitro display methods has a limit of sequences. 
A bigger number than the limit will just interfere with the process and many 
sequences could be lost. Smaller random peptides could still be tested for finding 
binding sequences. Also, shorter regions of the chemokine domain can still be 
randomized and new motifs found that have higher specificity for CX3CR1.  
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Chapter 6: Conclusions and Future work 
 
6.1 Discussion and Conclusions 
Each of the chapters includes a summary of the work carried out described. This 
final chapter discusses conclusions jointly to form an overview of the whole thesis 
project. The main aim of this research was to explore the properties and boundaries 
of cell-free systems and in vitro display methods so that they could be used more 
extensively in conjunction.  
The explored features of two different cell-free systems gave an insight into their 
dynamics and disclosed two different patterns for protein expression. Model 
analysis of the experimental results confirmed distinct pathways taken for cell-free 
systems from cell extracts and purified components. Results were consistent with 
the hypothesis that the extract-based system is mainly hindered by the presence of 
naturally found contaminants that decrease the availability of substrates. Methods 
to prevent or minimize this feature could be implemented in this type of cell-free 
system. For example, engineering of a minimal cell (top-down or bottom-up 
approach) could help eliminate these contaminants and enhance productivity. 
Once established, the economical and time benefits of the extract-based cell-free 
system could benefit many. The purified components based system (PURE system) 
had its limitation during protein translation, including depletion of resources and 
ribosome stalling. Since one of the main features of the PURE system is its ability 
for unbounded reaction modification and monitoring, these issues could be 




resolved further by supplementing resources (amino acids, energy molecules, etc) 
and mechanisms to assist the reaction processes (ribosome recycling and rescuing 
factors) into the reaction to improve the final yield.  
Apart from the cell-free discovered dynamics, single-base substitutions in a mutant 
library of T7 promoters allowed the discovery of variants with enhanced yield. 
With two simple, yet different, approaches, useful information could be obtained. 
Experiment data were recorded using straight forward time-course measurement 
of protein yield. Although a simple experimental approach, when combined with 
system modelling to create an interdisciplinary approach, useful information was 
revealed. Cell-free systems have potential and they are already used widely in 
different fields of synthetic biology. The dynamics of factor interaction could be 
easily disentangled with more effort.  
The information obtained from this experimental approach, which included the 
testing of mutant libraries and the building of a mathematical model, provided a 
knowledge of the strengths and limitations of each system. When exploring display 
methods, such as mRNA or ribosome display, several aspects become important. 
One is the security that during the screening and selection process, that the 
peptides samples have high purity levels. Any presence of contaminants or 
undesired molecules could hinder the interaction of the peptides with the binding 
target. Peptides and mRNA molecules could also be degraded. This lowers the 
possibility of finding a good candidate and reduces efficiency. So when working 
with display method, it is important to ensure the cleanliness of the experimental 




reaction. Also, to provide an efficient method of purification and sample recovery. 
During this thesis, these aspects were put to test. The inclusion of the PURE cell-
free system into both mRNA and cDNA display was explored. The election of this 
cell-free system over others, especially cell extract-based ones, came down to the 
low levels of mRNA degradation. For both mRNA and cDNA display, an mRNA 
molecule is attached to each peptide. As a short unprotected single-strand 
molecule, its stability is already low and the probability for degradation high. Using 
the PURE system minimized the possibility of degradation by nucleases. It also 
reduced the interaction with other unnecessary elements that could in exchange 
destabilize the mRNA-peptide complex or disturb the selection process. The lack 
of contaminants and unwanted elements in the PURE system also allows efficient 
cleaning and purification procedures: the fewer components that need to be 
cleaned from the sample, the more efficient the procedure will be. The PURE 
system was used in both mRNA and cDNA display methods. Both of these were 
selected for their in vitro properties. They can process libraries up to 1015 in size. 
The complexes they form with the peptides are small and less prone to 
disassembly. And since they are performed in vitro, rounds of selection can be done 
much faster. When comparing both methods, their efficiencies almost matched. It 
was thought the cDNA display will show superior efficiency since the mRNA 
molecule becomes more stable by being attached to cDNA. And although in 
theory, this makes sense, in practice it was not seen. The most plausible 
explanation comes to the use of the PURE system and highly efficient cleaning 




procedures. As it was already explained, these features improved the mRNA 
stability. With these conditions, the selection of mRNA display over cDNA display 
should be made. The mRNA-peptide complexes are smaller in size, which allows 
easier access to binding sites. But also by eliminating one single step, RT-PCR to 
form mRNA-cDNA, the number of extra components and procedures exposed to 
the mRNA-peptide complexes are reduced. And the whole selection process 
becomes faster. 
The combination of mRNA display and the PURE system resulted in satisfactory 
screening and selection of binding motifs from a random peptide library. Further 
exploration of this combined method could enhance the discovery of high-affinity 
peptide candidates for drug discovery.  
When it comes to the discovery of drug candidates for therapy treatment, one of 
the major candidates are membrane proteins. The location of these proteins, on 
the cell’s surface, makes them easily accessed by drug molecules. They are also 
involved in a wide variety of cellular processes and pathways, which in return 
results in various diseases appearing when they malfunction. G protein-coupled 
receptors (GPCRs) are the most promising candidates for membrane proteins drug 
discovery. They are found mostly every cell, in significant quantities and are 
involved in almost every signaling pathway.  
To research further into drug discovery for GPCRs, first more had to be understood 
about them. Since they are membrane proteins, they need the presence of 
synthetic lipid models to be produced and folded properly. The GPCR candidate 




chosen to investigate this field of drug discovery in membrane proteins was the 
receptor CX3CR1. It is highly involved in several signalling pathways, making it 
important in disorders such as cancer, inflammatory syndromes and cell apoptosis. 
CX3CR1 also shows polymorphisms. This feature can be used in the future for 
individual therapy. Since different versions of the protein are found in a different 
individual, each one could answer differently to a specific antibody or peptide 
targets. The selection of synthetic membrane for CX3CR1 production came down 
to two choices: lipid vesicles and nanodiscs. Two options were used to investigate 
further how they both differ when being involved is screening and selection 
processes. Lipid vesicles act like bioreactors. They are basic synthetic lipid models 
that are affordable and quite fast to produce. But when it comes to the 
disadvantages of this model, the main aspect is the probability of wrong insertion 
direction of the membrane protein. The binding motif of the protein could end up 
being on the inside of the liposome. Nanodiscs do not have this problem, as they 
allow the membrane protein to be accessible from both ends. On the other hand, 
they are more costly to make and the process takes longer.  
Production of CX3CR1 in both lipid models was also carried out by the PURE 
system, for the reasons already mentioned during the thesis. But apart from that, 
it was chosen for its ability to supplement the reaction with external components. 
In this case, elements were added to help the formation of disulphide bonds in the 
protein.  




The production of CX3CR1 membrane protein was satisfactory, and the final aim 
of the thesis involved the design of a method to screen and select possible peptide 
targets for this protein. The use of the PURE system and mRNA display would be 
part of this methodology as they have been proven during this thesis to be 
incredibly valuable. The whole concept of this method as one will be explained 
more in detail in the next section (Section 6.2 Future Work). CX3CR1 has a natural 
ligand, called CX3CL1. The knowledge of this molecule and its binding sequence 
helped in the design of a possible DNA library for CX3CR1 drug screening. The 
chemokine domain of CX3CL1 binds to CX3CR1. But this domain is still quite long 
at 76 amino acids. Complete randomization of the whole domain is not possible as 
the total number of possible variants would be too high for any display system. But 
a variation of some of the smaller domain motifs is possible.  In conjunction, all 
the motifs could give an idea of a variant chemokine domain protein with 
enhanced binding affinity for CX3CR1. Testing of smaller peptides instead of the 
whole domain is also possible and could yield important targets for the membrane 
protein.  
To finalize, this thesis has brought insight into the use of cell-free systems, display 
methods, membrane protein and synthetic lipid membranes. In a partnership, the 
possibility to create a screening and selection method of drug targets for 
membrane proteins is possible. This thesis has demonstrated the advantages and 
efficiency of all the elements discussed. The next step to be taken is to use this in 




conjunction in an interdisciplinary way to discover how far their possibilities can 
reach together.   
6.2 Future Work 
One important aspect that could be explored further is the molecular structure of 
the T7 promoter variants that both enhanced and lowered the final protein yield. 
The molecular aspect of the transcription process by the T7 RNA Polymerase (T7 
RNAP) has been studied before 1. And although explanations were hypothesised 
about the effect of the mutation’s position within the promoter, more can be 
explored with the information already available about the T7 RNAP. By looking 
individually at each substitution and the molecular interaction the new nucleotide 
has with the T7 RNA polymerase, more can be learned about why each specific 
mutation has certain effects on the transcription process like what has already been 
done with the core T7 promoter sequence 2. Combinations of more than one 
substitution in the promoter could enhance even more the activity of the T7 RNAP. 
Or just a random T7 promoter library could be further explored for intricate 
variations 3. The existence of a T7 promoter library with a spectrum of promoter 
strength is valuable when designing genetic circuits. As every pathway, whether 
natural or synthetic, has different yield outcomes, multiple combinations could be 
designed in the same reaction environment.  
When it comes to the membrane protein production in lipid vesicles, 
improvements are suggested here. The addition to the PURE system of certain 
elements can aid in the correct integration into the liposome surface. By 




implementing the complex protein system known as translocation channel, the 
integration of GPCRs into the liposome membrane can be enhanced 4. This could 
be used in further studies with different types of membrane proteins and GPCRs 
for liposome display methods. 
The production and purification efficiency of CX3CR1 in nanodiscs is another 
aspect worth investing more time and resources. The purification carried out was 
performed using the HA-tag located in the CX3CR1 receptor. The first thing to 
improve would be to elongate the linker sequence between the receptor and the 
tag. This will allow better access of the HAtag to the antibody surface, and thus 
allowing more samples to be bound and not washed away. The second thing would 
be to test different tag. The HA tag has 44% hydrophobic amino acids. These are 
more prone to interact with the nanodiscs phospholipids and be unavailable for 
binding and selection. A possible option to use could be the FLAG-tag, as it has no 
hydrophobic amino acids. Apart from the attached tag, modification of both the 
PURE system components and size and amount of nanodiscs in the reaction, could 
improve the final product yield too. So these parameters also need optimization 
for each different membrane protein. 
Different types of GPCRs are also worth testing. Although CX3CR1 was chosen, 
many more are also suitable targets, like CCR5. Furthermore, modifications of this 
protein could aid in their production or stability, making them more suitable for 
research. For example, insertion of a rubredoxin into the third intracellular loop of 
CCR5 enhanced thermostability 5–7. 




The lipid composition used for both liposomes and nanodiscs was already pre-
determined and for the expression of CX3CR1 it worked well. But this aspect has 
room to growth for the level of protein expression. Furthermore, if these samples 
were planned to be used in cells or for clinical trial, the composition is very 
important as the type of lipids used play an important role in membrane fluidity 
and absorption.  
The final and most important aspect of future work for this thesis is the integration 
of all the acquired knowledge. The creation of a method that could screen and 
select possible targets for membrane proteins is the final goal. During this thesis, 
it was learnt the beneficial aspect of the PURE system, of the use of mRNA display 
for screening and selection processes. The production of a G-coupled receptor 
protein was carried out in two different types of synthetic lipid membranes. Even 
a possible random DNA library of possible drug targets was designed. The 
proposed system (Figure 6.A) is based on the mRNA display method used in 
chapter 4.  It starts by using the PURE system to produce all the random mRNA-
peptides conjugates from the designed library. The selection process will use the 
produced membrane receptors, in both vesicles and nanodiscs, to scan for high-
affinity targets. By going through several rounds of selection, possible candidates 
and high binding motifs will be discovered.  
GPCRs, like most membrane proteins, are extremely difficult to produce and purify 
efficiently. Also, due to the difficulty in working with membrane proteins, 3D 
structures of most of them are not available 8. Screening of possible ligands for 




membrane proteins not only can be performed for drug targeting purposes but also 
to understand better the binding and structures of the receptors they bind to. By 
analysing the sequences and motifs of the candidates with high affinity, patterns 
can be observed and hypothesis can be proposed about the membrane protein 
structure or binding regions. This approach could help dissect the structures of 
proteins from the same family or that have the same function. Predicting new 
candidates using computer modelling is limited by the lack of available data 9. So 
the more data collected the better the aid in predicting new candidates for the 
target protein or other similar proteins. Furthermore, this lack of available data 
puts more focus on using High-Throughput Screening (HTS) methods that can 
cope with a high number of candidates in libraries and perform rapid testing 10. 
Minimization of unwanted interactions of the candidates with other molecules is 
also necessary to increase as much as possible the efficiency of screening. The 
demanding conditions for drug screening of membrane proteins could be 
summary in categories: (1) Rapid and easy production and purification of 
membrane proteins, (2) high-throughput screening of big libraries and rapid 
testing, and (3) high efficiency and minimal side interactions of the candidates 
and/or membrane protein.  
The proposed method (Figure 6.A) could meet these conditions. The production 
and purification of the GPCR receptor in both vesicles and nanodiscs were 
performed successfully. It was not a challenging task and could be performed 
within 1 day, as long as stocks of nanodiscs are present. The efficiency of 




purification was acceptable (63% efficiency showed in chapter 5) and the amount 
of protein obtained enough to perform further experiments (0.021 mg/ml CX3CR1 
quantification showed in chapter 5). But as already explained during this section, 
these parameters have the potential to be optimized. The use of mRNA display to 
screen and select for candidates already provides the possibility to test big libraries 
(1015). And the fact that it is performed in vitro already reduces the time needed to 
perform one round of selection (24 h) and minimizes the presence of unwanted 
components. Finally, the PURE system, as it is composed of purified components, 
minimizes contaminants in the reaction that could cause unwanted interactions. 
It also aids in the efficiency rate for mRNA-peptide conjugates (40% rate showed 
in chapter 4). Combining all these elements could create an optimal system for the 
screening and selection of membrane proteins.  





Figure 6.A: Scheme of possible mRNA display method for membrane proteins. The diagram 
shows how the display could be performed using membrane proteins in nanodiscs (upper) and lipid 
vesicles (lower). It starts by a random DNA library, which after translation by a cell-free system, it 
creates mRNA-peptides complexes. These conjugates are incubated with the membrane proteins 
to screen for possible targets. After binding and washing steps, the selected candidates will be 
sequenced. Several rounds can be performed to enhance the number of candidates with high 
binding affinity.   
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A.1 Appendix for Chapter 3 
 
A.1.1 Single mutation plots 
The individual plots of each variant (Figure A.1.1) were used to determine the 
expression rate of each one. It also shows differently the data found in the 
heatmaps (Chapter 3, Figure 3.G) as it can be seen that as the mutation advance 
more into the promoter sequence, they become more detrimental. Combined 
time-course plots for both cell-free systems (Figure A.1.2) shows better the wide 
range of protein expression variation that a mutant library provides. It also shows 
similar patterns as the simulated cases (Chapter 3, Figure 3.M) especially the cases 













Figure A.1.1 (next page): Time-course of GFP fluorescence over a period of 12 h for all the 51 
mutants. Each plot shows the time course of sfGFP expression by three variants for each position 
of the T7 promoter, along with that by the consensus sequence (denoted as WT) for comparison. 








































































Figure A.1.2: Time-course of GFP fluorescence using the consensus T7 promoter sequence 
and its variants. The data used in Figure A.1.1 were plotted in one graph. (A) Time-course of 
protein expression for the core sequence variants in the PURE system, (B) the core sequence 
variants in the extract-based system, (C) the extended sequence variants in the PURE system, and 















Figure A.1.3: Scatter plots for comparing two linear DNA templates. Normalized GFP 
fluorescence by the extended sequence (the core with extra bases at 5’ and 3’-ends, y-axis) was 
plotted against that by the core sequence (x-axis). (A) The PURE system. (B) The extract-based 
system. 
 
The reproducibility values (Figure A.1.2) comparing the core sequences and the 
extended versions show the difference in expression level that adding extra bases 
caused. The value is lower in the extract-based system proving that this base 
addition has a higher impact on this type of system. However, the correlation 
between extended and non-extended sequences showed good values suggesting 






A.1.3 Absolute expression levels 
 
Table A.1.1: Fold change of the maximum GFP fluorescence (right column) for each variant (left 
column) expressed in the extract-based system. Values in the middle column show the absolute 
maximum values of a variant in the core and extended sequence, respectively. 
 
Variant name Core Extended Fold change 
Consensus 2779 28456 10.24 
-17A 1739.5 13117 7.54 
-17C 10274.5 23652 2.30 
-17G 4457 10596 2.38 
-16C 579 2211 3.82 
-16G 1011 2373 2.35 
-16T 6066.5 17831 2.94 
-15C 799.5 1487 1.86 
-15G 714.5 1690 2.37 
-15T 5270 15626 2.96 
-14A 633 11837 18.70 
-14C 883.5 3428 3.88 
-14G 4148 1004 0.24 
-13C 1973.5 10131 5.13 
-13G 4316 12770 2.96 
-13T 5878.5 16383 2.79 
-12A 3950 12724 3.22 
-12G 2760.5 17495 6.34 
-12T 1105 10797 9.77 
-11A 1823.5 13436 7.37 
-11C 759.5 430 0.57 
-11T 640.5 505 0.79 
-10C 1132.5 7191 6.35 
-10G 418 1036 2.48 
-10T 696 3900 5.60 









The absolute expression levels increased more than four-fold on average for the 
extract-based system (Table A.1.1). For the PURE system, the sfGFP levels of the 
extended sequences were similar to those with no extra bases (Table A.1.2). 
 
Table A.1.2: Fold change of the maximum GFP fluorescence (right column) for each variant (left 
column) expressed in the PURE system. Values in the middle column show the absolute maximum 
values of a variant in the core and extended sequence, respectively. 
 
Variant name Core Extended Fold change 
Consensus 7424 9160.5 1.23 
-17A 11243.5 9151 0.81 
-17C 8517 9336 1.10 
-17G 10274 10016.5 0.97 
-16C 5056 4528 0.90 
-16G 7906 5624 0.71 
-16T 10061 9036 0.90 
-15C 3821.5 2693.5 0.70 
-15G 4532 3233.5 0.71 
-15T 9436.5 9273.5 0.98 
-14A 7693 10279 1.34 
-14C 6153.5 6836.5 1.11 
-14G 3563.5 3991.5 1.12 
-13C 9738.5 9850 1.01 
-13G 11084.5 8245.5 0.74 
-13T 9304.5 9340.5 1.00 
-12A 9901.5 8811 0.89 
-12G 9132.5 9297 1.02 
-12T 8813 9612.5 1.09 
-11A 11248 9752.5 0.87 
-11C 5540.5 1554 0.28 
-11T 1675.5 208 0.12 
-10C 9629.5 9571 0.99 
-10G 6302.5 2913 0.46 
-10T 8077 9100.5 1.13 







A.1.4 Modelling plots 
 
Figure A.1.4: (A) Simulated cell-free protein expression in the PURE system using the standard 
model. DNA concentration (top), mRNA concentration (middle), and protein expression 
(bottom) were shown. The parameter 𝑘𝑘𝑇𝑇𝑇𝑇 was varied (colours) while the other parameters were 
fixed. (B) Scatter plot of the rate of protein expression against the maximum protein expression. 





This plot (Figure A.1.3) shows the simulation performed on the PURE cell-free 
system with the same equations that were used for the extract-based system. Upon 
performing this simulation it could be seen that the expression patterns matched 
the observed ones, but the unique scatter pattern was not seen (Chapter 3, Figure 
3.K, A). This implied that some factors were not being taken into consideration in 







A.2 Appendix for Chapter 4 




Figure A.2.1: DNA library design. Two DNA libraries (FLAG-random and 10aa-random) were 
designed to validate the performance of our newly refined mRNA, cDNA display method. FLAG-
control DNA is used specifically for western blot analysis of mRNA-peptide and mRNA/cDNA-





The ‘FLAG-random library’ contained a fixed sequence for the first five amino acids 
of the FLAG epitope (DYKDDDDK); followed by three consecutive degenerate 
“RRN” codons corresponding to seven amino acids (Asn, Lys, Asp, Glu, Ser, Arg 
and Gly). The ‘10aa-random library’ contained ten degenerate codons (“VNN” and 
“NNY”) which corresponded to 16 and 17 different amino acids, respectively. The 
number of different sequences in both FLAG-random and 10aa-random libraries 
was 343 and 1.7 x 1012, respectively.  
Both DNA libraries contain a T7 promoter and ribosome binding site (RBS), for the 
use with a T7 RNA Polymerase. The leader sequence at the 3’ region was 











Figure A.2.2: Detailed image of the puromycin-FITC DNA tag ligation process. Parting from 
the DNA library, in vitro transcription was performed obtaining mRNA constructs. Afterwards, 
puromycin tags (DNA puro-tag) were attached by T4 RNA Ligase ligation.    
 
The DNA Puro-tag (Figure A.2.2) is ligated to the mRNA sequence by the T4 RNA 
ligase by connecting the 3’ end from the single-stranded mRNA construct to the 
phosphorylated 5’ end of the DNA tag. This tag will later react with the peptidyl-
tRNA to form a covalent link between mRNA and peptide. to connect. A rare GGA 
codon was placed at the 3’ end and a polyA (18 nt) in the puromycin-FITC DNA tag 







A.2.1 Gel images  
 
Figure A.2.3: Reverse transcription (RT)-PCR after selection. Affinity selected mRNA-peptide 
conjugates (mRNA display) and mRNA/cDNA-peptide conjugates (cDNA display) bound anti-
FLAG M2 antibody magnetic beads were subjected to RT-PCR. For each round, total 6 µl x 8 
reaction tubes were prepared for each display method to monitor the yield of amplified product for 







A test was performed (Figure A.2.3) to determine the optimal number of cycles for 
the RT-PCR. This is to avoid over-amplification of the samples. For each round of 
selection, the amplified product was checked every 5 cycles (from 0 to 35 cycles). 
Amplified DNA products, started being seen at the 15th cycle and were saturated 
at the 20th cycle. Band intensity of the 15th RT-PCR cycle was higher than previous 
rounds. This proves that the quantity of the sample was higher as the rounds 
progressed. A non-specific band, probably from non-specific binding of primers, 
appeared in every lane at around 200 bp. The optimal number of cycles for the first 






A.3 Appendix for Chapter 5 
 
A.3.1 Microscope visualization  
 
 
Figure A.3.1: Microscope images of lipid vesicles using the PURE system and sfGFP as the 
reporter gene. Vesicles have a lipid composition of POPC: Cholesterol (1: 1). The inner solution 
contains the PUREfrex 1.0 system and sfGFP DNA. The image on the left is phase contrast. The one 
on the middle shows fluorescence of NileRed attached to the lipid membrane. The image of the 
right represents the green fluorescence of sfGFP being produced inside the vesicles by the PURE 
system. The bar size, on the left upper corner of each image, is 50 µm.  
 
 
 
 
